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ABSTRACT 
Rett Syndrome (RTT) is a neurodevelopmental disorder affecting 1 out of 10,000 females 
worldwide. Mutations of the X-linked MECP2 gene encoding methyl CpG binding protein 2 
(MeCP2) accounts for >90% of RTT cases. People with RTT and mice with Mecp2 disruption 
show autonomic dysfunction, especially life-threatening breathing disorders, which involves 
defects in brainstem neurons for breathing controls, including neurons in the locus coeruleus (LC). 
Accumulating evidence obtained from Mecp2−/Y mice suggests that imbalanced 
excitation/inhibition or the impaired synaptic communications in central neurons plays a major 
role. LC neurons in Mecp2−/Y mice are hyperexcited, attributable to the deficiency in GABA 
synaptic inhibition. Several previous studies indicate that augmenting synaptic GABA receptors 
  
 
(GABARs) leads to a relief of RTT-like symptoms in mice. The extrasynaptic GABARs located 
outside synaptic cleft, which have the capability to produce sustained inhibition, and may be a 
potential therapeutic target for the rebalance of excitation/inhibition in RTT. In contrast to the rich 
information of the synaptic GABARs in RTT research, however, whether Mecp2 gene disruption 
affects the extrasynaptic GABARs remains unclear. In this study, we show evidence that the 
extrasynaptic GABAR mediated tonic inhibition of LC neurons was enhanced in Mecp2−/Y mice, 
which seems attributable to the augmented δ subunit expression. Low-dose THIP exposure, an 
agonist specific to δ subunit containing extrasynaptic GABARs, extended the lifespan, alleviated 
breathing abnormalities, enhanced motor function, and improved social behaviors of Mecp2−/Y 
mice. Such beneficial effects were associated with stabilization of brainstem neuronal 
hyperexcitability, including neurons in the LC and the mesencephalic trigeminal V nucleus (Me5), 
and improvement of norepinephrine (NE) biosynthesis. Such phenomena were found in 
symptomatic Mecp2+/− (sMecp2+/−) female mice model as well, in which the THIP exposure 
alleviated the hyperexcitability of both LC and Me5 neurons to a similar level as their counterparts 
in Mecp2−/Y mice, and improved breathing function. In identified LC neurons of sMecp2+/− mice, 
the hyperexcitability appeared to be determined by both MeCP2 expression and their 
environmental cues. In conclusion, intervention to extrasynaptic GABAAR by chronic treatment 
with THIP might be a therapeutic approach to RTT-like symptoms in both Mecp2−/Y and Mecp2+/− 
mice models and perhaps in people with RTT as well. 
 
INDEX WORDS: Rett Syndrome, Mecp2, extrasynaptic GABARs, THIP, imbalance of excitation 
and inhibition, locus coeruleus (LC), mesencephalic trigeminal neurons, breathing, social 
behaviors, motor function 
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1 SPECIFIC AIMS AND HYPOTHESES 
Rett Syndrome (RTT) is a neurodevelopmental disease with ~0.01% morbidity rate in live-
born females worldwide [1]. Mutations in the X-linked MECP2 gene encoding methyl CpG 
binding protein 2 (MeCP2), a transcription repressor/regulator, accounts for >90% of RTT cases 
[1]. Mice with Mecp2 knockout (Mecp2−/Y and Mecp2+/− mice) are widely used as RTT animal 
models.  
Patients with RTT and mouse models show dysfunctions in the autonomic nervous system 
such as breathing instability, gastrointestinal disorders and cardiac arrhythmia [2, 3]. The 
norepinephrine (NE) system in the brainstem is affected. Recent studies have shown that in Mecp2
−/Y mice, NE-ergic neurons in the locus coeruleus (LC), the major NE source in central nervous 
system (CNS), manifest themselves as hyperexcitability with reduced NE synthesis and impaired 
CO2 chemosensitivity [4-9]. The inadequate synaptic GABAergic inhibition may contribute to the 
LC neuronal defects as well as the consequent breathing abnormalities [10, 11]. Indeed, several 
recent studies have shown that enhancing synaptic GABAergic inhibition alleviates breathing 
abnormalities in Mecp2−/Y mice [12, 13]. In addition to the synaptic GABAARs, there is a group of 
extrasynaptic GABAARs, interfere with which may potentially be another approach to the neuronal 
hyperexcitation. In contrast to the rich information of the synaptic GABAARs in RTT research [10, 
14-18], however, whether the extrasynaptic GABAARs are affected by the Mecp2 disruption 
remains unknown.  
The extrasynaptic GABAARs are characterized by their high sensitivity to GABA, 
capability to produce long-lasting hyperpolarization (tonic inhibition), and availability for 
modulation by conventional GABAAR ligands as well as more selective extrasynaptic GABAAR 
modulators [19, 20]. With these characteristics, the extrasynaptic GABAARs may be a potential 
 2 
 
novel target for pharmacological and behavioral therapies to alleviate RTT-like symptoms. 
Therefore, we proposed studies to test the hypothesis that extrasynaptic GABAARs are potential 
therapeutical targets for alleviation of RTT-like symptoms in mouse models with RTT. These 
studies addressed four specific aims: 
1. To demonstrate how Mecp2 disruption affects LC neuronal excitability and breathing 
via extrasynaptic GABAARs. 
2. To elucidate how intervention to the extrasynaptic GABAARs moderates RTT-like 
symptoms in Mecp2−/Y mice. 
3. To determine the cellular mechanisms for the extrasynaptic GABAAR mediated 
symptom relieves in Mecp2−/Y mice. 
4. To intervene to neuronal hyperexcitability by extrasynaptic GABAAR agonists in 
Mecp2+/− mice.  
 3 
 
2 GENERAL INTRODUCTION 
2.1 Rett Syndrome  
2.1.1 Overview  
Rett Syndrome (RTT) is a neurodevelopmental disease with ~ 0.01% morbidity rate in live-
born girls worldwide [1]. The disease was first described by Dr. Andreas Rett in 1966 and named 
after him. The genetic link was unknown until 1999 Zoghbi lab at Baylor reported that RTT 
patients showed mutations in MECP2 gene in the X chromosome, demonstrating the underlying 
mechanism for most cases of the disease [21]. The RTT girls are diagnosed usually within 2 years 
after birth based on their symptoms and behaviors. Over 80% of the RTT suspects are further 
confirmed by genetic tests. Although there is no cure for RTT at present, multiple interventions 
are applied clinically, including physical therapy, speech therapy, occupational therapy and 
symptom-targeting medicine treatment. With optimal treatments, the RTT girls are expected to 
live in a better condition till middle Ages. 
2.1.2 Mutations of Mecp2 gene 
Mutations of the X-linked MECP2 gene encoding methyl CpG binding protein 2 (MeCP2) 
underlie over 90% of RTT cases clinically, including T158M and R106W point mutations as well 
as C-terminal truncations [22]. The North American database shows that the missense mutations 
are slightly more common than nonsense ones in RTT clinical cases [22]. The other RTT cases 
were diagnosed clinically as atypical RTT caused mostly by mutations in Forkhead box protein 
G1 (FOXG1) and cyclin-dependent kinase-like 5 (CDKL5) genes [23]. As a general transcriptional 
regulator, MeCP2 has two major functioning domains: the methyl-binding domain (MBD) and the 
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transcriptional repression domain (TRD) where loss-of-function mutations mostly occur. As a 
transcriptional repressor, MeCP2 usually binds to methylated DNA, interacting with repressor 
complexes, including Histone deacetylases (HDAC), and reducing the gene transcription. On the 
other hand, some studies also reported other regulatory roles as a splicing modulator and 
transcriptional activator [24, 25]. MeCP2, expressed in universal cell types, is essential for the 
normal function of nerve cells and particularly important for neuron maturation of CNS. Mutations 
in the MECP2 gene fail to regulate the downstream gene expressions, leading to the development 
of RTT. 
2.1.3 Animal models  
2.1.3.1 RTT male models 
Targeting on the Mecp2 gene, a variety of murine models has been developed in the RTT 
study. The most widely used mouse model is Mecp2−/Y with complete deletions of the functional 
exon 3 and 4 in Mecp2 gene, generated first from Adrian Bird lab [26]. Although fetal death 
happens in humans carrying such mutations, these Mecp2-null mice survive with around 8-week 
lifespan, which allows the laboratory manipulation to uncover the pathology of RTT with a 
uniform genetic background. Mecp2−/− females cannot be produced as the Mecp2−/Y males are 
infertile. These animals suffer most of the severe RTT-like neurological symptoms at 
approximately six weeks old, including social defects and motor dysfunction. The life-threatening 
breathing abnormalities can be detected as early as 3 weeks of age [8, 27].  
R168X is one of most prevalent MECP2 mutations (11.5%) in clinical RTT cases[28]. A 
mouse model Mecp2R168X was developed and widely accepted as well, with truncated protein at 
residue R168 and TRD missing. A study in our lab suggests the Mecp2R168X male model 
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recapitulates the RTT-like neuronal and phenotypical characteristics as Mecp2−/Y mice [29]. 
Indeed, a variety of RTT mouse models manipulating the Mecp2 gene has been generated for 
divergent study purposes. For example, to study the role of GABA system in the development of 
RTT, the mouse model with Mecp2 deletion only in GABAergic neurons was created by Cre-Lox 
recombination system [11]. In addition, the mouse models with point mutations as Mecp2T158M, 
Mecp2308, Mecp2R106W and models with Mecp2 overexpression as Mecp2Tg1 [30] were generated 
and applied to laboratory research as well.  
Recently a novel Mecp2-knockout rat model, the SD-Mecp2tm1sage rat, has been developed 
by Sage Labs in Horizon Discovery Group (Boyertown, PA). These Mecp2−/Y rats recapitulate 
numerous RTT-like symptoms displaying growth retardation, malocclusion, anxiety, and 
breathing difficulties, defects in motor function and social interactions and short lifespan, which 
are comparable to those seen in the Mecp2−/Y mouse model, while some appeared more or less 
severe. Therefore, concerning the limitation for in vivo studies in mice due to their small size, the 
novel rat model provides a valuable alternative model in the RTT studies [31-33]. 
2.1.3.2 Mecp2+/− mice and rats 
Although current studies are mostly performed in the male models that have a uniform 
genetic background, it is necessary to show how these research findings manifest themselves in 
the heterozygous Mecp2+/− females, which usually display phenotypic heterogeneity. This is 
particularly important when potential therapeutics are concerned.  
The heterozygous Mecp2+/− mouse generated in Bird lab is the widely accepted female 
model, which recapitulates divergent RTT-like symptoms but exhibits a much later symptom onset 
as 6 months old. Somaco et al. reported that some of the phenotypes can be detected as early as 5 
weeks old, such as apneic breathing difficulties [34]. Due to the X chromosome inactivation (XCI), 
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55%~85% Mecp2 levels of wide-type (WT) littermate were maintained in the CNS of these 
heterozygous mice with variation of regions, which seems to enable heterozygous Mecp2+/− mouse 
to develop symptoms to a less severe level than the male model with Mecp2 gene completely 
deleted [34]. The Mecp2+/− female rat model was demonstrated recently, which retains a half of 
the MeCP2 protein expression compared to their WT level [33]. Similar to the female mouse model, 
the Mecp2+/− rats display robust RTT-like behavioral and motor defects as well [32, 33], which 
provide a complementary tool for the cross-species study of RTT. In general, more studies of the 
pathophysiology in female RTT models are encouraged regarding their irreplaceable role in the 
potential disease-relevant preclinical study. 
2.2 Symptom development  
2.2.1 Physical condition and lifespan  
RTT is almost exclusively a female disease, due to the fetal death of the male patients. 
Although live birth happens in some the RTT male cases, they cannot survive beyond 2 years. As 
a neurodevelopmental disease, RTT symptoms progress in four stages. In stage I, the retardation 
of the development of language and behavior skills is the characteristic symptom onset in the 
patients, which occurs from 6 to 18 months after birth. The deceleration of the head growth and 
the stereotypic movement appear in this stage as well. In stage II, usually happening between 1 to 
4 years old, the girls exhibit the regression of development, including the deterioration of language 
skills and disinterest to other people. But such communication skills could be resumed at stage III, 
which usually lasts several years. Till Stage IV, more autism-like symptoms show up and may last 
up to decades, including anxiety, seizures, social defects, motor dysfunction and life-threatening 
breathing difficulties. The RTT girls do suffer shorter lifespan. But due to the great phenotype 
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variations among individuals, these girls can be expected to survive into the 40s, 50s and even 
beyond [35].  
RTT murine models (Mecp2−/Y and Mecp2+/−) recapitulate most of the RTT-like symptoms, 
enabling studies of the pathophysiology of the RTT and the potential clinic treatment. Distinct 
from the RTT male cases in human, Mecp2−/Y mice or rats are viable and appear normal at birth. 
Most of the symptoms exhibit from 2~3 weeks old, including malocclusion, hindlimb clasping, 
weight loss, shivering and irregular breathing. These male RTT models suffer short lifespan about 
50-60 days as well [26]. The heterozygous female mice display hindlimb clasping and mobility 
problems starting at around 6 months, with much longer lifespan than the male models. Although 
the brain weight was significantly reduced in RTT female mice and rats, these two models do 
exhibit a protracted disease progression with large variations due to the remaining Mecp2 
containing X chromosome and XCI [36, 37].  
2.2.2 Autonomic dysfunction 
2.2.2.1 General phenotypes in animal models and patients, especially breathing abnormalities 
The autonomic dysfunctions are commonly found in classic RTT cases, shown as breathing 
instability, gastrointestinal disorders, and cardiac arrhythmia. The cardiac rhythm abnormalities 
are described as bradycardic events, sinus pauses, atrioventricular block, premature ventricular 
contractions, non-sustained ventricular arrhythmias, and increased heart rate variability [38]. 
Gastroesophageal reflux, vomiting, gastroparesis, constipation and straining with bowel 
movement are the commonly seen as the gastrointestinal disorder in RTT patients.  
A previous study reported that 26% of RTT patients died of unexplained causes [39]. The 
high rate of sudden death can be attributed to the breathing disorders, characterized by episodic 
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apnea, hypoventilation, hyperventilation and air swallowing, etc.[40, 41] Such breathing 
abnormalities in Mecp2−/Y mice occur at 2~3 weeks old and deteriorate with time. Indeed, long 
lasting apnea is often seen a few days before animal death [42]. Improving breathing regularities 
thus facilitates the survival of Mecp2−/Y mice [43, 44]. Therefore, the severity of breathing 
disturbances may be correlated with the lifespan of mutant mice. As one of the major challenges 
in the RTT, the life-threatening breathing abnormalities need to be concerned seriously.  
2.2.2.2 Dysfunction in neuromodulation by norepinephrine and acetylcholine  
Development of RTT-like breathing difficulties results from multiple neuronal defects, 
including the synaptic imbalance and modulatory disturbance. The neuronal hyperexcitation was 
found in the brainstem, where the respiratory centers are located, involving altered glutamatergic 
excitation and GABAergic inhibition [10, 36, 45]. The neuromodulator NE modulates the synaptic 
transmission, affecting the neuronal networks in the brainstem and the consequent phenotype. In 
the mouse model and patients with RTT, the NE level in the CNS was significantly reduced [46]. 
Pre-Bötzinger complex (PBC) is the respiratory rhythmic generator in the ventrolateral medulla of 
the brainstem. NE modulates the bursting activity and the frequency of PBC neurons via 
noradrenergic receptors respectively. Reduced NE level disturbs the modulation and leads to the 
breathing irregularities in RTT cases, and enhancing the NE content by desipramine, an NE 
reuptake blocker, significantly improves the breathing irregularities in Mecp2-null mice [44, 47].  
A recent study showed that selective disruption of Mecp2 in cholinergic neurons 
recapitulated some RTT phenotypes, such as the cardiac rhythm abnormalities, hypothermia, and 
early death, in the RTT mouse model, and restoration of the gene in cholinergic neurons rescued 
these phenotypes [48]. Thus, the defects in the acetylcholine (Ach) system are involved in the 
autonomic dysfunction, contributing to the early death in RTT. Indeed, Ach modulates the PBC 
 9 
 
neurons via activation of muscarinic receptors, resulting in an increase in breathing frequency. 
Thus, the defect in cholinergic neurons contributes to the RTT-like breathing abnormalities as 
well. 
2.2.2.3 Locus coeruleus nuclei  
As the major NE source in the CNS, LC neurons show defects as altered intrinsic 
membrane prosperities, impaired chemosensitivity and deficit metabolic function in Mecp2-null 
mice [4, 6, 8]. Glutamate, GABA, glycine, Ach and serotonin send divergent signals to the LC 
nuclei, supporting their integrated function. Meanwhile, LC neurons project to divergent brain 
regions, such as the medulla, spinal cord, hypothalamus, and forebrain, affecting a series of 
behaviors. In Mecp2-null mice, both the GABAergic inhibition and Ach modulation in LC area 
were significantly reduced, leading to the neuronal hyperexcitability [10, 49]. This may contribute 
to the impaired NE synthesis and release in LC neurons, evidenced by the reduced expression of 
tyrosine hydroxylase (TH) and dopamine beta hydroxylase (DBH) in LC neurons and the reduced 
NE content in the brainstem [6, 50], and the consequent dysfunction of autonomic system in RTT 
mice. Interestingly, our study suggests that the severity of the breathing abnormalities is positively 
correlated to the neuronal hyperexcitability of LC neurons in Mecp2-null mice and stabilization of 
excessive firing in LC neurons alleviates the breathing difficulties [27]. Thus, the defects of LC 
neurons contribute to the development of autonomic dysfunction, especially breathing 
irregularities, via NE projections in RTT models. 
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2.2.3 Motor defects  
2.2.3.1 General phenotype and the involved systems 
A common feature of most RTT girls is the motor defect that keeps them in the wheelchair 
for the rest of their lives due to their deterioration of motor functions, including the loss of muscle 
tone, stereotypical hand movement, defects in motor coordination and mobility [26]. The abnormal 
gait (such as swaddling) and the retarded mobility are two major problems when scoring the 
phenotype severity of the RTT mouse models [51].  
The cooperation among pyramidal, extrapyramidal and propriosensory systems ensures the 
normal motor function. The pyramidal motor system starts from the motor cortex, control the 
voluntary muscles by directly innervating the motor neurons in the brainstem or spinal cord. The 
extrapyramidal system is part of the motor system contributing to the coordinated movements, 
which is also involved in the regulation or modulation of the motor neurons in the spinal cord. The 
propriosensory neurons contribute to the motor activity by sending the feedback information to 
the motor neurons to ensure the coordinated movement. Increasing evidence suggests that the 
impaired pyramidal motor system results in the motor defects in the RTT patients and mouse 
models. The mitochondria in the skeleton muscle were reported to be dysfunctional due to the 
accumulation of the free radicals and the increase of oxidative stress [52]. In comparison to the 
rich information in the pyramidal motor system, the propriosensory neurons have not been well 
studied yet. Recent studies in our lab showed the propriosensory system was impaired as well, 
contributing to the RTT-like motor defects [53]. 
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2.2.3.2 Mesencephalic trigeminal V nuclei 
The Me5 neurons are the only group of propriosensory neurons with soma located in the 
CNS, which provide servo feedback control to the jaw muscles. The Me5 neurons project to the 
trigeminal motor nucleus, mediating the jaw jerk reflex. In Mecp2-null and Mecp2168R/Y mice, the 
neuronal hyperexcitation was detected in Me5 neurons [29]. In vivo studies in Mecp2ZFN/Y rats 
suggested the hyperexcitation of Me5 neurons contribute the impaired jaw jerk reflex, which is 
consistent with the malocclusion in RTT rats, and defects of chewing, drinking, and teeth grinding 
in RTT [53-56]. Although the reason of Me5 neuronal hyperexcitability in Mecp2-null mice is still 
unknown, the impaired intrinsic membrane properties may contribute [27].  
2.2.4 Dysfunction in social behaviors 
RTT girls developed autism-like social defects, showing a lack of interest in other people, 
preference to be alone, impairment in social communication, etc. These neurological phenotypes 
are usually progressive and long lasting. The mouse models of RTT displayed similar phenotypes, 
which can be achieved by a series of experimental tests, such as social interaction test and three -
chamber test. Although the neurological mechanism underlying the social defects in RTT remains 
unclear, multiple brain regions are known to be involved, such as prefrontal cortex (PFC) and 
basolateral amygdala (BLA). A recent study in rats suggested a reduction of GABAergic inhibition 
in either medial PFC or BLA decreased sociability [57], which may underlie the social defects in 
RTT as the GABA transmission was globally declined in the CNS of RTT models. The impaired 
neuronal networks were widely seen in Mecp2-null mice. The autism-like social defects disorders 
were believed to be correlated to the weak connections in the default mode networks (DMN), 
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which is related to the self-reference, emotional processes, social activities and memory, involving 
the medial PFC and posterior cingulate cortex [58].  
NE plays a role in regulating the social behaviors as well. NE-ergic neurons in the LC 
project broadly to the other brain regions, including the prefrontal cortex (PFC), BLA and other 
cortical areas [59]. In Mecp2-null mice, the normal functions of these regions receiving LC-NE 
projections may be impaired due to the reduced NE content, leading to the progression of the RTT-
like phenotypes, including the social retard. A recent study also reported that the NE reuptake 
inhibitor atomoxetine decreased responding for social play in rats [60]. 
2.3 Potential cellular and molecular mechanisms underlying Symptom development 
2.3.1 Imbalanced inhibition/excitation in the CNS in Mecp2−/Y 
2.3.1.1 Neuronal hyperexcitation/ hypoexcitation  
The disruption of inhibition/excitation ratio in the CNS was believed as one of the 
mechanism of some psychiatric diseases, including schizophrenia, autism spectrum disease, 
Fragile X and Down syndrome [61, 62] [63-65]. In Fragile X syndrome, the reduced excitatory 
neuronal activity and the unaltered inhibitory neuronal activity in neocortical circuits result in the 
network hyperexcitability and consequent epilepsy and cognition problem [63]. In Down 
syndrome, the excessive synaptic inhibition contributes to the cognition impairment, and 
pharmacological innervation to the excitation/inhibition ratio rescued the behavior deficit [64]. 
Such an imbalance was found in mouse models of RTT as well, such as hypoexcited cortical 
activity, hyperexcited hippocampus network and hyperexcited neurons in pons [16, 53, 66, 67]. 
Thus, the imbalanced inhibition/excitation may underlie some pathology of the RTT-like 
symptoms, and maintaining the circuit homeostasis between excitation and inhibition may benefit 
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the patients and mouse models of RTT. Disturbances of the neurotransmission in the CNS caused 
by mutations of the Mecp2 gene may contribute to the network alteration.  
2.3.1.2 Neurotransmission abnormalities  
Although the Mecp2 gene was lost in all the cells in Mecp2-null mice, neurons do not show 
uniform responses. In general, the neuronal hyperexcitation is described in the brainstem nuclei, 
especially the neurons involved in the rhythmic respiration, whereas the neuronal hypoexcitation 
is a feature in the forebrain and midbrain [68]. The imbalanced excitation/inhibition ratio was 
attributed to the abnormal neurotransmission system, which involves GABA and glutamate.  
The GABAergic inhibition is reported to be reduced in the CNS, including the neurons of 
the brainstem, such as the Kölliker-Fuse (KF) and LC [10, 69], resulting in the neuronal 
hyperexcitability. The enhanced excitatory transmission contributes to the hyperexcitation as well 
in the nucleus tractus solitarius (nTS) [70]. The hyperexcitation in these nuclei is associated with 
defects in the autonomic system in RTT patients and mouse models, such as the RTT-like breathing 
abnormalities. On the other hand, the elevated glutamatergic excitation was reported in girls and 
mouse models with RTT [71]. In the forebrain, although the glutamatergic excitation was locally 
enhanced, the overall neuronal output show a hypoexcitation, consequent in the RTT-like 
cognition impairment, which may be related to the potential disinhibition in the neuronal network 
[68]. The downregulated excitatory postsynaptic currents (EPSCs) and the unchanged inhibitory 
postsynaptic currents (IPSCs) lead to the reduced cortical activity [16]. Indeed, ketamine, a NMDA 
glutamate receptor antagonist, rescued the phenotypes in the RTT mouse model [72]. Such a defect 
in the synaptic plasticity was reported as spatial and temporal related, which is consistent with the 
development of the symptoms. Therefore, correction of the disrupted excitation/inhibition ratio in 
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the mouse models and patients with RTT by innervating the GABAergic inhibition or 
glutamatergic excitation may be beneficial for the brain development. 
2.3.2 GABAergic inhibition in Mecp2−/Y mice 
2.3.2.1 GABAergic inhibition (synaptic and extrasynaptic) 
Previous study suggested selective deletion of the Mecp2 gene in GABA-ergic neurons 
recapitulates most RTT phenotypes in mice [11], and selective restoration of the gene in these 
GABAergic neurons resumed the multiple RTT-like symptoms in mouse models [73]. These 
indicate the crucial role of GABA system in the development of the RTT symptoms.  
As the most prominent inhibitory neurotransmitter in the brain, GABA acts via both 
synaptic and extrasynaptic GABARs. Activation of the synaptic GABAARs, usually located in the 
postsynaptic membranes, produces fast IPSCs and hyperpolarizes the postsynaptic cells. The 
extrasynaptic GABAARs known as tonic receptors are characterized by their extrasynaptic 
location, high sensitivity to GABA, and the capability to produce tonic currents with long-lasting 
hyperpolarization [19, 20].  
Both of the synaptic and extrasynaptic GABAARs are pentamers, usually composed of 2-
3 heteromeric subunits of a total 19 (α1-6, β1-3, γ1-3, δ, θ, ε, π, and ρ1-3) subunits [19]. The 
combination pattern of GABAARs shows spatial specificity. The γ2 -containing receptors are 
mainly localized at the synapse, playing a key role in the GABAergic synaptic transmission. The 
δ subunit, usually assembled with 2 α and 2 β subunits, is located exclusively out of the synaptic 
cleft [74]. These receptors are responsible for tonic GABAergic inhibition without interfering with 
synaptic transmission, which is due to their high affinity to GABA and weak desensitization. 
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2.3.2.2 Defects of the GABAergic neurons in Mecp2−/Y mice  
The impaired GABAergic inhibition is widely reported in patients with RTT and mouse 
models and mouse models. In RTT patients, a marked reduction in GABAAR density in the brain 
was reported. [75, 76]. In RTT animal models, the reduced synaptic GABAergic inhibition was 
found in multiple brain regions, including the hippocampus, substantia nigra pars reticulate (SNpr), 
cerebellum and brainstem [10, 17, 66]. Such a GABA deficit showed location-specific and age-
dependent variations in the CNS of RTT mouse model [17, 77]. An epigenetic study in a mouse 
model of RTT indicates that the GABAAR β3 subunit expression is reduced in the cerebellum, 
which was confirmed by another molecular study [78, 79]. In the ventrolateral medulla, where 
contains the respiration rhythm generators such as the pre-Bötzinger complex (PBC), the 
presynaptic GABAergic inhibition was defective and postsynaptic GABAergic inhibition was also 
impaired with reduced expression of α2 and α4 subunits in Mecp2-null mice. Such a defect in 
synaptic GABA system was found as early as 7 days in Mecp2-null mice before the RTT symptoms 
developed [18]. In LC, both GABAA and GABAB receptor mediated postsynaptic inhibition are 
reduced, and the GABA release from presynaptic terminals is significantly low [10], contributing 
to a rise in the excitability of the cells. 
In contrast to the widespread reduction of synaptic GABAergic inhibition, the 
extrasynaptic GABAARs seem well remained in the Mecp2-null mice. The extrasynaptic GABAA 
receptor-mediated tonic inhibition was dose-dependently enhanced in null mice, showing larger 
tonic GABA currents and higher expression level of δ subunit, a marker of extrasynaptic 
GABAARs [67]. The reason causing the different expression of synaptic and extrasynaptic 
GABAARs remains unclear. Considering the characteristic that the extrasynaptic GABAARs have 
the capability to change dynamically their expression levels under different physiological and 
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pathophysiological conditions [80], it is possible that compensatory neuroadaptation is involved. 
Indeed, such an enhancement of the extrasynaptic GABAA receptor-mediated tonic inhibition was 
found in Fragile X syndrome and Angelman syndrome as well, which share many phenotypical 
similarities with RTT [81, 82]. 
Taking the advantage of the GABA system defects, pharmacological interventions have 
been attempted in the RTT mouse models. The therapeutic synaptic GABAAR activators 
diazepines and the GABA reuptake blocker NNC-711 improved the RTT-like breathing 
abnormalities in animal models [12, 13]. However, intervening to the synaptic GABARs may lead 
to the several side effects, including sedation, tolerance and addiction. The extrasynaptic GABARs 
can provide an alternative to avoid such potential side effect, as manipulations of these receptors 
with selective agents do not interrupt GABAergic synaptic transmission. Indeed, exposure to the 
extrasynaptic GABAAR agonist THIP (also called Gaboxadol) relieves multiple RTT-symptoms 
in Mecp2−/Y mice, including the breathing abnormalities [67, 83].  
2.3.3 Glutamatergic excitation in Mecp2−/Y mice  
2.3.3.1 Glutamatergic transmission  
The imbalanced inhibition/excitation ratio in RTT may be attributable to the defected 
excitatory neurotransmission as well. As the major excitatory neurotransmitter present in over 50% 
neurons, glutamate usually depolarizes the postsynaptic cells by activating their metabotropic 
(mGluR) and inotropic receptors (iGluR). The iGluRs form the ion channel pore by four subunits, 
which tend to produce fast excitatory postsynaptic currents (EPSCs). According to their different 
affinity to agonists, the iGluRs are further classified into N-methyl-D-aspartate (NMDA) receptor, 
α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor and kainate (KA) 
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receptor. The mGluRs, G -protein -coupled receptors, indirectly activate ion channels through 
signaling cascades that involves G proteins, which favors producing a prolonged stimulus. 
Activation of the mGluR hyperpolarizes the postsynaptic cells by altering the K+ permeability and 
turning off the cyclic adenosine monophosphate (cAMP) -dependent pathway. 
The defects in glutamatergic signaling are believed to contribute to the autism-like 
characteristics. The enhanced glutamatergic transmission elevated the excitation/inhibition ratio, 
which is associated with epilepsy [84]. Down-regulation of the mGluR5 signaling to 50% 
rebalanced the excitation/inhibition and alleviated the symptoms in Fragile X syndrome [85]. 
Thus, glutamatergic dysfunction affects the excitation/inhibition balance, attributable to the 
development of RTT. 
2.3.3.2 Defects of glutamate system in Mecp2−/Y mice  
A recent study showed that selective deletion of the Mecp2 gene in glutamatergic neurons 
produced some RTT-like symptoms, including premature death, obesity, tremor and anxiety-like 
behaviors, which is different from the phenomena in animals without Mecp2 gene only in 
GABAergic neurons, and restoration of the gene rescued the phenotypes in RTT mouse models 
[45]. Thus, the defects of glutamatergic excitation contributes to the development of RTT 
symptoms in a distinct way from the impaired GABAergic system. 
The alteration of NMDA receptor density was reported to increase in RTT girls under 8 
years old and a reduction in girls older than 10 [71]. Such an alteration of NMDA receptor 
expression was found with location specificity as well in RTT mouse models. In the Mecp2-null 
mice, the age -dependent change of NMDA receptors was reported as bi-phasic in the visual cortex, 
whereas enhanced expression of NMDA receptors was found regardless of age in the thalamus 
[86]. Thus, mutations in the Mecp2 gene altered the glutamate transmission in the CNS as temporal 
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and spatial specificity, which contributes to the RTT-like phenotypes. Furthermore, in the nTS, 
the enhanced glutamatergic excitation leads to the neuronal hyperexcitation and the consequent 
breathing abnormalities [68, 70] in the mouse model with RTT. In the hippocampus, accompany 
with the reduced GABAergic inhibition, enhanced glutamatergic excitation was believed to 
contribute to the network hyperexcitability, consequent in the impairment of learning and memory. 
The altered synaptic trafficking of AMPA receptors contributes to the hyperexcited synaptic 
activity in hippocampus as well [87]. In general, in patients with RTT and mouse models, the 
glutamate level and the glutamate receptor expression were elevated [88], which may lead to the 
neuronal hyperexcitation in different brain regions, underling the disturbed inhibition/excitation 
ratio. Interestingly, Mecp2 mutation enhanced glutamatergic excitation in the forebrain, leading to 
the local hypoexcitation, instead of hyperexcitation, and exposure to the NMDA receptor 
antagonist ketamine alleviated the RTT‐like phenotypes, which may be related to disinhibition 
by presynaptic GABAergic neurons [68].  
2.3.4 Brain-derived neurotrophic factor and Insulin-like growth factor-1 
BDNF, as a member of growth factors, is involved in the neuronal survival, maturation, 
differentiation and synapse plasticity by activation of neurotrophic tyrosine kinase receptor type 2 
(TrkB) via signaling pathways, including PLCγ, PI3K/Akt, and MAPK/ERK. 
Previous genetic studies suggest MeCP2 acts as a transcriptional repressor of BDNF by 
binding to their promoter IV until MeCP2 is phosphorylated and released [89]. Mutations of the 
Mecp2 gene lead an early increase in BDNF content in MeCP2-deficient neurons, followed by the 
progressive reduction in total cellular BDNF in multiple brain regions, which is consistent with 
the delayed onset and the pathological phenotypes deterioration in a mouse model of RTT [90]. 
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One of the major consequences caused by the abnormal BDNF in Mecp2 mutated mice is the 
respiratory irregularity. In Mecp2-null mice, BDNF is critical for the normal development and 
maintenance in the brainstem and nodose ganglia, which are crucial in cardiorespiratory 
homeostasis and autonomic control [91]. The KF, PBC and nTS in the pons and brainstem, where 
the respiratory center located, are modulated by BDNF as well [70, 92, 93]. Reduced BDNF 
content in Mecp2 deficit mice results in the RTT-like breathing abnormalities and restoration of 
normal BDNF level rescued the defects [70, 91].  
In addition, the abnormal BDNF level in the MeCP2 deficit CNS modulates the synaptic 
transmission improperly, contributing to the imbalanced excitation/inhibition ratio and the 
consequent RTT-like symptoms. For example, in KF neurons, application of BDNF significantly 
reduced the IPSCs frequency [92]. BDNF modulates the glutamatergic transmission in nTS 
neurons as a strong reduction of AMPA receptor mediated currents by activating the TrkB 
receptors [94]. In Mecp2-null mice, indeed, the reduced BDNF resulted in the enhanced EPSCs in 
nTS, and exogenous application of BDNF rescued the synaptic defect by reducing the abnormal 
EPSCs [70]. 
Similar to BDNF, the insulin-like growth factor 1 (IGF-1) is widespread in the CNS and 
contributes to the neuron survival and synapse maturation. Studies in mouse models and patients 
with Rett syndrome also reported the beneficial effects of IGF-1, which share similar signaling 
pathways with BDNF [95]. Defects in synaptic structure and plasticity have been demonstrated in 
RTT [89]. IGF-1 treatment increased the synaptic growth and rescued a number of RTT-like 
symptoms in RTT mouse models [96]. Unlike BDNF, the capability of penetrating the blood -
brain barrier (BBB) makes IGF-1 a better candidate for clinical trials.  
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2.3.5 Epigenetic modification 
Epigenetics is a genetic process that changes the gene expression, which is heritable and 
not involved in the changes of DNA sequences. Methylation of genes, modification of histones 
and non-coding RNA (ncRNA)-associated gene silencing are the major types of mechanisms, 
leading to the phenotype changes without alteration in the genotype. Because of their methyl-CpG 
binding domain, MeCP2 binds to methylated DNA and forms a complex with histone deacetylase 
1 (HDAC1) to removes acetyl groups, leading to the chromatin condense and gene regulation. 
There are two methylated forms of DNA: hydroxymethylcytosine (hmC) and methylated cytosine 
followed by a nucleotide (mCH, where H = A, C or T) [97, 98]. These two marks on chromatin 
accumulate during the neuronal maturation and their accumulation is coincident with the increased 
MeCP2 expression. Thus, in RTT patients or mouse models, Mecp2 mutations may lead to the less 
binding to hmC and mCH markers, resulting in the onset of RTT [99]. In addition, in the Mecp2 
deficit neurons, the chromatin disorganization, evidenced by the differential localization of 
chromatin remodeling protein, coincides with phenotypic progression [100]. In general, the 
epigenetic mechanisms might contribute to the delayed onset of the RTT-like symptoms and the 
symptom progression [99].  
2.3.6 X inactivation in Mecp2+/− mice  
2.3.6.1 General information  
In female mammalians, only one copy of X chromosomes is active and the other is 
transcriptionally silenced or inactivated. Such a phenomenon is known as X chromosome 
random inactivation (XCI), which leads to the mosaic expression of the X-linked genes in the 
cells of female animals. Thematically, the X chromosomes from maternal or paternal origin 
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share the same probability to be inactivated, which renders half of the cells to express maternal 
or paternal X chromosome randomly in the early embryogenesis. However, such XCI is not 
always balanced, so that the nonrandom or skewed XCI has been reported, especially in RTT 
patients [101, 102]. Although the classic law of inheritance cannot explain XCI and the genetic 
mechanism remains unclear so far, a mathematical model of genetically influenced choice was 
proposed to fit the XCI pattern distributions [103].  
2.3.6.2 Nonrandom X chromosome inactivation and the impact on phenotypes 
RTT is mostly caused by the mutations of the X-linked Mecp2 gene in heterozygous 
females. Instead of a uniform expression, central neurons show mosaic patterns of MeCP2 
expression in the Mecp2+/− mice due to the XCI, which vary among regions and animal ages [104]. 
The XCI was believed to impact the phenotypic outcome in human patients and female animal 
models [105]. In many cases, RTT girls show random XCI with equal numbers of MeCP2 negative 
or positive cells, which theoretically renders 50% of Mecp2+/− individuals to carry the mutated 
gene. However, nonrandom XCI has been reported to contribute to clinical symptom variations in 
some RTT patients as well [106]. Skewed XCI to the WT may lead to the milder phenotypes in 
the RTT mouse model [102]. Our previous study also suggests that only ~20% the Mecp2+/− mice 
developed breathing disorders [107], which is consistent with the skewed XCI in RTT. Thus, 
nonrandom or preferential XCI may play a role in the phenotypic and individual variations of RTT.  
In addition, in heterozygous females, the MeCP2-negative neurons generally displays 
different morphology from MeCP2–positive cells as shorter dendritic length and smaller cell size 
[108]. The more skewed XCI from the WT allele, the more severe neuronal phenotype of the 
MeCP2-negative cells would be. On the other hand, the MeCP2-negative cells affect the 
development of surrounding WT cells in Mecp2+/− mice as well [109], Therefore, the nonrandom 
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XCI may contribute to the cross-interaction of the MeCP2-negative and –positive cells on 
structural and functional outcomes, depending on the skewed condition.  
2.3.7 Locus Coeruleus Nuclei  
2.3.7.1 Intrinsic membrane properties and CO2 chemosensitivity 
LC is located bilaterally in the dorsal area of the rostral pons, which is involved in many 
behaviors via the widespread projections, especially the regulating the autonomic function as 
breathing activity. Defects of LC neurons are involved in multiple neuropsychiatric disorders, 
including Parkinson's disease, Alzheimer's disease and posttraumatic stress disorder [110, 111]. 
Recent studies in our and other labs have shown that the LC neurons in Mecp2-null mice are 
defective as well, which underlie the pathology of some RTT-like phenotypes. The defect 
manifests itself as abnormal intrinsic membrane prosperities and impaired CO2 chemosensitivity 
[112, 113]. The intrinsic membrane properties of LC neurons were impaired by showing the 
shorter time constant, stronger inward rectification and smaller medium afterhyperpolarization 
(mAHP) amplitude, which may contribute to the LC dysfunction as excessive firing and reduced 
metabolic function [4, 10]. The CO2 central chemoreceptors (CCRs) were found in the brainstem, 
including the LC, which play a critical role in respiratory and cardiovascular controls. In Mecp2-
null mice, the CO2 chemosensitivity of LC neurons was defective, showing the abnormal 
response to mild hypercapnia but normal response to the severe hypercapnia. The overexpression 
of Kir4.1 channel, which reduced the pH sensitivity, in LC area may contribute, allowing the 
neurons detect CO2 until severe hypercapnia develops [8]. Such a defect in LC neurons 
contributes to the RTT-like breathing abnormalities, including high breathing frequency 
variation, apnea, and hyperventilation.  
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2.3.7.2 Norepinephrine biosynthesis and the homeostasis 
As the prominent NE recourses, LC produces ~70% NE throughout the CNS. In patients 
with RTT and mouse models, the monoamine level was significantly reduced, including NE [46], 
leading to the RTT-like phenotypes, such as abnormal breathing activity. It was confirmed by the 
later studies that the expression levels of tyrosine hydroxylase (TH) and dopamine beta 
hydroxylase (DBH), the rate-limiting enzyme in the NE synthesis, were significantly reduced in 
Mecp2-null LC neurons [114]. Desipramine, an inhibitor of NE reuptake, can improve 
respiratory rhythm activity, increases the number of NE containing neurons, and extends the 
lifespan of Mecp2-null mice [44, 47].  
The cause of the NE deficit remains unknown. Mutations of the Mecp2 gene, the general 
transcriptional regulator, may affect the enzyme expressions. The persistent hyperexcitation of 
LC neurons may contribute as well. There may be a homeostatic state between LC neuronal 
excitability and NE biosynthesis, allowing a stable release of NE at synapses. Although high LC 
neuronal excitation may lead to more NE release, persistent hyperexcitability may have adverse 
effects. In Mecp2-null mice, the excessive firing of LC neurons may contribute to their metabolic 
dysfunction by disturbing the homeostasis of NE synthesis, the NE production and NE release 
from presynaptic terminals. The idea is supported by our recent study that further stimulation of 
NE-ergic terminals in a mouse model with Mecp2 null did not improve the NE modulation to 
their target nuclei [115]. Coincidently, the LC neurons in Mecp2-null mice showed the age-
dependent deterioration [27] and the TH expression level was also progressively reduced [50], 
which is consistent with the homeostasis idea as well. Interestingly, our study has shown that the 
severity of breathing abnormalities increases with the increased LC firing rate in the 
symptomatic Mecp2-null mice at similar ages [27], which also indicate the potential linkage 
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between the neuronal hyperexcitability and the declining metabolic function. Other studies also 
reported the tight linkage between the neuronal firing activity and the behaviors of the animals. 
LC cells usually active firing during awake and become silence during rapid eye movement 
(REM) sleep [116]. The altered metabolic function or NE synthesis and release of LC neurons 
may underlie such linkage. In general, in patients with RTT and mouse models, the metabolic 
function of LC was impaired, which may be due to the imbalanced neuronal firing activity and 
NE synthesis. 
2.3.7.3 Defects of cell communications  
As the major NE-ergic nuclei, LC neurons receives signals from and projects to the broad 
brain regions and spinal cord, affecting diverse behaviors, such as breathing, cognition, attention, 
sleep, learning and memory [117]. The LC-NE system sends output to the medulla, where the 
respiratory centers are located, and regulates the breathing activities. The prefrontal cortex 
receives the LC-NE projection as well, which contributes to the cognitive functions, seizure and 
social behaviors [118]. Although previous studies indicate that the LC neurons may function as 
individual cells to innervate divergent brain area distinctively, a viral-genetic tracing study 
suggests LC-NE circuit receives convergent signals from many brain regions through axon 
projections, including cerebellar Purkinje cells, intervening the LC-NE modulation in the target 
regions and the associated behaviors [59]. GABA and glutamate are the major inhibitory and 
excitatory neurotransmitters regulating the LC-NE circuits. One study in our lab reported a local 
group of GABAergic neurons in the dorsomedial area of LC (dmLC) involves the direct or 
indirect regulation in LC-NE output [119]. In patients with RTT and mouse models, the 
abnormal synaptic input affects the normal outcome of LC-NE circuit [10, 14, 49, 67]. Together 
with their internal defects, the abnormal LC-NE circuit makes the system unable to maintain the 
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normal function and leads to multiple RTT-like symptoms. Improving the NE-LC circuits by 
innervating the inputs may benefit their target regions, leading to the alleviation of the associated 
abnormal behaviors in RTT. 
2.4 Therapeutical attempts 
2.4.1 Pharmaceutical intervention  
Since murine models with RTT were generated, pathophysiology of the RTT has been 
studied for decades. Increasing evidence reported the imbalanced neuronal excitation/inhibition 
may underlie the development of the disease. Targeting on the involved neurotransmitters may 
help to alleviate multiple RTT-like symptoms. As the major inhibitory neurotransmitter, GABA 
level was significantly reduced in RTT CNS, and global reduction of GABAergic inhibition shifts 
the excitation/inhibition ratio to the hyperexcitation side. The GABA reuptake blocker (NNC711), 
synaptic GABA receptor agonist (diazepam) and extrasynaptic GABA receptor agonist (THIP) 
significantly alleviate the symptoms, especially breathing irregularities [12]. The overall enhanced 
glutamatergic excitation leads to the skewed excitation/inhibition in the CNS. Ketamine, a 
glutamate receptor antagonist, alleviated the RTT-like phenotypes in the RTT as a disinhibition in 
the forebrain neuronal network [120]. Another weak NMDA receptor blocker, memantine, 
restored the post-tetanic potentiation and paired-pulse facilitation, favors the function 
reinstallation in RTT [121]. Although preclinical trials have not tested these pharmaceutical 
treatments via GABA or glutamate system, the beneficial effects on RTT mouse models 
demonstrated their potentiation.  
The reduced monoamine level was widely reported in patients with RTT and mouse 
models, including NE, dopamine, and serotonin, and increasing their level in the CNS alleviated 
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the RTT-like symptoms. Desipramine, an NE reuptake blocker, significantly ameliorated the 
breathing disorders and expanded their lifespan in Mecp2-null mice [44, 47]. Selective 5-HT1a 
receptor agonists F1599 and 8-OH-DPAT decreased apnea, corrected breathing irregularity and 
improved hand stereotypy and social skills via G protein-coupled inwardly rectifying potassium 
(GIRK) channels in both female and male RTT mouse models [122, 123]. The selective serotonin 
5-HT7 receptor agonist LP-211 rescued multiple RTT-related defective performances, including 
anxiety, motor disabilities, exploratory behavior and memory [124]. As a clinical medicine for l-
dopa-induced dyskinesia, Sarizotan, a 5-HT1a agonist and a dopamine D2-like agonist, was shown 
to have beneficial effects on breathing activity and locomotion in mouse models with RTT as well 
[125]. 
BDNF, involved in the neuronal survival and synaptic plasticity, has been widely 
demonstrated as an overall reduction in the Mecp2-null CNS by both multiple biochemistry and 
genetic methods. Application of exogenous BDNF rescued the synaptic dysfunction in nucleus 
tractors solitaries, leading to the alleviation of cardiorespiratory disorder in RTT [70]. CX546 is 
an ampakine drug, which promotes the activation of AMPA receptors. Chronic treatment of the 
CX546 resulted in the increased BDNF levels in the brainstem and nodose cranial sensory ganglia, 
leading to the rescue of normal respiration in Mecp2-null mice [70]. Environment enrichment, a 
physical intervention that enhances the synapse formation and plasticity, augmented the 
endogenous BDNF in RTT models and ameliorated several RTT-like symptoms, such motor 
coordination, motor learning, memory deficits and anxiety-related behaviors [126]. In general, 
mouse models and patients with RTT benefit from the restoration of normal BDNF level in their 
CNS. In addition, to overcome the limitation of the low-penetration to the BBB for BDNF, BDNF 
can mimic by its alternatives with similar functions were studied. Chronic administration of 7,8-
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dihydroxyflavone, which is able to activate the high -affinity BDNF receptor (TrkB), delayed the 
body weight loss, increased neuronal nuclei size, alleviated the locomotion defects and the 
breathing abnormalities in the RTT mouse model [127]. Insulin-like Growth Factor (IGF-1) was 
also reported to be beneficial to the RTT. In the RTT mouse model, treatment of an active peptide 
fragment of IGF-1 ameliorated the locomotor dysfunction, breathing abnormalities and the cardiac 
irregularities, leading to the extended lifespan [96]. 
In general, although more pharmacokinetics and pharmacodynamics work would be 
required before the clinical trials, these lab studies provide us multiple alternative targets and 
potential treatments for the RTT patients.  
2.4.2 Genetic restoration 
Genetic intervention has been shown to rescue certain phenotypes of RTT as well. Taking 
advantage of current genetic methods, such as Cre-Lox recombination system, the Mecp2 gene 
could be restored in specific nuclei or the whole CNS in RTT mouse models. Selectively 
restoration of Mecp2 gene in GABAergic neurons enhanced GABAergic inhibition, expanded 
lifespan, rescued motor defects and social abnormalities, but tremor or anxiety was not rescued in 
Mecp2-null mice. Such rescue was also detected in Mecp2+/− mice, although less dramatic [73]. 
Conditional mouse models with Mecp2 re-expressionon in glutamatergic neurons showed the 
enhanced abnormal EPSCs and the alleviation of RTT-like phenotypes [45]. Delayed global 
restoration of Mecp2 gene in the brain and body by crossing Mecp2+/− mice containing a “stop-
flox” cassette in Mecp2 gene of one allele with transgenic mice containing the tamoxifen-inducible 
estrogen receptor/Cre transgene in the ROSA26 locus improves the general phenotypic severity, 
rescued multiple RTT-like motor and social behaviors, and improves EEG oscillatory activity in 
Mecp2-deficient mice [128]. However, overexpression of Mecp2 gene in neurons leads to the 
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severe progressive neurological phenotypes as MeCP2 duplication symptom, although opposite 
changes in synaptic transmission were triggered in comparison to the Mecp2 deficiency 
(22781840). Therefore, the precise regulation of MeCP2 expression level is critical in rescuing the 
RTT-like symptoms in patients and mouse models. 
2.4.3 Other therapy 
In current clinical trials, multiple interventions have been applied aiming to improve the 
living quality of the RTT patients and their families, including physical therapy, speech therapy, 
and occupational therapy. Although these RTT patients have to limit achievements due to their 
neurological problems, proper physical interventions favor to maintain motor skills and 
transitional skills, alleviate deformities, discomfort and irritability and improve their independence 
[129]. The language retardation of these RTT girls is one of the major challenges in their daily life, 
which may obstacle the potential treatment due to the improper communication. Speech-language 
pathologists proposed the Augmentative and Alternative Communication (AAC), a 
communication method used in place of speech, could be used as the communication innervation 
in these RTT girls. Written language, body language, and facial expressions, as the typical 
examples of AAC can be used to communicate with the RTT patients [130]. Due to the 
deterioration of the symptoms, RTT girls may lose their independence gradually by reducing the 
meaningful activities in their daily life [131]. Thus, occupational therapy encourages them to 
maintain or improve these functional activities, as this has been shown to improve health. 
Therefore, although, there is no cure for the RTT, multiple innervations have been applied in the 
clinical trials and the RTT girls would benefit from the combination of the treatment. 
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3 SIGNIFICANCE 
Rett Syndrome (RTT) is a neurodevelopmental disease affecting 1 out of 10,000 female 
children worldwide. People with RTT usually develop autism symptoms, including extreme social 
anxiety and repetitive stereotype hand movements, which make RTT a serious clinical problem [1, 
132]. Currently, there is no cure for the disease, neither a therapeutic agent for symptom relieves. 
Thus, studies of seeking for therapeutic modalities are innovative and highly significant. 
Compared to synaptic GABAARs, the extrasynaptic GABAARs are characterized by their 
extrasynaptic location, high sensitivity to GABA, the capability to produce tonic currents, long-
lasting hyperpolarization, and availability for modulation by conventional GABAAR ligands as 
well as more selective extrasynaptic GABAAR modulators [19, 20]. Therefore, it is possible that 
the extrasynaptic GABAARs are potential targets for novel pharmacological and behavioral 
therapies for RTT symptom alleviation.  
THIP (also known as Gaboxadol), an agonist specific extrasynaptic GABAARs [133, 134], 
is an investigational drug, originally developed for insomnia. Clinical trials suggest that THIP 
(10mg/day) has no significant effects on sleep onset and total sleep time [135]. It does have effects 
on these measures in a higher dose (15mg) where the effects are inconsistent between genders, and 
side effects emerge including sedation and disorientation [135, 136]. Therefore, Merck and 
Lundbeck canceled further development of the drug. It is not unusual, however, that a preclinical 
drug fails in one application, but succeeds in another. The low efficacy of THIP on insomnia indeed 
may be beneficial for its applications to RTT, as the unnecessary sedation can be avoided. We 
have found that exposure of low-dose THIP alleviated the RTT-like breathing abnormalities, motor 
dysfunction, social impairment and extends lifespans of Mecp2-null mice [67]. Besides, THIP is 
currently under clinical trials for the Angelman Syndrome and Fragile X Syndrome, which share 
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many similarities with RTT. Therefore, pre-clinical studies of the drug in RTT-models as proposed 
in our studies are significant.  
 
  
 31 
 
4 MATERIAL AND METHODS 
4.1 Animal models 
Female heterozygous mice (Genotype: Mecp2+/−; Strain name: B6.129P2(C)-
Mecp2tm1.1Bird/J; Stock number 003890, Jackson Lab) from were crossbred with male C57BL/6 
mice to produce the RTT model mice with the genotype Mecp2+/− and Mecp2−/Y for further study. 
The PCR protocol from Jackson Lab was used to identify the genotypes. All experimental 
procedures were conducted in accordance with the National Institutes of Health (NIH) Guide for 
the Care and Use of Laboratory Animals and were approved by the Georgia State University 
Institutional Animal Care and Use Committee.  
4.2 THIP Administration 
THIP was delivered to the test animals orally in the drinking water. THIP was given to the 
mother in her drinking water (200mg/L), and then passed to pups of WT and Mecp2−/Y male mice 
via lactation [15]. This will last till weaning at P18. After that, THIP was given through pup’s 
drinking water (20mg/L) for another 5 weeks. In the vehicle control group, THIP was replaced by 
regular water. 
In Mecp2+/− mice, identification of RTT-like symptoms was done at 6-9 months of age. 
Then, the symptomatic mice were divided into two groups treated with THIP (20mg/L in drinking 
water with the calculated dose: 6.3 mg/kg/day in animals) or water alone (vehicle) for 5 
consecutive weeks. The same protocol was applied to WT females as controls.  
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4.3 Brain slice Preparation 
Mice were decapitated after deep anesthesia with inhalation of saturated isoflurane. The 
brain stem was obtained and immediately placed in ice-cold and sucrose-rich artificial 
cerebrospinal fluid (aCSF) containing (in mM): 220 sucrose, 1.9 KCl, 0.5 CaCl2, 6 MgCl2, 33 
NaHCO3, 1.2 NaH2PO4 and 10 D-glucose. The solution was bubbled with 95% O2 balanced with 
5% CO2 (pH 7. 40). The transverse pontine sections (150-250 µm) containing the LC area were 
obtained using a vibratome sectioning system and then recovered at 33°C for 60min in normal 
aCSF containing (in mM): 124 NaCl, 3 KCl, 2 CaCl2, 2 MgCl2, 26 NaHCO3, 1.3 NaH2PO4 and 10 
D-glucose. The brain slices were kept at room temperature before use. During recording, the slices 
were perfused with oxygenated aCSF at a rate of 2 ml/min and maintained at 34°C in a recording 
chamber by a dual automatic temperature control (Warner Instruments). 
4.4 Electrophysiology  
LC and Me5 neurons were identified as described previously [14, 53]. Whole-cell voltage 
clamp and whole-cell current clamp were performed with patch pipettes. Sutter pipette puller 
(Model P-97, Novato, CA) was used to pull the patch pipettes with resistance as 3–5 MΩ. Only 
the neurons with membrane potential less than -40 mV (LC) or -50mV (Me5) and action potential 
(AP) over 65 mV were accepted for further experiments. In voltage clamp, the pipettes were filled 
with solution containing in mM: 50 KCl, 85 CsCl, 2 MgCl2, 2 Mg-ATP, 1 Na-GTP, 10 HEPES, 
0.5 EGTA (pH 7.30). The brain slices were perfused with oxygenated aCSF containing in mM: 
130 NaCl, 3.5 KCl, 1.25 NaH2PO4, 1.5 MgSO4, 10 D-glucose, 24 NaHCO3, 2 CaCl2 (pH 7.40). 
GABAAR-mediated inhibitory postsynaptic currents (IPSCs) and tonic currents were isolated with 
following agents in the bath solution: 6-cyano-7-nitroquinoxaline-2, 3-dione (CNQX, 10 µM, 
 33 
 
Tocris, Minneapolis, MN, disodium salt), the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid (AMPA) receptor antagonist; DL-2-amino-5-phosphonopentanoic acid (DL-APV, 10 µM, 
Tocris, sodium salt), the N-methyl-D-aspartate (NMDA) receptor antagonist; and strychnine (1 
µM, Sigma-Aldrich, St. Louis, MO), the glycine receptor antagonist. All recordings were 
performed at a holding potential of –70 mV. Tetrahydroisoxazolo [5, 4-c] pyridin-3-ol 
hydrochloride (THIP, also known as gaboxadol, Tocris, hydrochloride), 4-chloro-N-[2-(2-thienyl) 
imidazo [1, 2-a] pyridin-3-yl] benzamide (DS2, Tocris), bicuculline (Tocris) and picrotoxin 
(Sigma-Aldrich) were used to measure the tonic current in the study. In current clamp, the pipette 
solution containing in mM: 130 K gluconate, 10 KCl, 10 HEPES, 2 Mg-ATP, 0.3 Na-GTP and 0.4 
EGTA (pH 7. 3). The bath solution was normal aCSF bubbled with 95% O2 and 5% CO2 (pH 7. 
40). Recorded signals were amplified with an Axopatch 200B amplifier (Molecular Devices, 
Union City, CA), digitized at 10 kHz, filtered at 1 kHz, and collected with the Clampex 8.2 data 
acquisition software (Molecular Devices). The temperature was maintained at 33°C during 
recording by a dual automatic temperature control (Warner Instruments, New Haven, CT).  
Membrane potentials were measured without any current injection. In LC neurons, the 
input resistance was calculated as the slope of the linear portion in the I-V curve in response to a 
series of injected pulse hyperpolarized currents (typically from 0.15nA to 0nA). The AP overshoot 
was measured as the amplitude from 0mV to the peak of more than 20 events. The threshold was 
determined at the initiation point of at least 20 spontaneous action potentials. In Me5 neurons, APs 
were evoked with depolarizing pulses. AP properties (threshold, amplitude, rise time and D50) 
were analyzed from the first evoked APs. 
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4.5 Molecule experiments 
4.5.1 Quantitative PCR  
Brain slices were obtained from 3-4 week old mice. Transcripts were obtained from 
micropunches (~ 1.5mm in diameter) from the LC area, and cDNAs were synthesized with the 
high-capacity cDNA reverse transcription kit (Life Technologies, Grand Island, NY). PCR primers 
for GAPDH, δ subunit, α4 subunit, α5 subunit, α6 subunit, β1 subunit, β2 subunit, β3 subunit, TH 
and DBH were designed with the primer express software and synthesized from Sigma Genesis 
(Sigma-Aldrich). The Quantitative PCR (qPCR) was performed with Fast SYBR® Green Master 
Mix (Applied Biosystems, Life Technologies) following the manufacturer’s instructions in a Fast 
Real-time PCR system (Applied Biosystems 7500) for 40 cycles. GAPDH was used as the internal 
control for the quantification. 
4.5.2 Single cell PCR  
Transcripts were obtained from single LC neurons that had been studied in whole-cell 
current clamp experiments. The cDNAs were synthesized with the high-capacity cDNA reverse 
transcription kit (Life Technologies, Grand Island, NY). Three microliters of reverse transcription 
product were used to perform PCR with Taq DNA Polymerase (Promega, Madison, WI) for 30 
cycles following the manufacturer’s instructions. Three microliters of the PCR product were 
performed using the same PCR cycling protocol as before. The second PCR product was run on 
2% agarose gels, which was then imaged using an Alpha Innotech AlphaImager 3400 Multi-
Function Gel Imager (Alpha Innotech, Santa Clara, CA). Glial fibrillary acidic protein (GFAP) 
was used as the negative control. Primers for Mecp2 were designed with online primer-BLAST 
and synthesized from Sigma (Sigma-Aldrich, St. Louis, MO).  
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4.5.3 Western Blot 
Pontine slices (300 µm thick) containing the LC area were obtained from 3- to 4-week-old 
mice by vibratome sectioning system and the pons was processed in RIPA buffer (Sigma-Aldrich) 
with 1% protease inhibitor. BCA protein assay reagent (Pierce, Rockford, IL) was used to estimate 
the protein concentrations and 30 µg proteins were used to detect δ subunit signals in 10% SDS-
PAGE gels and electrophoretically transferred to nitrocellulose membranes. The membranes were 
then blocked for 2 h in 5% non-fat milk and incubated overnight at 4 °C with rabbit GAPDH 
primary antibody (1:10000, Sigma-Aldrich) and rabbit δ subunit primary antibody (1:1000, EMD 
Millipore, Billerica, MA) [137]. After washed in PBS Tween, the membranes were incubated by 
HRP-conjugate goat anti-rabbit secondary antibody (1:10000, Life Technologies) for 1h at RT. 
The chemiluminescent detection system (Pierce) was used to expose the membrane to films (Hy 
Blot CL; Denville, Metuchen, NJ) and the photographs were scanned. The immunoblotting signals 
were quantified using the ImageJ software (NIH). The δ subunit signals were normalized to the 
internal GAPDH controls. 
4.5.4 Immunocytochemistry  
Mice were anesthetized by inhalation of saturated isoflurane and transcardially perfused 
with 0.9% saline and 4% (w/v) paraformaldehyde in 0.1M PBS, sequentially. Then, the brain was 
removed, fixed with 4% (w/v) paraformaldehyde for 2 hour and transferred to a 30% sucrose 
solution in 0.1M PBS. Pontine transverse sections (30 μm) containing the LC region were obtained 
on a cryostat (Leica, Wetzlar, Germany). Catecholaminergic neurons were labeled with anti-
dopamine β-hydroxylase (TH) and cells. MeCP2 expression was detected with anti-MeCP2 
antibodies. Briefly, the sections were incubated with primary anti-TH antibodies (mouse; 1:4,000; 
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Sigma, St. Louis, MO) and anti-MeCP2 antibodies (Rabbit; 1:1,000; Sigma, St. Louis, MO), 
followed by Alexa Fluor 488-conjugated donkey anti-mouse (1:400; Life Technologies) and Alexa 
Fluor 647-conjugated goat anti-rabbit (1:500; Life Technologies) secondary antibodies. All the 
steps were performed at room temperature.  
For quantification of TH or MeCP2 immunoreactivity, each slices were captured as two 
images, which were then analyzed using ImageJ software. Around 10 images were used in each 
animal, and the immunoreactivity of each cell was scored and recorded. In general, 4 animals in 
each group were used in the experiments. The median of TH-positive cell numbers in each image 
is ~25 in each image and percentages of MeCP2-positive and MeCP2–negative cells were 
analyzed. 
4.6 Behavior Tests 
4.6.1 Plethysmograph 
The breathing activities of unanesthetized mice were recorded by the plethysmograph 
system with a ~ 40 ml plethsmograph chamber and a connected reference chamber. The 
individual animal was kept in the plethysmograph chamber flowed by air at a rate of 60ml/min 
for at least 20 min for adaptation followed by a 20 min recording. The breathing activities were 
recorded continuously as the barometrical changes between the plethysmograph chamber and the 
reference chamber with a force-electricity transducer. The signal was amplified and collected 
with Pclamp 9 software. The animals were monitored via a video camera to ensure the awake 
status during tests. The data analysis was done blindly to the treatment. Apnea was considered 
only if the breathing cycle lasts twice or longer than the previous cycle. Breathing frequency 
variation was calculated as the division of standard deviation (SD) of the frequency by their 
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arithmetic mean. All of were measured from 200~300 successive breathing events, which were 
randomly sampled from three or four stretches with at least 50 breaths in each. 
4.6.2 Grip Strength 
When lifted by the tail, the forelimbs of a mouse (age 5-6 weeks) were allowed to grasp 
the sensor lever of a force-electricity transducer. The mouse was then gently pulled upward by the 
tail until it released the grip. Forces were continuously recorded with the Clampex 9 software. The 
grip strength of each mouse was measured as the maximum force before lever release, and 
averaged from three consecutive trails.  
4.6.3 Grid Walking 
A mouse (age 5-6 weeks) was placed on the metal rigid floor of a trial box (32 cm × 20 cm 
× 20 cm). The box was elevated by 50 cm with the floor made of 11 × 11 mm metal mesh. Mouse 
walking on the metal mesh floor was videotaped for 5 minutes. In the video record, the limb 
placement error was counted. A footfault was counted only when a limb missed the metal floor 
bar (0.5mm in diameter) completely and went through the grid opening. The footfault ratio was 
calculated by the overall numbers of footfaults divided by the total steps including both forelimbs 
and hindlimbs. 
4.6.4 Open Field test of spontaneous locomotion 
The experiment was performed as we described previously [31]. Mice aged 5-6 weeks were 
tested in an open field chamber made of white plexiglass boards (50 cm L × 50 cm W × 30 cm H) 
with 10 cm × 10 cm square lines. Test animals were kept in their home cages and habituated for 
30 min in the test room before testing. When tested, each animal was placed in the center square 
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and allowed to move freely in the chamber. Spontaneous locomotion activity was monitored by a 
video camera for 5 min. With the video record, square crosses (all four paws cross) were measured 
in each mouse. To eliminate potential residual odors and potential contaminants, 70 % ethanol was 
used to clean the apparatus followed by dd H2O rinse after each test. 
4.6.5 Three Chamber (Social Interaction) 
Mice, age 6-7 weeks, were tested in a box (60 cm L × 30 cm W × 40 cm H), in which there 
were three chambers (20 cm L × 30 cm W × 40 cm H) separated with transparent walls. A door 
was arranged diagonally in each wall allowing the tested mouse to travel freely in the chambers. 
Before test, mice were placed in the test room for 30 min habituation. Then sequential tests were 
performed in each mouse. Firstly, the tested mouse was placed in the center chamber, and allowed 
to move freely over all three chambers for 10 min. Its chamber preference was analyzed by the 
time spent in each chamber. Secondly, the social behavior test was performed by introducing a 
random littermate in one of the side chambers for 10 min, while times that the tested mice spent 
with the mice were measured. The littermate was randomly assigned in either side of the chamber 
to avoid the side bias. Lastly, the social novelty test was performed by introducing a new stranger 
mouse in the chamber and switching the familiar littermate to the other chamber. The time spent 
in both side the chambers were analyzed subsequently [138].  
4.6.6 Lifespan 
Mecp2−/Y mice used in the experiment were randomly selected and divided into two groups. 
One group was treated with THIP containing water, and the other treated with regular water as 
vehicle control. Their lifespan were monitored under the identical living condition. Their daily 
activity and general physical conditions, including feeding, movement, body weight, interaction 
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with other mice, were observed. Death date of each mouse was recorded when it occurred naturally 
or reached the humane end point that was determined by staff members in the animal facility at 
Georgia State University without any consultation with the investigators. One outlier, which was 
1.5 interquartile range (IQR) above the third quantile and below the first quantile, was removed 
from each group to minimize data variations.  
4.6.7 Phenotype scoring system 
To separate the Mecp2+/− mice, a two-step identification procedure was used. Firstly, we 
adopted the scoring system proposed previously [51] with modifications to determine potential 
symptomatic Mecp2+/− mice, which consisted of 1) abnormal mobility, 2) abnormal gait, 3) 
hindlimb clasping, 4) tremor, 5) abnormal breathing, and 6) weak general condition. Score 0 was 
assigned to a mouse if none of these signs was found; the animal was scored 1 if any one of the 6 
signs was shown to be mild (score 6 if the mouse showed all); score 2 if any of the signs was severe 
(maximum 12). The Mecp2+/− mouse was placed in the potential symptomatic group if it received 
3 scores or more. Secondly, the mouse was considered to be symptomatic when it also showed 
breathing abnormality in the plethysmograph test as we reported previously [107]. Only were the 
symptomatic Mecp2+/− (sMecp2+/−) mice used in the present study, which were divided into two 
groups and treated with vehicle or THIP.  
4.7 Double Blind 
The animals used in the study were randomly separated into vehicle group and THIP group. 
The patch experiments were done double-blindly by two to three people without information of 
mouse genotype and treatment. All the data analysis of behavior experiments, including breathing 
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activity, motor function and social behavior were done with no information of the genotype and 
treatment. 
4.8 Data Statistics 
The electrophysiological data and the plethysmograph data were analyzed with Clampfit 
10.3 software. The sample sizes in the experiments were examined with G-Power Analysis to yield 
sufficient statistical power [139]. Data are presented as means ± SE or median ± IQR. Mantel-Cox 
test was used in the lifespan experiment. Two-tailed Student’s t-test, ANOVA, Tukey’s or Fisher’s 
LSD post-hoc, Kruskal-Wallis test, Pearson correlation and Spearman’s correlation were used to 
perform the statistical analysis. Difference was considered significant when P < 0.05.  
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Table 4.1: Primers for PCRs 
Target gene Primers Sequences 
GAPDH  Fw: CCAGCCTCGTCCCGTAGA 
 Re: TGCCGTGAGTGGAGTCATACTG 
δ subunit  Fw: GGCTTCTTGGGCTTTACC 
 Re: CACCCCCACTGTTTTTCTC 
α4 subunit  Fw: GTGGGAAATCACTCCAGCAAG 
 Re: AATGCAGGGCGAGTGGAAG 
α5 subunit  Fw: CAAAAGAGCAGCCTCCAG 
 Re: GAAAGTGCCAAACAAGATGG 
α6 subunit  Fw: GACTTTGCCCATCGTTCC 
 Re: TGCAAAAGCTACTGGGAAGAG 
β1 subunit  Fw: TGGTTTTCGATCTTGTGTGTCAG 
 Re: AGCCACCTCTCTCTTTGTGTTTG 
β2 subunit  Fw: TTCCCACTGCTGTTTCTCACATAC 
 Re: ATCCTAACCACTTCTCCTTTTTTCC 
β3 subunit  Fw: GTTGAGTGGTTGTGTTGCCAATG 
 Re: ATGTCCCCGTGTTGGCATC 
TH  Fw: TGGCTGACCGCACATTTG 
 Re: CCTGCACCGTAAGCCTTCA 
DBH  Fw: TACCACAACCCACGGAAGATA 
 Re: CGGTCAACACAAAGGCAGTCT 
Mecp2  Fw: CCAAATCTCCCAAAGCTCCA 
 Re: GCTTGGAAAGGCATCTTGAC 
 
GAPDH; glyceraldehyde 3-phosphate dehydrogenase, TH; tyrosine hydroxylase, DBH; 
dopamine b-hydroxylase. 
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5.1 Abstract 
People with Rett Syndrome (RTT) and mouse models show autonomic dysfunction 
involving brainstem locus coeruleus (LC). Neurons in the LC of Mecp2-null mice are overly 
excited, likely to result from defect in neuronal intrinsic membrane properties and deficiency in 
GABA synaptic inhibition. In addition to the synaptic GABA receptors, there is a group of GABAA 
receptors (GABAARs), which is located extrasynaptically, and mediates tonic inhibition. Here we 
show evidence for augmentation of the extrasynaptic GABAARs in Mecp2-null mice. In brain 
slices, exposure of LC neurons to GABAAR agonists increased tonic currents that were blocked 
by GABAAR antagonists. With 10 µM GABA, the bicuculline-sensitive tonic currents were ~ 4 
folds larger in Mecp2-null LC neurons than the wild-type (WT). Single-cell PCR analysis showed 
that δ subunit, the principal subunit of extrasynaptic GABAARs, was present in LC neurons. 
Expression levels of the δ were ~ 50% higher in Mecp2-null neurons than in the WT. Also 
increased in expression in Mecp2-null mice was another extrasynaptic GABAAR subunit α6 by ~ 
4 folds. The δ subunit-selective agonists THIP and DS2 activated the tonic GABAA currents in LC 
neurons and reduced neuronal excitability to a greater degree in Mecp2-null mice than in the WT. 
Consistent with these findings, in-vivo application of THIP alleviated breathing abnormalities of 
conscious Mecp2-null mice. These results suggest that extrasynaptic GABAARs seem to be 
augmented with Mecp2 disruption, which may be a compensatory response to the deficiency in 
GABA-ergic synaptic inhibition and allow a control of neuronal excitability and breathing 
abnormalities.  
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5.2 Introduction 
Rett Syndrome (RTT) is a neurodevelopmental disease with ~ 0.01% morbidity rate in live-
born females worldwide [1]. Over 90% of RTT cases are caused by mutations of the X-linked 
MECP2 gene encoding methyl CpG binding protein 2 (MeCP2), a transcription regulator [1]. 
People with RTT usually develop autism-like symptoms 6 to 18 months after birth, which include 
stereotypical repetitive hand movements, social anxiety and seizures. Dysfunctions in the 
autonomic nervous system such as breathing instability, gastrointestinal disorders and cardiac 
arrhythmia are common [2, 3].  
The NE system in the brainstem is involved in autonomic function, especially NE-ergic 
neurons in the locus coeruleus (LC). Recent studies in our and other labs have shown that the LC 
neurons in Mecp2-null mice are abnormal or defective. The defect manifests itself as reduced 
expression of NE synthetic enzymes, hyperexcitability and impaired CO2 chemosensitivity [4-9]. 
The hyperexcitability of LC neurons is attributable to the intrinsic membrane properties of the cells 
and a decrease in synaptic inhibition mediated by γ-aminobutyric acid (GABA) [4, 10]. Both 
GABAA and GABAB receptor mediated postsynaptic inhibition are reduced, and the GABA 
release from presynaptic terminals is significantly low [10]. Consistent with these observations, 
defects in the GABAA receptor (GABAAR) system are also found in other brain regions [17, 18, 
78, 140]. Selective deletion of the Mecp2 gene in GABA-ergic neurons recapitulates most RTT 
phenotypes in mice [11]. These findings indicate that the GABA system plays an important role 
in the development of RTT.  
GABA is the most prominent inhibitory neurotransmitter in the brain acting on both 
synaptic and extrasynaptic GABARs. The synaptic GABAARs are found in postsynaptic 
membranes of neurons. In adult neurons, activation of the synaptic GABAARs produces fast 
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inhibitory postsynaptic currents and hyperpolarization of the postsynaptic cells. The extrasynaptic 
GABAARs known as tonic receptors are characterized by their extrasynaptic location, high 
sensitivity to GABA, capability to produce tonic currents with long-lasting hyperpolarization, and 
availability for modulation by conventional GABAAR ligands as well as more selective 
extrasynaptic GABAAR modulators [19, 20]. 
Both of the synaptic and extrasynaptic GABAARs are pentamers, usually composed of 2-
3 heteromeric subunits with a total 19 (α1-6, β1-3, γ1-3, δ, θ, ε, π, and ρ1-3) [19]. GABAARs with 
different combinations of subunits are found in different neurons. γ2 containing receptors are 
mainly localized at the synapse, playing a key role in the GABA synaptic transmission [141, 142]. 
The δ subunit, usually assembled with 2 α and 2 β subunits, is the major contributor of the 
extrasynaptic GABAARs [20, 142]. These receptors are responsible for tonic GABA inhibition 
without interfering with synaptic transmission, which is due to their high affinity to GABA and 
weak desensitization. 
The findings of defects in synaptic GABAAR-mediated synaptic inhibition in Mecp2-null 
mice are encouraging because therapeutical GABAAR activators are widely available. These drugs 
may be used to correct the defects in the GABA system and relieve RTT-like symptoms. Indeed, 
several recent studies have shown that the breathing disorders of Mecp2-null mice can be alleviated 
by augmenting GABA synaptic inhibition [12, 13]. In contrast to the rich information of the 
synaptic GABAARs in RTT research [10, 14-18], how the extrasynaptic GABAARs are affected 
by the Mecp2 disruption remains unknown. The capability of these tonic GABAARs to reduce 
neuronal excitability without interrupting synaptic transmission suggests that these receptors may 
allow an alternative therapeutic intervention to RTT. Therefore, we studied the extrasynaptic 
GABAA currents in LC neurons in wild-type (WT) and the mouse model of RTT. 
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5.3 Results 
5.3.1 GABAA-ergic tonic currents in WT neurons 
To determine the GABAA tonic currents in LC neurons, whole-cell voltage clamp was 
performed in brain slices of WT mice. Inward Cl− currents were studied, with 135 mM Cl− in both 
the pipette and bath solutions at a holding potential of -70 mV, with glutamatergic and glycinergic 
currents were blocked (see Methods). Under this condition, the LC neurons showed spontaneous 
GABA-ergic IPSCs that were blocked by bicuculline (50 µM) or picrotoxin (20 µM). Meanwhile, 
we found that these GABAA-R blockers also suppressed tonic inward currents. Thus, we studied 
the GABAA-ergic tonic currents. The currents histograms were generated at stable condition before 
and after GABAAR blockade, which were then fit with Gaussian distribution. The opening of the 
ionotropic receptors also increases the current noise levels, which were measured as the standard 
variation of the Gaussian distribution. We analyzed the ratio of noise levels before vs after a 
treatment with GABAAR blockers.  
Bicuculline reduced the tonic currents by 2.9 ± 0.6 pA (n = 5), and the noise ratio is 1.31 
± 0.06 (n = 5) (Fig. 5-1B). Similar results were obtained with picrotoxin (Fig. 5-1A). The effects 
of bicuculline on the tonic currents and the noise ratio were more obvious in the presence of GABA 
in the perfusion solution. A pre-treatment with 1 μM GABA augmented the tonic currents to 5.0 
± 1.0 pA, and the noise ratio to 1.37 ± 0.08 (n = 5) (Fig 5-1C). With 10 μM GABA, the tonic 
currents were raised to 13.6 ± 1.4 pA (n = 6), and the noise ratio to 3.97 ± 0.76 (n = 6) (Fig 5-1D). 
The bicuculline sensitive tonic currents and noise augmentation increased dose-dependently with 
increased GABA concentrations (P < 0.001, One-way ANOVA) (Fig. 5-1E, F, G).  
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5.3.2 Enhancement of GABAA-ergic tonic currents in Mecp2-null mice  
At baseline, the bicuculline-sensitive tonic currents were significantly larger in Mecp2-null 
mice than in WT mice (6.4 ± 0.8 pA, n = 5 vs. 2.9 ± 0.6 pA, n = 5; P ˂ 0.01, Student’s t-test; Fig. 
5-2A, D, E). These tonic currents in Mecp2-null mice became even greater in the presence of 1 
µM or 10 µM GABA, which were 13.5 ± 1.7 pA (n = 5) and 49.8 ±10.7 pA (n = 6) respectively. 
Both were significantly higher than in the WT neurons (P ˂ 0.001 and P ˂ 0.01, Student’s t-test; 
Fig. 5-2B, C, D, E). In Mecp2-null mice, the noise ratio also increased dose-dependently with these 
GABA concentrations (1.74 ± 0.08 and 7.77 ± 1.21, respectively; P < 0.01 and P < 0.05, 
respectively; Student’s t-test; Fig. 5-2F) although significant difference was not found at baseline. 
These results suggest that the bicuculline-sensitive tonic currents are significantly increased in 
Mecp2-null LC neurons. 
5.3.3 Effects of specific agonists for extrasynaptic GABAARs 
The GABAA-ergic tonic currents are likely to be mediated by extrasynaptic GABAARs 
expressed in the LC neurons. Because the molecular compositions of extrasynaptic GABAARs are 
different from those of synaptic GABAARs, these extrasynaptic receptors can be activated with 
selective agonists such as THIP and DS2 that do not affect the synaptic GABAARs [133, 134]. In 
the presence of 1 µM THIP in the bath solution, the GABAA-ergic tonic currents (18.6 ± 2.9 pA, 
n = 5) and noise ratio (1.94 ± 0.07, n = 5) were both augmented in WT neurons (Fig. 5-3A). In 
Mecp2-null neurons the same concentration of THIP raised the tonic currents (55.3 ± 6.6 pA, n = 
5) and the noise ratio (2.91 ± 0.29, n = 5) to significantly greater degrees than in the WT neurons 
(P < 0.001 and P < 0.01, respectively, Student’s t-test; Fig. 5-3B-E). THIP did not affect frequency 
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and amplitude of the GABA-ergic IPSCs in both WT and Mecp2-null LC neurons (Student’s t-
test; Fig. 5-3F-I).  
Similarly, application of DS2 (20 µM), a positive allosteric modulator of extrasynaptic 
GABAARs, augmented the tonic currents and noise ratio. This effect was larger in Mecp2-null 
mice (19.5 ± 2.3 pA, 2.32 ± 0.21, respectively; n = 5) than in the WT mice (8.5 ± 1.2 pA, 1.53 ± 
0.07, respectively; n = 5; P < 0.01 and P < 0.01, respectively, Student’s t-test; Fig. 5-4A-E). Unlike 
THIP, DS2 augmented the frequency and amplitude of the GABA-ergic IPSCs in LC neurons, 
which may be attributed to their affinity for the αβ type GABAARs. Despite this, we did not find 
significant differences between WT and Mecp2-null mice (Student’s t-test; Fig. 5-4F-I). These 
results indicate that the extrasynaptic GABAARs existing in LC neurons seem to have a greater 
effect on LC neuronal activity in Mecp2-null mice. 
5.3.4 Differential expression of GABAAR subunits in WT and Mecp2-null mice 
The δ subunit is the principal component of extrasynaptic GABAARs, which is localized 
exclusively outside of the synaptic cleft, mediating the GABAA-ergic tonic currents [143]. If 
Mecp2-null LC neurons have more extrasynaptic GABAARs, the δ subunit should be expressed in 
these cells at a higher level than in the WT neurons. To test this possibility, we studied the δ subunit 
expression in mRNA and protein levels. Single-cell PCR analysis showed that the δ subunit was 
expressed in most LC neurons in both WT and Mecp2-null mice (14 of 14 WT neurons and 15 of 
17 Mecp2-null cells; Fig. 5-5A), consistent with the presence of GABAA-ergic tonic currents in 
the LC neurons.  
In quantitative PCR (qPCR), the δ subunit was found to be expressed in the WT LC neurons 
with the 2−∆Ct method. With the 2−∆∆Ct method, the expression level of the δ subunit increased by 
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1.8 ± 0.5 folds in LC tissue micropunches obtained from Mecp2-null mice in comparison to the 
WT (n = 9, P < 0.01, Student’s t-test; Fig. 5-5B-D). The Western blot analysis showed that the δ 
subunit protein expression was increased by 1.6 ± 0.1 folds in Mecp2-null mice over the WT (n = 
6, P < 0.01; Student’s t-test, Fig. 5-5E, F). These results suggest that the δ subunit is expressed in 
LC neurons, and its increased expression in Mecp2-null mice may contribute to the abundant tonic 
GABAA currents. 
The α5 subunit is another important contributor to the extrasynaptic GABAARs [144, 145]. 
In single-cell PCR, the α5 transcript was barely detected in LC neurons (0 out of 14 in WT and 2 
out of 17 in Mecp2-null). The qPCR analysis showed that α5 expression in LC neurons was only 
about one third of δ subunit expression in WT mice. There was a significant reduction of α5 
expression in Mecp2-null mice (n = 5, P < 0.05, Student’s t-test; Fig. 5-5B-D), suggesting that the 
large tonic currents in Mecp2-null mice were unlikely to be produced by increased α5 expression.  
The δ containing extrasynaptic GABAARs are usually composed of 2 α and 2 β subunits. 
Previous studies report that all the 3 β subunits (β 1 – 3) and α4, α6 subunits contribute to the 
assembling of extrasynaptic GABAARs [20, 74, 146]. In qPCR, α6 expression was increased by ~ 
4 folds in Mecp2-null mice over the WT levels, while α4 expression was reduced (n = 4, P < 0.001, 
Student’s t-test; Fig. 5-5H). Transcript levels of β1 and β2 subunits were both reduced (n = 5, P < 
0.001, Student’s t-test), while β3 transcript did not change (Fig. 5-5H).  
5.3.5 Modulation of LC neuronal firing activity by extrasynaptic GABAAR agonists 
LC neuronal electrophysiological activity was studied in current clamp. In WT mice, THIP 
reduced the input resistance (Rm) from 480.5 ± 7.1 MΩ to 458.7 ± 7.6 MΩ. Meanwhile, THIP 
hyperpolarized the cells by 1.1 ± 0.4 mV and decreased firing rate by 17.3 ± 3.3% (n = 14, Fig. 5-
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6A1-A3, C, D, E). In Mecp2-null mice, the same THIP treatment reduced the input resistance from 
500.5 ± 8.7 MΩ to 424.9 ± 17.7 MΩ, hyperpolarized the cells by 3.0 ± 0.5 mV, and lowered the 
firing rate from 5.1 ± 1.3 Hz to 3.6 ± 1.6 Hz (n = 9; P < 0.05, P < 0.05 and P < 0.05, respectively, 
Student’s t-test; Fig. 5-6B1-B3, C, D, E), which is approximate to the baseline level in WT LC 
neurons (2.9 ± 0.2 Hz in WT baseline, n = 14, Fig 5-6E). All these percentile changes were 
significantly greater than in the WT neurons (P < 0.01, P < 0.01 and P < 0.05, respectively, 
Student’s t-test; Fig. 5-6F-H).  
In either WT or Mecp2-null mice, 1 μM THIP did not affect the super-threshold and 
repetitive firing properties, including action potential morphology, afterhyperpolarization (Fig. 5-
7), spike frequency adaptation (Fig. 5-8), and delayed excitation (Fig. 5-9), when synaptic 
transmission was deliberately blocked. Post inhibitory rebound and bursting activity were not 
found in LC neurons before and after THIP treatment in neither WT mice nor Mecp2-null mice. 
Taken together, these results indicate that activation of δ-subunit containing GABAARs leads to 
an inhibition of LC neurons, an effect that is greater in Mecp2-null mice than in the WT, which 
brings the neuronal firing from hyperexcitable status to the level of WT neurons. 
5.3.6 The effect of extrasynaptic GABAAR agonist on breathing 
Previously studies indicate that LC neurons are sensitive to high CO2 and low pH, and they play 
an important role in regulating the breathing activity [8]. In Mecp2-null mice, several groups of 
neurons including the LC neurons are hyper-excitable [4, 12, 15, 147], which appears to contribute 
to the breathing disorders in Mecp2-null mice. To test whether activation of the extrasynaptic 
GABAARs can alleviate the breathing abnormities, we studied breathing activity using 
plethysmography in conscious Mecp2-null mice. The mice were divided into two groups with one 
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receiving THIP injections (10 mg/kg, i.p.), and the other was given saline injection. At the 3 weeks 
of age, Mecp2-null mice start to develop breathing disorders with obvious breathing frequency 
variation and frequent apneas. Therefore, we monitored the breathing activity of Mecp2-mull mice 
with THIP/saline injection once a day for 7 consecutive days starting from 26 days of age. After 
the 7 day treatment, Mecp2-null mice with saline injection continued to develop severe breathing 
disorders with 89 ± 16 apneas/hour, a ~ 50% increase compared to day 0 (n = 5, Fig. 5-10A, C), 
and 0.29 ± 0.03 F variation, a ~ 20% increase (n = 5, Fig. 5-10A, D). THIP treatment markedly 
reduced breathing disorders to 46 ± 6 apnea/hour, a 18% reduction compared to day 0 (n = 5, Fig. 
5-10B, C), and 0.17 ± 0.04 F variation, a 32% reduction (n = 5, 6-. 5-10B, D). Both the breathing 
parameters are significantly improved in the THIP group over their saline counterparts (Fig. 5-
10C, D, two-way ANOVA and Tukey’s post-hoc test). Therefore, the results suggest that the 
extrasynaptic GABAAR agonist THIP alleviates the breathing disorders of Mecp2-null mice. 
 
5.4 Discussion 
To our knowledge, this is the first demonstration of extrasynaptic GABAA currents in the 
mouse model of RTT. Our results have shown that tonic GABAA currents in LC neurons are 
significantly larger in Mecp2-null neurons than in the WT, likely to be due to the overexpression 
of the GABAAR species containing δ and α6 subunits. Furthermore, activation of the extrasynaptic 
GABAARs appears to reduce neuronal excitability and alleviate breathing abnormalities of Mecp2-
null mice.  
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5.4.1 Defects in synaptic GABAARs in Mecp2-null mice 
Previous studies have shown that the GABAA system is defective in Mecp2-null mice and 
people with RTT. In mice, this is associated with multiple RTT-like phenotypes, including 
progressive motor dysfunction and abnormal breathing [11]. In GABA-ergic neurons, impaired 
GABA synthesis and the consequent reduction in the GABA quanta release have been found [10, 
11, 18]. In postsynaptic cells, there is a marked reduction in GABAAR density in the brain of RTT 
patients and Mecp2-null mice [75, 76]. An epigenetic study in a mouse model of RTT indicates 
that the GABAAR β3 subunit expression is reduced in the cerebellum, and another molecular study 
confirmed the down-regulation of β3 subunit in cerebellum [78, 79]. The α1 subunit in the frontal 
cortex, and α2 and α4 subunits in the ventrolateral medulla were also reduced in Mecp2-null mice 
[18]. In LC neurons our previous studies have shown that the postsynaptic GABAA and GABAB 
currents both are defective in Mecp2-null mice [10]. Consistent with these findings, the therapeutic 
GABAAR activators diazepines and the reuptake blocker NO-711 improve RTT symptoms in 
animal models, including breathing [12, 13]. However, it is still unclear how the extrasynaptic 
GABAARs are affected in Mecp2-null mice, which makes our present study remarkable.  
5.4.2 Presence of extrasynaptic GABAARs in LC neurons 
Extrasynaptic GABAARs were first described in cerebellar cortical grey matter [148], and 
later found in many other brain areas, such as cerebral cortex, dentate gyrus granule, thalamus and 
neocortex [149-154]. The extrasynaptic GABAARs are sensitive to low levels of ambient GABA 
with little desensitization. They are likely key targets for neurosteroids and alcohol [143, 155-157], 
and useful targets for the treatment of some neuronal disease such as sleep disorders, epilepsy, 
stroke and Parkinson’s disease [158, 159]. The δ subunit is the primary component of extrasynaptic 
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GABAARs found exclusively in extrasynaptic locations meditating tonic inhibition [20, 142]. 
Some other GABAAR subtypes may be also involved in extrasynaptic GABAARs, such as α5-
subunit containing receptors [144, 145, 160]. Our results from this study suggest that extrasynaptic 
GABAARs are also present in LC neurons. Activation of these receptors results in tonic 
hyperpolarizing currents that are sensitive to GABA and the GABAAR blockers bicuculline and 
picrotoxin. Consistent with these electrophysiological studies, our molecular biological evidence 
indicates that the δ subunit is expressed in LC neurons.  
Accompanying with the δ subunit are another 2 α and 3 β subunits forming pentameric 
extrasynaptic GABAARs. Our qPCR results suggest that the α6 containing extrasynaptic 
GABAARs seem to play a major role in Mecp2-null LC neurons, which has been described in 
mature cerebellar granule cells [161]. The β1 – 3 subunits are necessary components in both 
extrasynaptic and synaptic GABAARs. Previous studies report a ~ 30% reduction in postsynaptic 
GABAergic IPSCs in Mecp2-null LC neurons. The reduced α4 level found in this study is thus 
consistent with the deficiency in synaptic GABAARs. Regarding the increase in the α6 transcript 
level, it is possible that deletion of Mecp2 leads to reorganization of the GABA receptor species 
in LC neurons by increasing the α6 subunit expression and reducing the expression of other α 
subunits. Similar reorganization has been found in nicotinic ACh receptors in Mecp2-null LC 
neurons [49]. The increased α6 subunits may assemble the extrasynaptic receptors together with 
the δ subunit as well as synaptic GABAARs with β and γ subunits. Because all the β subunits 
contribute to the synaptic GABAARs, and because the synaptic GABAARs are lowered with the 
Mecp2 knockout, it is possible that their overall reduction masks the potential up-regulation of 
some subunits in the extrasynaptic location. Another possibility is that the extrasynaptic 
GABAARs in Mecp2-null mice might be composed of more than 2 α subunits, which may explain 
 54 
 
the reduced expression of β subunits and the unproportionally increased expression of α6 subunits 
although the 2 α, 2 β, and 1 δ stoichiometry of GABAARs has previously been shown in an 
exogenous expression system [162]. Despite the uncertainty of β subunits, it is likely that the 
overly expressed GABAAR species in Mecp2-null mice appears to contain δ and α6 subunits. 
5.4.3 Tonic GABAA currents in Mecp2-null mice 
The presence of tonic GABAA currents in LC neurons motivated us to study the 
extrasynaptic GABAARs in Mecp2-null mice. We found that the bicuculline-sensitive GABAA-
ergic tonic currents not only existed in Mecp2-null mice, but also were markedly enhanced, as 
extrasynaptic GABAAR agonists also elicited significantly larger tonic GABAA currents in Mecp2-
null neurons. What underlies the large tonic GABAA currents in Mecp2-null neurons is unclear, 
which may result from a relief of direct transcription repression by MeCP2 or its indirect effects 
on other transcriptional regulators and second messenger systems as a result of the Mecp2 
disruption. It is also possible that the increased GABAA tonic currents result from compensatory 
mechanisms for insufficient GABA synaptic input in Mecp2-null neurons [10]. Multiple types of 
neurons are hyperexcitable in Mecp2-null mice, such as hippocampal neurons, neocortical 
neurons, LC neurons, hypoglossal neurons, etc. [4, 12, 18, 147, 163-165], which is likely to be due 
to impaired synaptic transmission and intrinsic membrane properties. The highly excitable state of 
some of these neurons seems to contribute to cognitive defects, motor abnormality and breathing 
disturbances [8, 12, 163, 164]. Clearly, such an over-excitation in central neurons can be alleviated 
by GABA-ergic inhibition, in which excessive extrasynaptic GABAARs are beneficial. 
Interestingly, this seemingly compensatory up-regulation of GABA-ergic inhibition has been 
reported in the synaptic GABAA system [16, 166, 167]. In neocortical layer 5 neurons of Mecp2-
null mice, an increase of spontaneous IPSCs were recorded, which seems to result from the deficit 
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in GABA release from presynaptic terminals [16]. Therefore, the large tonic GABAA-ergic 
currents in LC neurons of Mecp2-null mice found in the present study might be a compensatory 
response to the deficient GABA synaptic inhibition. 
Although the expression level suggests that the large tonic GABAA currents in Mecp2-null 
mice are likely to be due to the overexpression of δ subunit-containing receptors, our data cannot 
rule out the possibilities that other expression patterns of GABAARs or a change in GABA affinity 
could also contribute to the enhanced tonic GABA inhibition in Mecp2-null mice. Nevertheless, 
RTT patients and Mecp2-null mice with insufficient GABA-ergic inhibition may benefit from 
these overexpressed extrasynaptic GABAARs, as they may provide alternative targets for 
pharmaceutical interventions in addition to synaptic GABAARs. 
5.4.4 Modulation of neuronal activity and breathing 
Experimental evidence suggests that LC neurons play an important role in brainstem CO2 
chemosensitivity and breathing regulation [8, 42, 147]. Several groups of respiratory neurons and 
motoneurons are modulated by NE, in which NE augments cellular excitability via α adrenoceptors 
[168, 169]. This NE-ergic modulation relies on firing activity and NE biosynthesis in LC neurons. 
It is possible that there is a homeostatic state between LC neuronal excitability and NE 
biosynthesis, allowing a stable release of NE at synapses. Although high LC neuronal excitability 
may lead to more NE release, persistent hyperexcitability may have adverse effects. 
Hyperexcitability often leads to Ca++ overload, while a persistent elevation of cytosolic Ca++ can 
activate a variety of degradative enzymes including proteases, lipases and endonucleases [170, 
171]. These may trigger a cascade of events leading to abnormal cellular activity and metabolic 
dysfunction, which may paradoxically compromise NE biosynthesis.  
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Mecp2 disruption in mice also causes hyperexcitability in LC neurons and impaired 
metabolic activity, which is attributable to the defects in neuronal intrinsic membrane properties 
and insufficient GABA inputs [4, 8, 147]. Consistent with these findings, treatment with GABA 
or diazepam rebalances the hyperexcitability of expiratory neurons, and improves the breathing 
activity in Mecp2-null mice [12, 13]. In the present study, we have found that administration of 
THIP activates extrasynaptic GABAARs and reduces excitability of LC neurons as well. Like 
diazepam, the THIP treatment alleviates the breathing abnormalities of Mecp2-null mice. 
Therefore, the excitability stabilization appears crucial for reinstallation of brainstem autonomic 
function. To avoid potential effects of THIP on arousal states, we monitored the animal activity 
with a video camera during plethysmograph recordings and confirmed that they were not in 
behavioral sleep. 
In Mecp2-null mice, over-excitation of LC neurons may contribute to their metabolic 
dysfunction by disturbing the homeostasis of NE synthesis, the NE production and NE release by 
presynaptic terminals. A previous study reported that in Cos-7 cells, chronic over-excitation 
impaired the homeostatic synaptic plasticity by decreasing the AMPA receptors expression [172]. 
Indeed, decreased expression of tyrosine hydroxylase (TH) and dopamine β hydroxylase (DBH) 
are known to occur in LC neurons of Mecp2-null mice, leading to insufficient NE biosynthesis [6, 
50]. THIP application seems to correct the LC neuronal hyperexcitability by activation of 
extrasynaptic GABAARs as shown in this study, which we believe may stabilize neuronal activity 
and metabolism rebalancing the homeostatic state and improving the NE biosynthesis.  
In conclusion, bicuculline-sensitive tonic currents were recorded from LC neurons, which 
were increased dose-dependently with increased GABA concentrations. In comparison to WT 
mice, these GABAA-ergic tonic currents were increased significantly in Mecp2-null mice. 
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Agonists specific to extrasynaptic GABAARs triggered larger tonic GABAA currents in Mecp2-
null LC neurons. Consistently, the δ subunit, the principal component of extrasynaptic GABAARs, 
was expressed in LC neurons, whose expression level together with the α6 expression in the LC 
area became higher in Mecp2-null mice than in the WT, which may contribute to the enhanced 
tonic GABAA currents. The presence of extrasynaptic GABAARs in Mecp2-null mice seems to 
allow a control of neuronal excitability and breathing abnormalities with GABAAR activators. 
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Figure 5- 1. GABAAR antagonists reduce the tonic currents of LC neurons in WT mice.  
Tonic GABAA currents were recorded in whole-cell voltage clamp by ion substitution and 
selective receptor blockers. (A-B) In the absence of exogenous GABA in the bath solution 
(baseline), tonic currents were measured as the difference before and after treatment of 
GABAARs antagonists. Picrotoxin (20 µM) and bicuculline (50 µM) reduced the both the 
synaptic GABAA currents (IPSCs) and the tonic GABAA currents of LC neurons in WT mice. 
Noise was measured as standard deviation of the currents, and shown as a ratio with vs. without 
GABAARs antagonist treatment. The noise level was reduced with the treatment of these two 
GABAARs antagonists. (C-D) Pre-treatments with 1 µM and 10 µM GABA boost larger 
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bicuculline-sensitive tonic current in WT LC neurons. (E-G) The effects of bicuculline on the 
tonic currents and noise ratio increased dose-dependently with an increased in GABA 
concentrations (*, P < 0.05; **, P < 0.01; ***, P < 0.001; One-way ANOVA).  
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Figure 5- 2. Bicuculline sensitive tonic currents are increased in Mecp2−/Y mice. 
 (A) In comparison to WT mice, bicuculline (50 µM) reduced more tonic currents and noise in 
Mecp2-null mice in the absence of exogenous GABA (baseline). (B-C) In the presence of 1 µM 
or 10 µM GABA, the bicuculline effects on the tonic currents and noise ratio were significantly 
even larger in Mecp2-null neurons than the WT. (D-F) Both tonic currents and the noise ratio 
increased dose-dependently with an increase in GABA concentrations. Such effects were more 
obvious in Mecp2-null mice (*, P < 0.05; **, P < 0.01; ***, P < 0.001; Student’s t-test).  
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Figure 5- 3. THIP boosts larger tonic currents in Mecp2−/Y mice. 
 (A-E) THIP (1 µM) applied to the bath solution triggered bicuculline-sensitive tonic currents 
measured 18.6 ± 2.9 pA and noise ratio 1.94 ± 0.07 in WT neurons. In Mecp2-null neurons, the 
THIP activated tonic currents were augmented by 3 folds compared to WT cells, and the noise 
ratio was also significantly increased. (F-G) The effects of THIP on IPSC frequency and amplitude 
were not significantly different between WT and Mecp2-null LC neurons. (H-I) Analysis of 
cumulative fraction of IPSCs showed that 1 µM THIP treatment did not alter the inter-event 
interval and amplitude of GABA-ergic IPSCs in WT neurons; (*, P < 0.05; **, P < 0.01; ***, P < 
0.001; Student’s t-test). 
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Figure 5- 4. DS2 raises tonic currents in Mecp2−/Y mice. 
(A-E) Application of DS2 (20 µM) enhanced the tonic currents by ~ 3 folds and raised the noise 
ratio to a significantly greater degree in Mecp2-null neurons than in the WT. (F-G) The effects of 
DS2 on IPSC frequency and amplitude were not significantly different between WT and Mecp2-
null LC neurons. (H-I) The cumulative analysis of IPSCs showed that DS2 shifted the inter-event 
interval to the higher frequency range without altering the amplitude of IPSC in WT LC neurons 
(**, P < 0.01; Student’s t-test).  
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Figure 5- 5. GABAAR δ subunit was overexpressed in the LC region of Mecp2−/Y mice. 
(A) Single-cell PCR showed δ subunit, the essential subunit for extrasynaptic GABAARs, was 
expressed in most LC neurons with negative GFAP and positive GAPDH expression in both WT 
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and Mecp2-null mice. (B-D) qPCR analysis indicated the expression level of the δ and α5 subunits 
in WT mice (B, 2−∆Ct). The δ subunit level was significantly increased and α5 subunit level was 
significantly reduced in Mecp2-null mice (C, 2−∆∆Ct); E-F: Western analysis showed a significant 
increase of δ subunit protein expression in Mecp2-null mice; (G-H) qPCR analysis showed the 
transcript level of α4, α6, β1 – 3 subunits in WT mice (G, 2−∆Ct). The α6 subunit level was 
significantly increased in Mecp2-null mice (H, 2−∆∆Ct). (*, P < 0.05; **, P < 0.01; Student’s t-test) 
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Figure 5- 6. THIP inhibits the LC firing activity by activating extrasynaptic GABAARs. 
(A1-A3) Application of 1µM THIP suppressed the spontaneous firing activity with a 
hyperpolarization and a decrease in input resistance (Rm) of LC neurons in WT mice. The effects 
were abolished in the presence of bicuculline. Magnified inset with hyperpolarizing current 
injection indicates the input resistance. (B1-B3) LC neurons in Mecp2-null mice showed the 
similar response to 1 µM THIP; (C-E) Membrane potential and firing rate showed significant 
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differences at the baseline (normal aCSF without exogenous GABA) between WT and Mecp2-null 
neurons, and THIP abolished the differences. THIP treatment also produced a significant decrease 
in input resistance. (F-H) In comparison to the WT, THIP had significantly larger effects on input 
resistance, membrane potential and firing rate in Mecp2-null neurons (*, P < 0.05; **, P < 0.01; 
Student’s t-test).  
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Figure 5- 7. THIP does not affect the morphology of action potential (AP) and 
afterhyperpolarization (AHP) in either WT or Mecp2-null neurons.  
(A) Spontaneous APs recorded from an LC neuron. No obvious changes in AP morphology were 
found after exposure to THIP. (B-E) In the presence of ionotropic receptor blockers (AP5, CNQX 
and strychnine) in the bath solution, THIP did not change the AP threshold (the potential at AP 
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initiation point), AP amplitude (the amplitude from threshold to peak), rise time and half width 
(D1/2, measured at 50% amplitude) of APs in either WT or Mecp2-null neurons (n = 7 and n = 12; 
P > 0.05 and P > 0.05, respectively; Student’s t-test). (F-G) In the presence of ionotropic receptor 
blockers, AHP was also not affected by THIP in WT and Mecp2-null neurons. AHP amplitude was 
measured from AP threshold to the lowest hyperpolarization point, and the time constant of AHP 
was described with single exponential in the period from 10% to 90% of the AHP amplitude (n = 
7 and n = 12; P > 0.05 and P > 0.05, respectively; Student’s t-test).  
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Figure 5- 8. THIP does not affect the spike frequency adaptation (SFA) in either WT or 
Mecp2-null neurons. 
(A) The SFA was studied with series of depolarizing currents (0 – 0.15 nA). The firing rate of the 
neurons declined with a long period of depolarization. (B) The SFA ratio was obtained by division 
of peak frequency, measured between the first two APs, by steady state frequency, measured 
between the last two APs with the same current injection. The SFA ratio was increased with the 
increasing depolarizing currents. THIP treatment did not affect the SFA ratio in both WT and 
Mecp2-null neurons. (C) With a 0.06 nA current injection, THIP affected the SFA ratio neither in 
WT nor Mecp2-null neurons (n = 6 and n = 9; P > 0.05 and P > 0.05, respectively; Student’s t-
test). 
  
      
     
 
 
 
  
 
  
 
 
              
        
    
      
       
    
 
 
 
  
 
  
 
 
                       
                   
                        
             
                  
     
 
 
    
 
 71 
 
 
Figure 5- 9. THIP does not affect the delayed excitation (DE) in both WT and Mecp2-null 
neurons.  
 (A) The DE was measured as the time delay between the starting point of depolarization pulse 
and initiation of the first action potential after a prior hyperpolarization. (B) The DE was 
described as the function of the conditioning hyperpolarization, which was fit with Boltzmann 
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Equation as D = Dmax/{1+exp[(V-V1/2)/k]}, where Dmax is the maximum DE period, V is the 
hyperpolarizing membrane potential, V1/2 is the half-inactivation, and k is the Boltzmann 
constant or slop factor. (C-E) Neither WT nor Mecp2-null neurons showed significant difference 
on V1/2, slop factor and DE period before and after THIP treatment (n = 8 and n=7; P > 0.05 and 
P > 0.05, respectively; Student’s t-test). 
  
 73 
 
 
Figure 5- 10. THIP alleviates the breathing abnormalities in Mecp2−/Y mice. 
 (A-B) The Mecp2-null mice were injected with THIP (10 mg/kg, i.p.) or saline for 7 consecutive 
days. Breathing activity was recorded in plethysmograph system 2 days before the injection. The 
injection started at Day 0 when mice were 26 days after birth. All the animals developed breathing 
disorders before THIP injection, showing apnea and clear breathing frequency (f) variation at day 
0. At Day 8, both were alleviated after the THIP treatment for 7 days by showing less apnea and 
smaller breathing f variation. (C-D) When apnea occurrence (events/h, C) and breathing f variation 
(SD/mean, D) were compared between THIP and saline injected groups, THIP improved 
significantly both apnea and f variation in Mecp2-null mice. In box a & box c, there was no 
significant difference (NS) in the main effect, neither significant interaction. In box b & box d, 
there was significant difference in the main effect (##, P < 0.01; Two-way ANOVA) of drug 
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treatment. No significant effect of age and no significant age-drug interaction were found (*, P < 
0.05; **, P < 0.01; Tukey’s post-hoc test). 
  
 75 
 
6 CHAPTER2: THE BENEFICIAL EFFECTS OF EARLY INTERVENTION TO THE 
EXTRASYNAPTIC GABAARS ON PHENOTYPE DEVELOPMENT IN THE 
MECP2-NULL MOUSE MODEL OF RETT SYNDROME 
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6.1 Abstract 
Rett Syndrome (RTT) is a neurodevelopmental disorder caused mostly by disruptions in 
the MECP2 gene. Mecp2-null mice show imbalances in neuronal excitability and synaptic 
communications. Several previous studies indicate that augmenting synaptic GABA receptors 
(GABAARs) can alleviate RTT-like symptoms in mice. In addition to the synaptic GABAARs, 
there is a group of GABAARs found outside synaptic cleft with the capability to produce sustained 
inhibition, which may be potential therapeutic targets for the control of neuronal excitability in 
RTT. Enhancing the GABARergic synaptic inhibition alleviated the RTT-like breathing 
difficulties. It is possible that intervention to such extrasynaptic GABAARs would have beneficial 
effects on RTT-like symptoms in Mecp2-null mice as well. Therefore, in our study, we randomly 
divided wild-type and Mecp2-null mice into four groups, which received the extrasynaptic 
GABAAR agonist THIP and vehicle control, respectively. Low-dose THIP was administered to 
neonatal mice through lactation. RTT-like symptoms including lifespan, breathing, motor function 
and social behaviors were studied when mice became mature. Changes in neuronal excitability 
and NE biosynthesis enzyme expression were studied in electrophysiology and molecular biology. 
With no evident sedation and other adverse side-effects, early-life exposure to THIP extended the 
lifespan, alleviated breathing abnormalities, enhanced motor function, and improved social 
behaviors of Mecp2-null mice. Such beneficial effects were associated with stabilization of locus 
coeruleus neuronal excitability and improvement of NE biosynthesis enzyme expression. In 
conclusion, THIP treatment in early lives might be a therapeutic approach to RTT-like symptoms 
in Mecp2-null mice and perhaps in people with RTT as well. 
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6.2 Introduction 
Rett Syndrome (RTT) caused mostly by disruptions in the Mecp2 gene is a 
neurodevelopmental disorder occurring in 1/10,000 live female births [1]. One of the major 
consequences of the Mecp2 disruption is dysfunction of brainstem neurons [3, 107, 147, 173]. In 
Mecp2-null mice, several groups of brainstem neurons including those in the locus coeruleus (LC) 
show increased membrane excitability. As a result of the excessive neuronal excitability, the 
balance of excitation and inhibition in local neuronal networks is impaired, affecting normal 
brainstem functions for breathing control, cardiovascular regulation, gastrointestinal activity, 
arousal and locomotion, consistent with RTT manifestations in humans [3, 8].  
The increased neuronal excitability in the brainstem is attributable to abnormal intrinsic 
membrane properties and deficiency in GABAergic synaptic inhibitions [4, 10, 14, 18, 49]. In 
Mecp2-null mice, both GABAA and GABAB synaptic currents are reduced in LC neurons [10]. In 
contrast, our recent studies indicate that extrasynaptic GABAA currents are well retained in LC 
neurons of Mecp2-null mice [67], which is encouraging as the extrasynaptic GABAARs may 
provide an alternative pharmaceutical target to relieve the excessive neuronal excitability and its 
associated RTT symptoms. Indeed, we have found that the extrasynaptic GABAAR agonist THIP 
(tetrahydroisoxazolo [5,4-c]-pyridin-3-ol) is beneficial to RTT-like symptom relief in Mecp2−/Y 
mice.  
THIP or gaboxadol is an investigational drug, originally developed for insomnia, Clinical 
trials suggest that THIP (10mg/day) has no significant effects on sleep onset and total sleep time 
[135]. It does have effects on these measures in a higher dose (15mg) where the effects are 
inconsistent between genders, and side effects emerge including sedation and disorientation [135, 
136]. Therefore, Merck and Lundbeck canceled further development of the drug. It is not unusual, 
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however, that a preclinical drug fails in one application, but succeeds in another. The low efficacy 
of THIP on insomnia indeed may be beneficial for its applications to RTT, as the unnecessary 
sedation can be avoided. We have found that intraperitoneal injection of THIP alleviates the 
breathing abnormalities and extends lifespans of Mecp2-null mice [67]. However, intraperitoneal 
injection may introduce stress and subject the animals to infection. To overcome this potential 
problem, oral administration was given to mice in this study. Also we chose to use a low and non-
sedative dose of THIP to avoid potential side-effects. RTT symptoms start in 6-18 months after 
birth, causing a loss of certain acquired motor and language skills in humans. To intervene to this 
early period of development, we exposed neonatal mice to THIP one day after birth before the 
RTT-like symptoms manifest themselves. Therefore, this study was conducted in a way that was 
close to therapeutic condition and very much different from our previous study [67]. 
 
6.3 Results 
6.3.1 THIP Administration 
Symptoms of RTT patients and mouse models start after a period of postnatal development. 
In Mecp2-null mice, breathing disorders started at 2-3 weeks after birth, and defects in motor and 
social behaviors begin at 4-6 weeks [42, 174]. Early intervention to extrasynaptic GABAARs may 
affect the development of the symptoms. Therefore, we started the THIP treatment of Mecp2-null 
mice from the birth day, and maintained the level till mice were fully mature.  
Following strategies were used to determine THIP dosing. a) Based on water consumptions 
in our studies, the dose given to the mother was 61.0 ± 2.2 mg/kg/day. Consistent with previous 
studies, the mother with this dose did not show any evident sedation, neither had any behavioral 
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alterations [175]. The infants received maximally one tenth of the dose to the mother via lactation 
[176-178], i.e., ~6 mg/kg/day. After weaning, these mice received 6.3 ± 0.4 mg/kg/day THIP in 
their drinking water, which were also calculated based on their daily water intake. b) According to 
a THIP patent report, the LD50 in mice is 320mg/kg orally, which is 2.2 times higher than i.p. 
(LD50 145mg/kg) [179]. The THIP dose used in mouse models of Angelman syndrome and 
Fragile X syndrome is 2-3mg/kg i.p. [81, 82, 180], equivalent to 5-7 mg/kg in oral after 
multiplication by 2.2, which is approximately the same as used in our studies. c) THIP 
pharmacokinetics has been well studied in humans and laboratory animals [181-184]. According 
to the visual observation, THIP treatment had no evident effects on feeding, movement, body 
weight, and other general physical conditions in both WT and Mecp2-null mice. 
6.3.2 Lifespan 
Lifespan of the mice was studied with THIP or vehicle treatment. In the vehicle group, 
about 50% of the Mecp2-null animals died at P52 with only 1 out of 14 tested animals surviving 
beyond P80. In contrast, Mecp2-null mice with THIP treatment reached 50% fatality (LD50) on 
P82, and one third (5 out of 15) mice lived beyond P90 (Fig. 6-1A-B). When comparing LD50, 
the THIP administration extended the lifespan of Mecp2-null mice by over 50%, which was 
statistically significant as well (Fig. 6-1A; P = 0.004, Mantel-Cox test). The same THIP and 
vehicle treatments did not cause any lethality in WT mice. 
6.3.3 Breathing Abnormalities 
Like people with RTT, Mecp2-null mice developed severe breathing abnormalities by 
showing significantly high apnea rate and high breathing frequency variation [8, 185], which may 
lead to the early death or unexpected sudden death seen in RTT patients and the RTT mouse model. 
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It is possible that the extended lifespan in Mecp2-null mice is attributable to the alleviation of 
breathing abnormalities through THIP treatment. Therefore, we studied mouse breathing activity 
using plethysmography. Early-life administration of THIP prevented the development of breathing 
abnormalities in Mecp2-null mice (Fig. 6-2B, D). In age 6 – 8 weeks, both the apnea rate and 
breathing frequency variation were significantly reduced in Mecp2-null mice treated with THIP 
(Fig. 6-2A1, A2, C, E).  
6.3.4 Motor Function 
The grip strength and grid walking tests were performed to evaluate muscle strength and 
motor coordination, respectively. Our results showed that in 5-6 week-old Mecp2-null mice, THIP 
treatment improved the grip strength from 58.5 ± 2.1 g to 74.0 ± 1.7 g (Fig. 6-3A), and the footfault 
ratio from 4.3 ± 0.5 % to 2.7 ± 0.2 % (Fig. 6-3B). Both were significantly different from those of 
the vehicle controls. These results were unlikely to be due to the sedative effects of THIP, as in 
the open field test THIP did not affect the spontaneous locomotion of either WT or Mecp2-null 
mice (Fig. 6-3C). Therefore, chronic treatment of THIP moderated certain motor defects in Mecp2-
null mice, such as muscle strength and motor coordination.  
6.3.5 Social Behaviors 
The three-chambered tests are used widely in the studies of sociability and social novelty 
[138]. In our current study, only the animals showing no preference to either side chamber during 
the exploration period were used for further testing (Fig. 6-4A). Both of the WT and Mecp2-null 
mice in the experiments showed the similar time spending in the side chambers, indicating that 
none of the animals were in the sedative state. THIP treatment did not alter the chamber transitions 
or the chamber preference either (Fig. 6-4B).  
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In the sociability test, we found that WT mice tended to spend significantly longer time in 
the chamber with an animal than without (267.9 ± 16.7 sec in the animal chamber vs. 155.9 ± 14.6 
sec in the empty chamber), whereas Mecp2-null mice in the vehicle group did not show such 
preference (252.7 ± 36.3 sec in the animal chamber 1 vs. 240.0 ± 39.4 sec in the empty). THIP 
administration improved significantly the social interaction or sociability of the Mecp2-null mice 
(313.5 ± 43.1 sec in the animal chamber 1 vs. 153.5 ± 35.9 sec in the empty) (Fig; 6-4C).  
In the social novelty preference test, WT mice spent significantly more time in the chamber 
with novel animals than the chamber with the familiar one (349.3 ± 32.1 sec in the animal 1 
chamber vs. 138.4 ± 22.8 sec in the animal 2 chamber), whereas the Mecp2-null mice did not show 
such a preference (321.7 ± 44.1 sec in the animal 1 chamber vs. 200.9 ± 50.9 sec in the animal 2 
chamber). THIP treatment improved significantly the social novelty preference of the Mecp2-null 
mice (386.7 ± 29.1 sec in the animal 1 chamber vs. 122.2 ± 22.6 sec in the animal 2 chamber) (Fig. 
6-4D), suggesting that THIP treatment seems to alleviate the defects of sociability and social 
novelty as well.  
 
6.4 Discussion 
In these studies, we have shown that early-life exposure of the Mecp2-null mice to a non-
sedative dose of the extrasynaptic GABAARs agonist THIP has several beneficial effects on 
lifespan, breathing activity, motor function and social behaviors.  
The extrasynaptic GABAARs have several properties different from the synaptic 
GABAARs, which may be unique in interventions to neuronal excitability. They are located outside 
the synaptic area, produce tonic or long-lasting Cl⁻ currents, show very little desensitization upon 
activation, and are sensitive to some synaptic GABAAR agonists and extrasynaptic GABAAR-
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specific agonists [20, 141, 186]. They have the capability to change dynamically their expression 
levels under different physiological and pathophysiological conditions [67, 80, 187]. 
Manipulations of these receptors with selective agents do not interrupt GABAergic synaptic 
transmission mediated by the synaptic GABAARs. Thus, therapeutic activation of these 
extrasynaptic GABAARs may avoid several side effects of the synaptic GABAAR activators 
including sedation, tolerance and addiction. 
To minimize potential side-effects of THIP, we chose to use THIP chronically in low 
dosage. Although pharmacokinetic studies were not performed in this report, such information has 
been collected in previous studies on mice, rats, dogs and humans [181-184]. With a daily dose of 
10 mg in humans, THIP reaches the maximum plasma concentration ~140ng/ml in 2.0 h, and the 
terminal plasma half-life time is 1.7 h [181]. Another preclinical study in humans, rats and mice 
shows a rapid and complete absorption of THIP with the peak concentration reached within 0.5 h 
in several organs include the brain [29]. A clinical report indicates that therapeutic dosages of 
THIP by long-term oral administration range from 20-120mg daily in human patients [188]. 
Higher doses of THIP may cause adverse side effects, including sedation, confusion and dizziness 
[136]. In our present study, the oral dose of THIP was calculated to be ~ 6 mg, which appears 
effective for alleviating multiple RTT-like symptoms in Mecp2-null mice. Our test of spontaneous 
locomotion supports the non-sedative effects of the dosage. The dosage given to the mother during 
lactation was 61.0 ± 2.2 mg/kg/day, which was also reported to have no sedative effects and neither 
behavioral alterations [175].  
Similar to the dosages that we used in the study, several previous studies have reported to 
use THIP for treatment of mouse models of Fragile X syndrome and Angelman Syndrome. Since 
these diseases share multiple similarities to RTT, such as impaired GABA system, neuronal 
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hyperexcitability and autism-like symptoms [81, 82, 189], the information shown in the present 
study is likely to benefit to moving the drug for further clinical trials in all these diseases.  
The impaired neuron networks were widely seen in Mecp2-null mice [80, 190]. The social 
defects of autism spectrum disorders were believed to be correlated to the weak connections in the 
default networks including the medial prefrontal cortex and posterior cingulate cortex [58]. With 
the beneficial effects found in this study, we speculate that THIP might contribute to reinforcement 
of these connections as well as amelioration of the phenotypes. 
In comparison to the Mecp2-null mice the most widely used RTT mouse model, the 
Mecp2+/− mice tend to display large variations in RTT-like symptoms due to the random X-
chromosome inactivation. According to our previous study, only 15-20% Mecp2+/− mice showed 
the RTT-like symptom of breathing abnormalities, suggesting that the wild-type allele is not 
randomly inactivated [107]. Generally, ~50% the neurons in the CNS of Mecp2+/− mice retained 
MeCP2 expression [102, 191], which may allow the Mecp2+/− mice to recapitulate the normal 
behaviors to some degree, compared to the Mecp2-null mice. However, the MeCP2 mosaic 
expression pattern is not uniform in the CNS, and it varies between individuals, ages and brain 
regions [102, 191]. Regional expression levels of MeCP2 was reported be correlated to the specific 
symptoms in the Mecp2+/− mice. Hippocampus MeCP2 expression is related to the exploratory 
activity behaviors and anxiety-like behaviors. Cortical MeCP2 expression affects the general 
symptomatic severity [104]. The age-dependent mosaic pattern suggests that even the X-
chromosome inactivation ratio may also be affected by MeCP2 deficiency in the RTT mice brain 
and the consequent variation of postnatal brain functions in RTT [191]. Thus, the age-dependent 
and region-specific expression pattern of MeCP2 in the CNS contributes to the large variation of 
the phenotypic outcome in Mecp2+/− mice, which all need to be considered in studies of female 
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RTT models. Furthermore, Mecp2+/− mice usually develop the diagnostic symptoms when they 
become sexually mature. The periodical hormone alternations in Mecp2+/− mice may affect mouse 
performance in the behavioral tests complicating the interpretation of the THIP effects. A previous 
study reports significant variations in the open field, tail flick and suspension tests in female mice 
during their estrous cycle [192]. With all these complications in the female models, therefore, 
studies under Mecp2-null condition in the male model seems beneficial as the first step of 
investigation before sophisticated preclinical trials are conducted, which can be based on Mecp2+/− 
female mice and may benefit from the experimental evidence obtained from the male RTT models. 
Selective restoration of Mecp2 in GABAergic neurons rescues multiple phenotypes in both 
Mecp2−/Y and Mecp2+/− mice [73], which suggests that the GABA system is a feasible target to 
manipulate in RTT female mouse model and RTT patients. Although the sexual difference of LC 
neurons might be a concern of the potential effects of THIP, a morphological study suggested 
female LC neurons showed a higher frequency of communication with dmLC neurons in 
comparison to the male [119, 193], indicating that THIP may have a greater effect in female RTT 
mouse model or patients. A previous study reports that for some unknown reasons, THIP tends to 
have a greater efficacy in women than in men [135], further suggesting that the potential beneficial 
effects of THIP in RTT female mouse model and patients. Nevertheless, further studies on 
Mecp2+/− mice are needed, which may be conducted as deliberate, thorough and systematic 
investigations that might benefit from our findings in the male model. 
In conclusion, consistent with our previous study showing that the daily injection of THIP 
in a high dose alleviates breathing abnormalities by stabilizing the neuronal activity [67], our 
current study shows that early-life exposure to a low dose of THIP affects multiple RTT-like 
symptoms. The early-life exposure to THIP extends the lifespan of Mecp2-null mice, reduces 
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breathing disorders and motor dysfunction, and improves social behaviors. These results suggest 
that THIP has beneficial effects on RTT-like symptoms in the mouse model with complete 
knockout of the Mecp2 gene.  
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Figure 6- 1. THIP administration extended the lifespan of Mecp2-null mice.  
(A) Twenty-nine Mecp2-null mice were used in the survival experiment and fourteen of them 
were delivered THIP orally (solid line) and thirteen without THIP treatment (dash line). (** P < 
0.01; Mantel-Cox test). (B) Percentage of survival in the tested mice. In the vehicle group, 50% 
Mecp2-null mice died within 52 days, while THIP treatment expanded the 50% lifespan to 82 
days.  
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Figure 6- 2. THIP administration alleviated the breathing abnormalities in Mecp2-null 
mice.  
(A1-A2) Typical records of breathing activity from both WT and Mecp2-null mice with and 
without THIP administration. (B) Distributions of apnea count in different aged Mecp2-null mice 
with and without THIP treatment. (C) In Mecp2-null mice, THIP administration significantly 
reduced the apnea count at ages of 4-6 weeks (vehicle: n = 26, THIP: n = 8, P = 0.002) and 6-8 
weeks (vehicle: n = 19, THIP: n = 8, P = 0.021), although the significance was not found in 2-4 
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weeks (vehicle: n = 45, THIP: n = 7, P = 0.081; ### P < 0.001 in Kruskal-Wallis test; * P < 0.05, 
** P < 0.01 in Mann-Whitney post hoc comparison). (D-E) Similar effects of THIP treatment on 
breathing frequency variation was observed in these mice (2-4 weeks: P = 0.037; 4-6 weeks: P = 
0.004; 6-8 weeks: P < 0.001; * P < 0.05, ** P < 0.01, *** P < 0.001; One-way ANOVA and 
Tukey’s post-hoc).  
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Figure 6- 3. THIP administration improved motor function of Mecp2-null mice. 
(A) Significant main effects of THIP treatment (F = 23.74, df = 1, P < 0.001) and genotype (F = 
147.85, df = 1, P < 0.001) were observed, as well as a significant interaction (F = 12.04, df = 1, P 
< 0.001). (### P < 0.001, Two-way ANOVA) The grip strength of Mecp2-null mice was 
significantly increased with THIP treatment (WT: n = 18 and n = 18 mice; Mecp2-null: n = 23 
and n = 22; vehicle and THIP, respectively; *** P < 0.001, Tukey’s post hoc). (B) Significant 
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main effects of THIP treatment (F = 5.26, df = 1, P < 0.05) and genotype (F = 30.4, df = 1, P < 
0.001) were observed, as well as a significant interaction (F = 13.25, df = 1, P < 0.001) (# P < 
0.05, Two-way ANOVA). THIP administration significantly reduced the footfault ratio 
(including both hindlimb and forelimb) of Mecp2-null mice (WT: n = 22 and n = 23 mice; 
Mecp2-null: n = 20 and n = 25; vehicle and THIP, respectively; *** P < 0.001, Tukey’s post 
hoc) (C) The spontaneous locomotion of WT and Mecp2-null mice was not significantly affected 
by THIP treatment. The main effect of THIP treatment was not significant (F = 0.26, df = 1, P = 
0.614), as the main effect of genotype (F = 3.00, df = 1, P = 0.095). The interaction of these two 
factors was not significant (F = 0.99, df = 1, P = 0.329) (WT: n = 8 and n = 7 mice; Mecp2-null: 
n = 9 and n = 6; vehicle and THIP, respectively; Two-way ANOVA).  
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Figure 6- 4. THIP administration alleviated the defects of social behaviors in Mecp2-null 
mice.  
(A-B) During the habituation period in the three chamber test, both WT and null mice took 
similar amount of times (A) and transitions (B) in either side of the chambers indicating no 
preference. The main effect preference was not significant. (A: F = 1.72, df = 1, P = 0.195; B: F 
= 0.20, df = 1, P = 0.656; Three-way ANOVA). The transitions between the chambers also 
suggested that the tested animals are not in a sedative state. (C) In the sociability test, a 
significant difference was detected within the main factor of preference (F = 23.31, df = 1, ### P 
< 0.001, three-way ANOVA). WT mice spent significantly more time in the chamber containing 
an animal than the empty one, whereas the Mecp2-null mice lost such a preference. THIP 
administration increased the time expenditure of Mecp2-null mice in interacting with another 
mouse (* P < 0.05; Tukey’s post hoc). No significant differences were found in the main factor 
of genotype (F = 1.20, df = 1, P = 0.278) or THIP treatment (F = 0.03, df = 1, P = 0.863). The 
interactions of genotype × treatment (F = 0.46, df = 1, P = 0.500), genotype × preference (F = 
 92 
 
1.41, df = 1, P = 0.239), treatment × preference (F = 3.31, df = 1, P = 0.074) or genotype × THIP 
treatment × preference (F = 2.08, df = 1, P = 0.155) were not significant as well (Three-way 
ANOVA). (D) In the social novelty test, the main factor of preference showed a significant 
difference (F = 54.48, df = 1, ### P < 0.001, three-way ANOVA). WT mice spent significantly 
more time in the chamber with a novel animal than the chamber with a familiar one, whereas the 
Mecp2-null mice did not show the preference to either chamber. With THIP treatment the 
novelty preference was improved in the Mecp2-null mice; (** P < 0.01, *** P < 0.001; Tukey’s 
post hoc). No significant differences were found in the main factor of genotype (F = 0.57, df = 1, 
P = 0.453) or THIP treatment (F = 0.17, df = 1, P = 0.681). The interactions of genotype × 
treatment (F = 0.02, df = 1, P = 0.888), genotype × preference (F = 0.49, df = 1, P = 0.487), 
treatment × preference (F = 1.58, df = 1, P = 0.213) or genotype × THIP treatment × preference 
(F = 1.35, df = 1, P = 0.250) were not significant as well (Vehicle: n = 12 and n = 9; THIP: n = 8 
and n = 6; WT and Mecp2-null, respectively; Three-way ANOVA). 
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7 CHAPTER3: CELLULAR MECHANISMS OF THE BENEFICIAL EFFECTS OF 
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7.1 Abstract 
Rett syndrome (RTT) is mostly caused by mutations of the X-linked MECP2 gene. 
Although the causal neuronal mechanisms are still unclear, accumulating experimental evidence 
obtained from Mecp2−/Y mice suggests that imbalanced excitation/inhibition in central neurons 
plays a major role. Several approaches may help to rebalance the excitation/inhibition, including 
agonists of GABAA receptors (GABAAR). Indeed, our previous studies have shown that early-life 
exposure of Mecp2-null mice to the extrasynaptic GABAAR agonist THIP alleviates several RTT-
like symptoms including breathing disorders, motor dysfunction, social behaviors, and lifespan. 
However, how the chronic THIP affects the Mecp2−/Y mice at the cellular level remains elusive. 
Here, we show that the THIP exposure in early lives markedly alleviated hyperexcitability of two 
types of brainstem neurons in Mecp2−/Y mice. In neurons of the locus coeruleus (LC), known to be 
involved in breathing regulation, the hyperexcitability showed clear age-dependence, which was 
associated with age-dependent deterioration of the RTT-like breathing irregularities. Both the 
neuronal hyperexcitability and the breathing disorders were relieved with early THIP treatment. 
In neurons of the mesencephalic trigeminal nucleus (Me5), both the neuronal hyperexcitability and 
the changes in intrinsic membrane properties were alleviated with the THIP treatment in Mecp2-
null mice. The effects of THIP on both LC and Me5 neuronal excitability remained one week after 
withdrawal. Persistent alleviation of breathing abnormalities in Mecp2−/Y mice was also observed 
a week after THIP withdrawal. These results suggest that early-life exposure to THIP, a potential 
therapeutic medicine, appears capable of controlling neuronal hyperexcitability in Mecp2−/Y mice, 
which occurs in the absence of THIP in the recording solution, lasts at least one week after 
withdrawal, and may contribute to the RTT-like symptom mitigation. 
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7.2 Introduction 
Rett syndrome (RTT) is a neurodevelopmental disorder, caused mostly by mutations of the 
X-linked Mecp2 gene, a transcriptional regulator. Patients with RTT, almost exclusively girls, 
develop various symptoms, such as stereotype behaviors, autism-like social defects, motor 
dysfunctions and life-threatening breathing abnormalities [194]. As a widely used RTT mouse 
model, Mecp2−/Y mice with Mecp2 gene turned off in all cells recapitulate most of these RTT-like 
symptoms and die in early ages [26]. Besides uncovering RTT symptomatic and pathological 
changes, the mouse model is useful for finding potential therapeutic agents. 
The studies in Mecp2−/Y mice suggest that imbalanced excitation/inhibition in the central 
nervous system (CNS) play a major role in the development of RTT. The altered excitation and 
inhibition have been found in multiple brain regions, including the brainstem [53, 147, 168] and 
the hippocampus [66]. In Mecp2-null mice, excessive excitatory activity was seen in expiratory 
cranial and spinal nerves [12]. Neurons in the LC, the major NE source in the CNS, are overly 
excitable in Mecp2-null mice, which is attributable to their defective intrinsic membrane properties 
and the reduced GABAergic inhibition, and may contribute to breathing abnormalities [4, 10, 147]. 
Neurons in the mesencephalic trigeminal nucleus (Me5) nucleus, located adjacent to the LC, were 
found hyperexcitable as well [53, 56], which may contribute to the difficulties in chewing and 
eating in people with RTT [54, 55].  
The neuronal hyperexcitability involves the GABA system. Mice with Mecp2 gene 
deletion selectively in the GABAergic neurons display RTT-like phenotypes [11]. Restoration of 
the gene in the Mecp2-null GABAergic cells rescued these symptoms, including lifespan, social 
behaviors and motor functions [73]. Therefore, enhancing GABAergic inhibition may help to 
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rebalance the excitation/inhibition in mouse models and perhaps human patients with RTT, leading 
to alleviation of the RTT-like symptoms. Consistent with the idea, treatment with GABA reuptake 
blocker NO711 and synaptic GABAR agonist benzodiazepine relieves the RTT-like breathing 
difficulties in Mecp2-null mice [12, 13].  
In Mecp2-null LC neurons, both GABAAR and GABABR are deficient [10]. In contrast to 
the synaptic GABAA receptors, the expression level of extrasynaptic GABAAR is well maintained 
in Mecp2-null LC neurons [67]. They may provide an alternative target to alter the 
excitation/inhibition balance. Indeed, we have recently shown that early treatment with THIP (also 
known as Gaboxadol), an extrasynaptic GABAAR agonist, alleviates the RTT-like motor 
dysfunction, breathing abnormalities and the defects in social behaviors, expands the lifespan by 
enhancing the tonic GABAergic inhibition in Mecp2-null mice [83]. However, several questions 
remain: How does the THIP treatment affect the Mecp2-null mice at the cellular level? Will the 
systemic THIP treatment affect other brainstem neurons? Are the THIP effects lost totally after 
THIP clearance with withdrawal? Does a rebound excitation occur after THIP withdrawal? To 
address these questions, therefore, we performed the experiments. 
 
7.3 Results 
7.3.1 Age-dependent hyperexcitability of LC and Me5 neurons in Mecp2−/Y mice 
All experiments were done in male Mecp2−/Y mice because the males offer a completely 
Mecp2-null condition that is not always available in Mecp2+/− females owing to X-chromosome 
inactivation. 
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Previous studies indicate that LC neurons are overly excitable in Mecp2-null mice 
compared to the WT [4, 147]. To show how such hyperexcitability progresses with age, we studied 
LC neuronal excitability in three age groups of WT and Mecp2-null mice. Our results showed that 
such neuronal hyperexcitability was age-dependent (Fig. 7-1A1-2). When the spontaneous firing 
rate of LC neurons was plotted against ages, a linear age-dependent increase in the firing rate is 
seen, in which the regression is significant in Mecp2-null but not WT mice (Fig. 7-1A3; WT: R = 
0.14, n = 82, P = 0.21; Mecp2-null: R = 0.65, n = 79, P < 0.001; WT vs. Mecp2-null: P = 0.001). 
A significant increase in spontaneous firing activity of LC neurons started at 2-4 weeks, and 
became more obvious at age 4-6 weeks. The neuronal firing rate doubled that of the WT at 6-8 
weeks (Fig. 7-1A4; 2-4 weeks: n = 45 and n = 38; 4-6 weeks: n = 17 and n = 20; 6-8 weeks: n = 12 
and n = 21; WT and Mecp2-null, respectively). Both are consistent with the onset time of RTT-
like symptoms and the age-dependent symptom deterioration of Mecp2-null mice. In contrast, the 
age-dependent increase in LC neuronal excitability was not observed in WT mice (Fig. 7-1A4). 
Me5 neurons were silent at basal condition without current injection in both WT and 
Mecp2-null mice. In response to depolarizing current injection, the Me5 neurons in Mecp2-null 
mice tended to fire multiple action potentials (APs) in comparison to one or two APs in their WT 
counterparts (Fig. 7-1B1-B2). With comparable levels of current injection, Me5 neurons showed 
significantly higher firing rate in Mecp2-null mice than in the WT, indicating that they also are 
hyperexcitable. Unlike LC neurons, the Me5 neuronal hyperexcitability did not show significant 
age dependence (Fig. 7-1A4; WT: n = 14; Mecp2-null 4-6 weeks: n = 17; Mecp2-null 6-8 weeks: 
n = 14; Fig. 7-1B3). 
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7.3.2 Relationship of LC neuronal excitability with breathing abnormalities 
It is possible that inhibition of LC neuronal hyperexcitability by THIP may affect breathing 
abnormalities, as LC neurons play a role in breathing regulation, and as the age-dependent 
deterioration was found the Mecp2-null mice in our previous studies [83] , Therefore, we 
performed electrophysiological recording from in 6-8 week-old mice whose breathing activity was 
measured on the same day immediately before euthanasia (Fig. 7-2A). When LC neuronal firing 
rate was plotted against apnea rate (Fig. 7-2B, n = 20) or breathing frequency variation (Fig. 7-2C, 
n = 20), we found that the LC neuronal firing rate increases proportionally with the severity of 
these breathing abnormalities. Both can be described with a linear regression (Mecp2-null: Fig. 7-
2B: R = 0.66, P < 0.01; 2C: R = 0.62, P < 0.01). Such proportional changes in firing rate with 
breathing abnormalities were not seen in WT neurons (Fig. 7-2B,C). 
7.3.3 THIP alleviates LC neuronal hyperexcitability in Mecp2−/Y mice 
One of the common features of RTT in humans and animal models is the defect in the NE 
system [5, 42, 47]. Previous studies have shown that excitability of LC neurons increases in 
Mecp2-null mice [4, 147]. The LC neurons are the main source of NE in the CNS, and play an 
important role in breathing regulation, locomotion, arousal, emotion and other behaviors [3, 8, 
195]. Therefore, we chose these neurons to find whether THIP treatment may stabilize LC 
neuronal excitability in Mecp2-null mice.  
In the brain slice preparation, whole-cell current clamp was performed in LC neurons from 
mice with and without THIP treatment. Of four groups of mice, only did the LC neurons from 
Mecp2-null mice in vehicle control show an obvious increase in spontaneous firing activity (Fig. 
7-3A, B). Detailed analysis of the passive and active membrane properties showed that the THIP 
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treatment did not significantly change membrane potential, input resistance, action potential 
overshoot and firing threshold of either groups of neurons (Fig. 7-3C, D, E, F). In Mecp2-null 
neurons, the spontaneous firing rate is significantly higher than that in WT. The THIP treatment, 
however, abolished the difference (Vehicle: 3.1 ± 0.3 Hz and 5.1 ± 0.3 Hz; THIP: 3.6 ± 0.2 Hz and 
3.7 ± 0.3 Hz; WT and Mecp2-null, respectively; Fig. 7-3G). Thus, these results suggest that the 
LC neuronal hyperexcitability in Mecp2-null mice is significantly reduced after THIP exposure.  
7.3.4 Mitigation of Me5 neuronal hyperexcitability with THIP exposure 
To test how the extrasynaptic GABAAR agonist THIP affects other hyperexcited brainstem 
neurons, such as Me5 neurons, WT and Mecp2-null mice were exposed to THIP in their drinking 
water as described in the Methods. With continuing THIP treatment for 5~6 weeks starting from 
birth, brain slices were obtained from the mice without drug withdrawal, in which neuronal activity 
was studied. Note that no THIP was added to the recording solutions. A similar excitability relief 
was found in Me5 neurons of Mecp2-null mice (Fig. 7-4B). The evoked firing activity with 
depolarizing current injection was significantly lower in Me5 cells from THIP-treated Mecp2-null 
mice than the vehicle-treated (Fig. 7-4A; vehicle: n = 14; THIP: n = 18). No significant difference 
in Me5 neuronal firing rates was found between the THIP- and vehicle-treated WT (Fig. 7-4B). 
With the current injection, some Me5 cells fired repetitive APs. The ratio of cells with multiple 
APs vs those with one or two APs was significantly higher in Mecp2-null mice than in the WT. 
Such a difference was abolished with the THIP treatment (Fig. 7-4C; vehicle: n = 14 and n = 17; 
THIP: n = 18 and n = 16; WT and Mecp2-null, respectively). Together, these results suggest that 
early-life THIP exposure significantly suppressed the hyperexcitability of both LC and Me5 
neurons in Mecp2-null mice. 
 100 
 
7.3.5 THIP effects on intrinsic membrane properties of null Me5 neurons 
The early-life exposure to THIP may affect these brainstem neurons by changing their 
intrinsic membrane properties. Thus, we performed detailed studies of subthreshold and 
suprathreshold properties. Since we had done similar studies in LC neurons before [4, 56], we 
were focused on Me5 neurons in the present study. 
In the Me5 neurons, AP amplitude was measured from its threshold level to the peak. The 
rise time of AP was measured as the period from the AP threshold to the peak. AP width (D50) 
measured as the width at half AP amplitude. To measure the resistance, Sag and post-inhibitory 
rebound (PIR), neurons were injected with a series of hyperpolarizing currents. After the 
termination of each command, the cell responded with a post-inhibitory depolarization or AP 
(when the rebound reached AP threshold). The three parameters were calculated based on the trace 
immediately before the AP was initiated. The input resistance was measured as the ratio of steady-
state voltage at the command current. The sag was calculated as the difference between the peak 
hyperpolarization during the current injection and the steady-state potential. The PIR was defined 
as the difference between the peak depolarization of the rebound and the resting membrane 
potential.  
Similar to LC neurons, the chronic THIP did not show significant effects on the membrane 
potential, input resistance, AP properties (amplitude, rise time and D50), Sag and PIR of Me5 
neurons (Fig. 7-5), whereas the firing threshold of Me5 neurons in Mecp2-null mice was shifted 
to more depolarizing potentials with THIP treatment, which was significant in comparison to the 
vehicle control (Fig. 7-5C). Therefore, in Mecp2-null mice, early treatment of THIP seems to raise 
firing threshold without affecting other intrinsic membrane properties of Me5 neurons.  
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7.3.6 Persistent inhibition of neuronal excitability 1-week after THIP withdrawal 
The suppression of brainstem neuronal excitability may be affected by THIP withdrawal, 
as rebound excitation usually merges with withdrawal of certain neuronal suppressants. Therefore, 
we studied neuronal activity after THIP withdrawal. To avoid the likelihood that residue THIP 
may exist in the body, we chose to do the experiments 7 days after withdrawal. 
The firing rate of LC neurons in THIP-treated mice remained significantly lower than that 
of the vehicle control (Fig. 7-6A; WT: 3.6 ± 0.8 Hz and 3.6 ± 1.2 Hz, n = 14 and n = 12; Mecp2-
null: 6.8 ± 2.2 Hz and 5.0 ± 1.6 Hz, n = 21 and n = 12; vehicle and THIP, respectively). No rebound 
excitation was found in Me5 neurons either. Instead, the evoked firing rate of Me5 neurons from 
THIP-treated Mecp2-null mice was significantly lower than that of vehicle control a week after 
THIP withdrawal (Fig. 7-6B1). Furthermore, the ratio of Me5 cells with vs without multiple APs 
remained about the same between Mecp2-null and WT mice, in comparison to the significant 
difference in the ratio between vehicle controls (Fig. 7-6B2). These results suggest that THIP 
withdrawal does not seem to cause rebound excitation. Instead, the THIP effects seem persistent, 
as both LC and Me5 neurons of Mecp2-null mice retained their excitability similar to their WT 
counterparts one week after THIP withdrawal (Fig. 7-6B1-B2; vehicle: n = 14 and n = 17; THIP: n 
= 9 and n = 13; WT and Mecp2-null, respectively). 
7.3.7 Breathing abnormalities remained suppressed one-week after THIP withdrawal 
Our previous study has shown that the same THIP treatment significantly suppressed the 
breathing abnormalities [83] . We thus studied how breathing was affected by THIP withdrawal. 
One week after THIP withdrawal, both apnea events and breathing frequency variation in 
Mecp2-null mice remained lower than the vehicle control (Fig. 7-7A1-A2). Statistical analysis 
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showed that in Mecp2-null mice, the apnea rate and breathing frequency variation were 
significantly lower in mice that had been treated with THIP than those treated with vehicle (Fig. 
7-7B-C; WT: n = 17 and n = 3; Mecp2-null: n = 19 and n = 8; sham and THIP, respectively). These 
results, consistent with the prolonged neuronal excitability depression, indicate that the effects of 
THIP treatment seem to persist at least for one week after THIP withdrawal without apparent 
rebound excitation.  
7.3.8 THIP affects the gene expressions in Mecp2−/Y mice 
Previous studies have shown that the Mecp2 disruption leads to reductions in NE content 
in the CNS and expression levels of the rate-limiting enzymes TH and DBH for NE biosynthesis 
[6, 42, 50, 147]. Persistent hyperexcitation of LC neurons may interfere with the homeostatic state 
in NE biosynthesis and release, leading to the reduced expression of TH and DBH in Mecp2-null 
mice [67]. Thus, moderation of LC neuronal hyperexcitability may improve expression of TH and 
DBH in Mecp2-null mice. To test this possibility, we studied the TH and DBH at mRNA and 
protein levels. The qPCR analysis showed that THIP treatment significantly increased both TH 
and DBH transcript levels in the pontine extracts of Mecp2-null mice (Fig. 7-8A-C). Western blot 
analysis showed ~2 fold increase in TH protein level and ~1.5 fold increase in DBH protein level 
(Fig. 7-8D-F). 
Early-life exposure to THIP might also reshuffle the GABA receptor subunits. Therefore, 
quantitative PCR was performed to detect the mRNA levels of δ, α6, β1 and β2 subunits, which 
were reported as significantly changed in Mecp2-null LC area. In comparison with vehicle control, 
a significant reduction of α6 subunit was detected in Mecp2-null mice with THIP treatment, while 
no significant changes in other subunit expression were found (Fig. 7-9). 
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7.4 Discussion 
This is the first study of the cellular outcome of early-life exposure to THIP. We have 
found that the THIP exposure markedly alleviates hyperexcitability of two types of brainstem 
neurons in Mecp2−/Y mice. In LC neurons known to be involved in breathing regulation, the 
hyperexcitability shows clear age-dependence associated with age-dependent deterioration of the 
RTT-like breathing irregularities, both of which are relieved with early THIP treatment. In Me5 
neurons of Mecp2-null mice, the hyperexcitability as well as the changes in intrinsic membrane 
properties are both improved with the THIP treatment. One week after THIP withdrawal, 
excitability of both LC and Me5 neurons remained depressed. Consistent with the proportional 
relationship between LC firing rate and breathing irregularities and the persistent effects of THIP 
on cellular excitability, RTT-like breathing abnormalities of Mecp2-null mice remain low in the 
time period after THIP withdrawal. In addition, early exposure of THIP improved the biosynthesis 
enzyme gene expression in Mecp2-null LC neurons.  
Mecp2-null mice start to display a range of RTT-like symptoms, including mobility 
problems and breathing difficulties around 3 weeks after birth, and most of the animals die within 
2 months of age [26]. The symptom development is consistent with the onset and deterioration of 
the neuronal hyperexcitation, especially LC neurons as shown in the present study. Indeed, our 
results have shown that LC neuronal excitability increases proportionally with the severity of 
breathing abnormalities. Thus, the defects in LC neuronal excitability may play a role in the 
development of the RTT-like symptoms in the mouse model. Consistent with this idea, the chronic 
THIP stabilizes LC neuronal excitability and breathing abnormalities to a similar degree (Fig. 7-
3A). Also consistent with the idea are our recent studies showing that by enhancing the tonic 
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GABAergic inhibition, early-life exposure of Mecp2-null mice to THIP alleviates various RTT-
like symptoms and extends lifespan [83].  
Although THIP may affect other brain regions by augmenting local extrasynaptic GABAA 
receptors, the stabilization of LC neuronal excitability may benefit a range of target regions. The 
LC is the major NE source in the CNS. The homeostasis of the LC neuronal excitability vs the NE 
synthesis, ensures the persistent production and release of NE. LC neuronal hyperexcitability may 
interrupt this balance and lead to impairment of the NE system, including the reduced expression 
of rate-limiting enzyme, tyrosine hydroxylase (TH) and dopamine beta hydroxylase (DBH), and 
reduced NE concentration in the CNS [5, 6, 50, 115, 147]. A relief of LC hyperexcitability may 
reinstall the homeostatic state in the cells and improve NE output, which may benefit the LC-NE 
projected target regions, including the brainstem, the spinal cord and the prefrontal cortex, brains 
areas critical for breathing, motor function and social behaviors [59, 164].  
The hyperexcitation is not limited to LC neurons. Our results have shown that Me5 neurons 
are also hyperexcitable [53]. The Me5 neurons are the only group of propriosensory neurons with 
soma located in the CNS, which provide servo feedback control to the jaw muscles. The increased 
excitability in these neurons may impair these cranial muscles, consistent with the defects of 
chewing, drinking, speaking and teeth grinding in people with RTT [53-56]. Suppression of overly 
excited Me5 neurons may lead to a correction in the proprioception of muscles, leading to the 
improvement of motor function in RTT. The Me5 neuronal hyperexcitability may be attributable 
to the impaired intrinsic membrane properties in Mecp2-null mice.  
Our results show that early-life THIP exposure suppresses the neuronal hyperexcitability 
without affecting most of the intrinsic membrane properties, which suggests that THIP seems to 
restore the normal function of Mecp2-null neurons via presynaptic inhibition. However, the firing 
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threshold is shifted to more depolarizing potentials in both LC and Me5 neurons, indicating THIP 
may also alter postsynaptic mechanisms such as Na+ channel expressions that have been shown 
abnormal in Mecp2-null mice [4, 53].  
In contrast to the neuronal hyperexcitability, hypoexcitability is found in certain forebrain 
neurons, which may contribute to the impaired sensorimotor gating function in RTT [68]. 
Interestingly, inhibition of the NMDA receptors with ketamine can reverse the neuronal 
hypoexcitability and improve associated behaviors in Mecp2-null mice, likely by disinhibiting 
cortical pyramidal cells [68, 120]. Apparently, excessive excitation may also be a problem in the 
cortical neuronal networks, which responds to NMDA receptor antagonism. Besides ketamine, 
enhancing the GABAergic inhibition might benefit hypoexcitability of certain forebrain neurons 
in Mecp2-null mice as well. 
THIP was previously tested as a potential clinical medicine for insomnia. With a short half-
life time around half an hour, the THIP concentration in the plasma diminished within 3 hours 
[183]. However, continuous oral treatment may allow the THIP to remain at a certain level for a 
long period in the plasma and CNS, leading to the persistent effects on neurons and the associated 
phenotypes.  
Due to the fast decay of the THIP, the withdrawal for one week may allow a total clearance 
of THIP from the plasma and the CNS. This time period seems adequate for evaluation of the 
persistence of its effects. Our results indicate that the THIP effects on relieving neuronal 
hyperexcitability remain one week after THIP withdrawal, which suggest chronic treatment of 
THIP may alter the expression of certain proteins involving the rebalance of excitation vs 
inhibition in the CNS. The results are consistent with the expanded lifespan in the THIP treated 
Mecp2-null mice [83] . Although neuronal activity and breathing abnormalities remained 
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alleviated with the THIP withdrawal in Mecp2-null mice, their absolute levels were higher than 
the WT, indicating a gradual decline of the THIP effects.  
Our results do not support the presence of rebound excitation one week after THIP 
withdrawal. However, the results cannot rule out the possibility of rebound excitation during the 
period of 1-6 days after THIP withdrawal. Because of the availability of these Mecp2-null mice, 
we could not perform these follow-up studies. Thus, further studies are needed to reveal the time 
course 1-6 days after THIP withdrawal.  
LC neurons, the major NE source in the CNS, projects broadly to the other brain regions, 
including the medulla where the respiratory center located, and the prefrontal cortex where the NE 
system affects cognitive functions, seizure and social behaviors [59, 164]. In Mecp2-null mice with 
THIP treatment, the target regions of LC-NE projection may benefit from the enhanced NE 
synthesis, leading to the alleviation of the associated abnormal behaviors.  
People with RTT and the mouse models show the delayed onset and progressive symptoms. 
Although the mechanism for the delayed symptom onset remains unclear, some factors may 
contribute to it, such as dynamic spatiotemporal relationship between MeCP2 and methylated 
DNA [196] and the altered allopregananallone modulation of the GABA system during perinatal 
period [14]. Thus, interfere with neuronal hyperexcitability before the symptom onset may be a 
potential way to prevent or delay the development of the disease. The δ subunit containing 
extrasynaptic GABAARs are expressed dynamically with growth [187]. Since severe defects in the 
synaptic GABAAR system have been demonstrated mature Mecp2-null mice, treatment with THIP 
in early lives may be beneficial with respect to enforcement of the inhibitory system in the 
neurodevelopment of Mecp2-null mice.  
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The reduced expression of α6 subunits suggests that early treatment of THIP may lower 
the GABAR expression and the consequent GABAergic inhibition. The α6 subunit is known to 
contribute to both the extrasynaptic receptors together with the δ subunit and the synaptic 
GABAARs with β and γ subunits [19]. The reduction in these GABAARs might possibly lead to 
rebound excitation after THIP withdraw. The stabilization of neuronal excitability, however, might 
affect cellular mechanisms reducing abnormalities, which could result in a long-term reduction in 
neuronal hyperexcitabiltiy after THIP withdraw, contributing to the outcome of THIP in breathing, 
motor function, social behaviors and lifespan. 
In conclusion, cellular hyperexcitability has been found in multiple neurons of Mecp2-null 
mice, associated with RTT-like symptoms. Early-life treatment with THIP reduces significantly 
the hyperexcitability of both LC and Me5 neurons in Mecp2-null mice without affecting most of 
the intrinsic membrane properties. The gene expressions, including the genes of biosynthesis 
enzyme gene and receptor subunits, are affected in Mecp2-null LC neurons. The THIP effect 
persists for at least one week after THIP withdrawal. The results suggest that THIP, a potential 
therapeutic medicine, seems capable of stabilizing neuronal excitability and improvement of the 
biosynthesis enzyme expression in Mecp2-null mice, which may contribute to the RTT-like 
symptom mitigation.  
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Figure 7- 1. Age-dependent increase in excitability of LC and Me5 neurons in Mecp2−/Y 
mice.  
(A1-A2) Neuronal activity was studied in whole-cell current clamp, LC neurons in Mecp2−/Y mouse 
showed increased firing frequency in comparison to its WT counterpart. Such hyperexcitability 
deteriorated with growth. (A3-A4) Statistically, the increased LC neuronal excitability in Mecp2-
null mice was significantly different from the WT, and showed age dependence (A3: Pearson 
correlation. A4: Significant differences were found in the main factors of genotype (df = 1, F = 
66.14, P < 0.001) and age (df = 1, F = 16.53, P < 0.001). Significant interaction was found between 
the two factors as well. ###P < 0.01; Two-way ANOVA and **P < 0.01, ***P < 0.001; Tukey’s 
 109 
 
post-hoc). (B1-B2) With injections of a series of depolarizing currents, most of the Me5 neurons in 
WT neurons fired single action potential, while the Mecp2-null Me5 ones fired multiple action 
potentials. The excitability of Me5 neurons in Mecp2-null did not show the age dependence (NS, 
not significantly different; Student’s t-test). 
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Figure 7- 2. Relationship of LC neuronal excitability with breathing abnormalities. 
(A1-A3) Typical records of breathing activity from both WT and Mecp2-null mice at different ages 
and the breathing abnormalities deterioration with the age. (B-C) Breathing activity was measured 
immediately before Mecp2-null mice were used for brain slice studies. In the Mecp2-null mice 
older than 6 weeks, LC neuronal firing rate increased proportionally with the severities of apnea 
rate and breathing frequency variation (Pearson correlation). Such relationship was not found in 
the WT mice.  
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Figure 7- 3. THIP administration suppressed the hyperexcitability of LC neurons in Mecp2-null 
mice.  
(A1-A2) Typical recordings of spontaneous firing of LC neurons in WT and Mecp2-null mice at 
one-month of age without THIP treatment. (B1-B2) Spontaneous firing of LC neurons in WT and 
Mecp2-null mice of the same age with THIP treatment. (C-F) THIP administration did not 
significantly change membrane potentials, input resistance, action potential overshoot and action 
potential threshold in both WT and Mecp2-null mice. No significant main effect of THIP treatment 
(F = 0.09, df = 1, P = 0.765; F = 1.15, df = 1, P = 0.289; F = 0.27, df = 1, P = 0.606; F = 0.76, df 
= 1, P = 0.387; Fig C, D, E, F, respectively) and genotype (F = 1.45, df = 1, P = 0.234; F = 0.09, 
df = 1, P = 0.765; F = 0.01, df = 1, P = 0.921; F = 0.99, df = 1, P = 0.324; Fig C, D, E, F, 
respectively) were observed, either the interaction (F = 0, df = 1, P = 1.000; F = 1.46, df = 1, P = 
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0.232; F = 0.03, df = 1, P = 0.863; F = 3.58, df = 1, P = 0.064; Fig C, D, E, F, respectively). (G) 
The main effect of genotype was significant (F = 10.06, df = 1, P < 0.01), whereas the main effect 
of THIP treatment was not (F = 1.72, df = 1, P = 0.196). The interaction of these two factors was 
significant (F = 8.6, df = 1, P < 0.01) as well (## P < 0.01; Two-way ANOVA). The firing activity 
of LC neurons in Mecp2-null mice is significantly increased compared to the WT and chronic 
treatment with THIP abolished the hyperexcitability (Vehicle: n = 14 and n = 13; THIP: n = 13 
and n = 16; in WT and Mecp2-null, respectively; *** P < 0.001; Tukey’s post hoc).  
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Figure 7- 4. THIP exposure alleviated the Me5 neuronal hyperexcitability.  
(A-C) THIP significantly reduced the firing rate of Me5 neurons in Mecp2-null mice with 
comparative amount of current injections (A). Such a relief of Me5 neuronal excitability was not 
found in the WT mice (B). In comparison to the WT, a significantly larger number of Me5 neurons 
     
   
 
                      
*
*
*
 
 
  
  
 
  
 
  
  
 
 
          
       
   ** 
                        
                
                
                 
 
  
 
  
  
 
 
 
  
  
 
  
 
 
   
 
        -     
   
 
 
 
 
   
 
 
 
 
   
 114 
 
in Mecp2-null mice fired multiple action potentials, which was also suppressed by THIP treatment 
(C) (*** P < 0.001, ** P < 0.01; Student’s t-test and χ2-test).  
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Figure 7- 5. THIP effects on intrinsic membrane properties of Mecp2-null Me5 neurons.  
(A-B) The membrane potential and input resistance were not altered with THIP treatment in either 
Mecp2-null Me5 cells or WT ones. (C-F) THIP significantly shifted the firing threshold of Me5 
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neurons to more depolarizing potentials in Mecp2-null mice, but not in WT (C). THIP did not 
change the other parameters of AP morphology, including amplitude, rise time and half width (D50, 
measured at 50% amplitude) in either WT or Mecp2-null neurons (D-F). (G-H) In Me5 cells, Sag 
and PIR was not significantly changed with THIP treatment as well (* P < 0.05; Student’s t-test).  
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Figure 7- 6. The THIP effects on neuronal excitability one week after withdrawal.  
 (A) The hyperexcitability of LC neurons was significantly lower in Mecp2-null mice with THIP 
treatment than in those without. Significant differences were found in the main factors of genotype 
(df = 1, F = 34.27, P < 0.001) and treatment (df = 1, F = 7.55, P = 0.008). No significant interaction 
was found between the two factors (##P < 0.01, Two-way ANOVA and ***P < 0.001, Tukey’s 
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post-hoc). (B) In Mecp2-null Me5 neurons, the suppression of neuronal excitability by THIP was 
remained (B1). The number of cells with repetitive firing activity was significantly reduced with 
THIP treatment in comparison to those without (B2) (*P < 0.05; Student’s t-test and χ2-test).  
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Figure 7- 7. Breathing abnormalities remained suppressed one-week after THIP 
withdrawal.  
 (A1-A2) Typical records of breathing activity from both WT and Mecp2-null mice at P61. (B-C) 
The apnea rate (B) and breathing frequency variation (C) in Mecp2-null mice were significantly 
reduced in comparison to the vehicle control. Significant differences were found in the main 
factors of genotype (B: df = 1, F = 57.89, P < 0.001; C: df = 1, F = 34.44, P < 0.001) and treatment 
(B: df = 1, F = 8.11, P = 0.007; C: df = 1, F = 10.33, P = 0.003). Significant interactions were 
found between the two factors in apnea, but not in breathing frequency variation (##P < 0.01, Two-
way ANOVA and ***P < 0.001, Tukey’s post-hoc). 
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Figure 7- 8. Improvement of TH and DBH expressions with THIP administration in 
Mecp2-null mice.  
 (A-B) qPCR analysis showed that during THIP treatment (P37), both TH and DBH transcript 
levels were significantly increased (Vehicle: n = 4 and n = 4 animals; THIP: n = 5 and n = 5 
animals; WT and Mecp2-null, respectively). (C-D) The Western analysis also indicated that 
THIP treatment significantly increased the protein expressions of both TH and DBH (Vehicle: n 
= 4 and n = 4 animals; THIP: n = 4 and n = 4 animals; WT and Mecp2-null, respectively; * P < 
0.05, **P < 0.01, ***P < 0.001; One-tailed Student’s t-test).  
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Figure 7- 9. Alteration of GABAAR subunits in the LC area of Mecp2-null mice. 
qPCR analysis indicated that the mRNA levels of δ and α6 subunits were 2.0 and 3.5 Times 
higher than the WT levels, while THIP treatment significantly reduced the expression level of α6 
subunit, without alteration of δ, β1 and β2 subunits (Vehicle: n = 4 and n = 4 animals; THIP: n = 
5 and n = 5 animals; WT and Mecp2-null, respectively; ** P < 0.01; Student’s t-test). 
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8 CHAPTER4: EFFECTS OF EXTRASYNAPTIC GABAAR AGONISTS EXPOSURE 
ON BRAINSTEM NEURONAL EXCITABILITY IN THE FEMALE MOUSE 
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8.1 Abstract 
Rett Syndrome (RTT) is a neurodevelopmental disorder caused by mutations of the 
MECP2 gene, affecting predominantly females. One of the characteristic features of the disease is 
defective brainstem autonomic function. In Mecp2−/Y mice, several groups of brainstem neurons 
are overly excitable, which causes destabilization of neuronal networks for the autonomic control. 
We have previously shown that the extrasynaptic GABAA receptor agonist THIP relieves many 
RTT-like symptoms in Mecp2−/Y mice. Although neuronal activity is inhibited by acute THIP 
exposure, how a chronic treatment affects neuronal excitability remains elusive. Thus, we 
performed studies to address whether increased excitability occurs in brainstem neurons of female 
Mecp2+/− mice, how the MeCP expression affects the neuronal excitability, and whether chronic 
THIP exposure improves the neuronal hyperexcitability. Symptomatic Mecp2+/− (sMecp2+/−) 
female mice were identified with a two-step screening system. Whole-cell recording was 
performed in brain slices after a prior exposure of the sMecp2+/− mice to a 5-week low-dose THIP. 
Neurons in the locus coeruleus (LC) and the mesencephalic trigeminal nucleus (Me5) showed 
excessive firing activity in the sMecp2+/− mice. THIP pretreatment reduced the hyperexcitability 
of both LC and Me5 neurons in the sMecp2+/− mice, to a similar level as their counterparts in 
Mecp2−/Y mice. In identified LC neurons, the hyperexcitability appeared to be determined by not 
only the MeCP2 expression, but also their environmental cues. The alleviation of LC neuronal 
hyperexcitability seems to benefit brainstem autonomic function as THIP also improved breathing 
abnormalities of these sMecp2+/− mice.  
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8.2 Introduction 
Rett Syndrome (RTT) is an X chromosome-linked neurodevelopmental disorder, affecting 
1/10,000 live-birth females worldwide [1]. The major cause of the disease is mutations in the 
MECP2 gene encoding the transcriptional regulator methyl-CpG binding protein 2 (MeCP2). 
Targeting on the Mecp2 gene, a variety of rodent models has been developed in the RTT study. 
Like humans with RTT, the animal models show many RTT-like symptoms, including the motor 
dysfunction, social behavioral defects and dysfunctions in the autonomic nervous system [3, 107, 
173].  
Mutations in the Mecp2 gene cause defects in neurons of the CNS as well. In the Mecp2−/Y 
mice, the locus coeruleus (LC) neurons show increased membrane excitability, which may 
interfere with their NE biosynthesis, leading to the defects in the autonomic functions including 
breathing abnormalities [6, 50, 147]. Hyperexcitability also occurs in neurons in the mesencephalic 
trigeminal nucleus (Me5), which may affect proprioceptive control of several cranial motoneurons 
[53, 56], consistent with clinical manifestations of RTT such as difficulties in chewing, swallowing 
and tooth grinding [54, 55]. 
The neuronal hyperexcitability may be relieved by interventions to neurotransmission and 
neuromodulation. GABA is the prominent inhibitory neurotransmitter in the brain. In Mecp2−/Y 
mice, neurotransmission mediated by both GABAA-receptors and GABAB-receptors is defective 
[10]. The insufficient GABAergic inhibition may contribute to the neuronal hyperexcitability and 
several RTT-like symptoms. Indeed, inhibition of the neuronal hyperexcitability with GABA 
reuptake blocker NO711 and the GABAA receptor agonist benzodiazepine improves the breathing 
activity in Mecp2−/Y mice [12, 13]. In addition to these synaptic GABAA receptors, there is a group 
of extrasynaptic GABAA receptors. We have recently found that 4,5,6,7-tetrahydroisoxazolo(5,4-
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c)pyridin-3-ol (THIP, also known as Gaboxadol), an extrasynaptic GABAA-receptor agonist, 
alleviated the breathing abnormalities, motor dysfunctions and defects in social activities in 
Mecp2−/Y mice by enhancing the GABAergic inhibition and stabilizing the neuronal 
hyperexcitability [67]. Thus, further studies of the effects of THIP on the neuronal 
hyperexcitability and the consequent RTT-like symptoms in animal models may lead to a potential 
therapeutic agent for the disease. 
Although current studies are mostly performed in the male models that have a clean Mecp2-
null genetic background, it is necessary to show how these research findings manifest themselves 
in the heterozygous Mecp2+/− females. This is particularly important when potential therapeutics 
are concerned. Several factors may affect the symptom development in the Mecp2+/− mice 
differently from the males. 1) The X inactivation impacts the phenotypic outcome [105]. Although 
the random X chromosome inactivation would theoretically render a half of Mecp2+/− individuals 
to carry the mutated gene, our previous study suggests that only ~20% the Mecp2+/− mice 
developed breathing disorders [107]. Indeed, the nonrandom X (or preferred) inactivation has been 
reported to contribute to clinical symptom variations [106]. 2) Instead of uniform expression, 
central neurons show mosaic patterns of MeCP2 expression in the Mecp2+/− mice, which vary 
among regions and animal ages [104]. The MeCP2 expression may affect symptom development 
in human patients and female animal models. 3) A previous study has shown that neurons with 
defective MeCP2 can affect the development of surrounding cells in Mecp2+/− mice [109], a 
phenomenon that may affect neuronal response to interfering with their membrane excitability in 
the Mecp2+/− mice.  
However, it is still unknown what happens to excitability of brainstem neurons in the 
Mecp2+/− mice, how the neuronal excitability is related to MeCP2 expression, and whether the 
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THIP treatment may lead to different effects on the neuronal excitability in the Mecp2+/− mice from 
Mecp2−/Y mice. To address these questions, we performed this study in two groups of brainstem 
neurons in the Mecp2+/− mice, and compared their excitability as well as THIP effects with those 
in Mecp2−/Y mice. A special attention was paid to the cellular outcome of the THIP administration 
in LC neurons with respect to neuronal firing activity and breathing abnormalities.  
 
8.3 Results 
8.3.1 LC neurons in symptomatic Mecp2+/− mice showed hyperexcitability that was alleviated 
with THIP exposure in early life 
Owing to random inactivation of the X chromosome, symptoms varied between 
heterozygous females. To separate these mice, a two-step identification procedure was used. 
Firstly, we adopted the scoring system proposed previously [51] with modifications to determine 
potential symptomatic Mecp2+/− mice, which consisted of 1) abnormal mobility, 2) abnormal gait, 
3) hindlimb clasping, 4) tremor, 5) breathing abnormalities and 6) weak general condition. Score 
0 was assigned to a mouse if none of these signs was found; the animal was scored 1 if any one of 
the 6 signs was shown to be mild (score 6 if the mouse showed all); score 2 if any of the signs was 
severe (maximum 12). The Mecp2+/− mouse was placed in the potential symptomatic group if it 
received 3 scores or more. Secondly, the mouse was considered to be symptomatic when it also 
showed breathing abnormality in the plethysmograph test as we reported previously [107]. Only 
were the symptomatic Mecp2+/− (sMecp2+/−) mice used in the present study, which were divided 
into two groups and treated with vehicle or THIP as described in the Methods.  
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LC neurons were recorded from the sMecp2+/− and WT Mecp2+/+ mice in whole-cell current 
clamp. In the vehicle-treated group, the LC neurons showed significantly higher firing activity in 
the sMecp2+/− mice than in the Mecp2+/+ mice (Fig. 8-1A). The firing rate of these neurons was 5.7 
± 0.3 Hz in sMecp2+/− mice and 4.0 ± 0.4 Hz in Mecp2+/+ mice, respectively. They were 
significantly different from each other (Mecp2+/+: n = 15; sMecp2+/−: n = 27; P = 0.002; Fig. 8-
1C).  
In the THIP group treated for 5 consecutive weeks, LC neuronal firing activity was similar 
between sMecp2+/− and Mecp2+/+ mice (Fig. 8-1B). Statistical analysis indicated that THIP 
treatment significantly reduced the firing rate to 3.8 ± 0.4 Hz in sMecp2+/− mice (Mecp2+/+: n = 15 
and n = 11; sMecp2+/−: n = 27 and n = 22; Vehicle and THIP, respectively; Fig. 1D, Table 1). Note 
that there was no THIP added to the recording chamber in this and the rest of our studies. Thus, 
LC neurons in the sMecp2+/− mice showed excessive firing activity like cells in their male 
Mecp2−/Y counterpart, and chronic exposure to THIP reduced the neuronal hyperexcitability. 
8.3.2 The THIP exposure affected both MeCP2-positive and MeCP2-negative LC neurons 
Because of the mosaic expression of MeCP2 in the female neurons, cells with different 
genetic backgrounds may contribute unevenly to the overall LC NE-ergic output in sMecp2+/− 
females, leading to variant responses to the THIP pretreatment. To test this possibility, single-cell 
PCR (scPCR) was performed to identify the MeCP2 expression in each individual LC cell. In the 
experiment, a strong negative pressure was applied to the recording pipette for ~10s immediately 
after the electrophysiological recording. The pipette was then placed in a cold RNAase inhibitor 
containing buffer solution with the pipette tip carefully broken, followed by PCR test (Fig. 8-2D). 
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In comparison to the WT cells, both MeCP2-positive and MeCP2-negative LC neurons 
showed increased firing activity, although the latter appeared slightly higher (Fig. 8-2A-C). 
Statistically, the firing rate of both was significantly different from WT LC neurons, whereas no 
significant difference was found between the MeCP2-positive and MeCP2-negative cells 
(Mecp2+/+: n = 13; MeCP2-positive: n = 14; MeCP2-negative: n = 11; Fig. 8-2E, Table 2), 
suggesting that the hyperexcitability of LC neurons may not be determined solely by endogenous 
MeCP2 expression, and exogenous factors or presynaptic events seem to play a role as well.  
To show how the chronic THIP exposure affects hyperexcitability of LC neurons with and 
without MeCP2 expression, we compared the firing rate of identified LC neurons with respect to 
MeCP2 expression. The chronic THIP treatment significantly reduced the firing rate of both 
MeCP2-positive and MeCP2-negative cells in sMecp2+/− mice (Mecp2+/+: n = 13 and n = 11; 
MeCP2-positive: n = 14 and n = 11; MeCP2-negative: n = 11 and n = 9; Vehicle and THIP, 
respectively; Fig. 8-3A, C, Table 2), while in the vehicle control cells from either group remained 
hyperexcitable (Fig. 8-3B). When the percentage inhibition of LC neuronal firing rate by the THIP 
exposure was compared, no significant difference was seen between MeCP2-positive cells, 
MeCP2-negative cells and cells from sMecp2+/− mice without MeCP2 identification (MeCP2-
positive: n = 11; MeCP2-negative : n = 9; sMecp2+/−: n = 20; Fig. 8-3D). Therefore, the THIP 
exposure suppressed the excessive firing activity of LC neurons in sMecp2+/− mice to a similar 
degree in MeCP2-positive and MeCP2-negative cells. 
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8.3.3 The THIP pretreatment did not change MeCP2 expression in LC neurons of Mecp2+/− 
mice 
To test whether THIP pretreatment alters the MeCP2 expression pattern in LC neurons of 
Mecp2+/− mice, immunocytochemistry was used to visualize the MeCP2 expression. In the LC 
area, ~70% TH-positive cells showed positive MeCP2 immunoreactivity. The THIP pretreatment 
for 5 weeks did not change the expression ratio (Vehicle: 4 animals; THIP: 4 animals; Fig. 8-
4A,B).  
The presence of MeCP2 mRNA was examined with scPCR in individual cells that had 
undergone electrophysiological studies. The scPCR experiment showed a slightly lower 
occurrence rate (~60%) of MeCP2-positive cells than immunocytochemistry. This ratio was not 
enhanced after the 5-week THIP treatment (Vehicle: 2 animals; THIP: 4 animals; Fig. 8-4C). 
Therefore, the alleviation of the LC neuronal hyperexcitability with THIP pretreatment did not 
seem to be mediated by increased MeCP2-positive cells in sMecp2+/− mice. 
8.3.4 THIP exposure relieved Me5 neuronal hyperexcitability in symptomatic Mecp2+/− mice 
It is possible that the THIP exposure improves hyperexcitability in other neurons as well. 
We have previously found that neurons in the mesencephalic trigeminal nucleus (Me5), located 
adjacent to the LC nuclei in the brainstem, are hyperexcitable in male Mecp2-null mice [53, 56]. 
Therefore, we chose the Me5 neurons to further examine the THIP effects. Although the Me5 
neurons are silent at basal condition in both WT and Mecp2-null mice, their excitability can be 
tested with depolarizing current injections.  
With step depolarizing currents the Me5 neurons showed firing activity. When the firing 
rate was compared, we found that the Me5 neurons in sMecp2+/− mice fired a significantly higher 
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frequency of action potentials than the cells in WT (Mecp2+/+) mice (Fig. 8-5A, B). With the 
comparable current injection, the Me5 neuronal firing rate was significantly higher in sMecp2+/− 
mice than in WT mice (P < 0.001; Fig. 8-5C). The chronic THIP treatment reduced Me5 neuronal 
hyperexcitability in sMecp2+/− mice (P < 0.001, Fig. 8-5D) without affecting the membrane 
potential and input resistance (Table 1) suggesting that THIP exposure affects excitability of 
multiple neuronal types in sMecp2+/− mice. 
8.3.5 The THIP effect on neuronal excitability was comparable between Mecp2−/Y and 
symptomatic Mecp2+/− mice 
How do the remaining MeCP2-positive neurons contribute to the THIP effects on neuronal 
hyperexcitability in the sMecp2+/− mice? To address this question, we compared the THIP effects 
in the sMecp2+/− mice with those in male Mecp2-null mice. Under the Mecp2-null condition, 
spontaneous firing rate of LC neurons was much higher than in the male WT, consistent with 
previous reports [67, 147]. The neuronal hyperexcitability was significantly reduced with THIP 
pretreatment compared to the vehicle control (WT: n = 14 and n = 13, Mecp2−/Y: n = 14 and n = 
13; Vehicle and THIP, respectively; Fig. 8-6A). THIP exposure also affected firing activity of Me5 
neurons in Mecp2-null mice. With comparable current injections, The THIP pretreatment 
markedly suppressed the evoked firing of Me5 neurons in Mecp2-null mice (Vehicle: n = 17, 
THIP: n = 16; P < 0.001; Fig. 8-6B2), whereas there was no significant alteration in WT cells 
(Vehicle: n = 14, THIP: n = 18; P > 0.05; Fig. 8-6B1).  
To compare the THIP effects on neuronal excitability between Mecp2−/Y and sMecp2+/− 
mice, the firing rate of these Mecp2-defective neurons was normalized to their vehicle control. 
Chronic THIP exposure reduced the excessive firing of LC neurons by 30% in sMecp2+/− mice, 
 131 
 
which was similar to the Mecp2−/Y mice (sMecp2+/−: n = 22; Mecp2−/Y: n = 13; P > 0.05; Fig. 8-
7A1). The reduction in LC neuronal firing activity with the THIP pretreatment made the FR of 
sMecp2+/− mice similar to that in the WT control, which also resembled Mecp2−/Y mice when the 
data were described as the percentage of the WT levels (P > 0.05; Fig. 8-7A2). In Me5 neurons, 
THIP produced similar levels of reductions in neuronal firing activity in Mecp2−/Y and sMecp2+/− 
mice with 400-500pA injection (sMecp2+/−: n = 13; Mecp2−/Y: n = 17; P > 0.05; Fig. 8-7B1). 
Compared to the WT controls, the degree of the THIP effect was not significantly different 
between Mecp2−/Y and sMecp2+/− mice (P > 0.05; Fig. 8-7B2). Therefore, these results suggested 
that chronic THIP treatment significantly suppressed the neuronal hyperexcitability to the similar 
degree in Mecp2-null and sMecp2+/− mice. 
8.3.6 The THIP pretreatment improved breathing in symptomatic Mecp2+/− mice 
LC neurons are known to play a role in breathing regulation, and the moderation of its 
hyperexcitation may improve breathing abnormalities. Therefore, we studied breathing activity in 
plethysmography. In the experiment, 14 sMecp2+/− animals were randomly separated into two 
groups. One group was pretreated with THIP as described in the Methods and the other was 
pretreated with regular water as vehicle control. Similarly, 14 Mecp2+/+ mice were grouped, 
serving for negative controls. Breathing abnormalities were found in sMecp2+/− mice as 
significantly higher apnea rate and breathing frequency variation in comparison to their WT 
counterpart before THIP pretreatment (WT: n = 7 and n = 7, Mecp2−/Y: n = 7 and n = 7; Vehicle 
and THIP, respectively; Fig. 8-8). The chronic THIP treatment for 5 weeks abolished the difference 
between sMecp2+/− and Mecp2+/+ mice. Such an effect was not seen in the vehicle treated group. 
Therefore, the THIP pretreatment also alleviated the breathing abnormalities in sMecp2+/− mice.  
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To compare the 5-week THIP effects on breathing activity between Mecp2−/Y and 
sMecp2+/− mice, the apnea rate and frequency variation were normalized to their vehicle control. 
THIP reduced the apnea rate by half in sMecp2+/− mice, and 45% in the Mecp2−/Y mice. No 
significant difference was found (sMecp2+/−: n = 7; Mecp2−/Y: n = 8; P > 0.05; Fig 8-9A), 
suggesting THIP pretreatment seems to have similar effects on these two models. Although the 
relief of in sMecp2+/− mice was significantly lower than the Mecp2−/Y ones (P = 0.016; Fig 8-9B1), 
THIP brought the variation to their WT level similarly in both sMecp2+/− and Mecp2−/Y mice 
(sMecp2+/−: n = 7; Mecp2−/Y: n = 8; P > 0.05; Fig 8-9B2).  
 
8.4 Discussion 
We have shown evidence for increased neuronal excitability in sMecp2+/− mice. In 
identified LC neurons, the hyperexcitability seems to be determined by not only the MeCP2 
expression pattern, but also their environmental cues. The neuronal hyperexcitation is also found 
in Me5 neurons in the sMecp2+/− mice. Chronic THIP treatment reduced the hyperexcitability of 
both LC and Me5 neurons in the sMecp2+/− mice, to a similar level as their counterparts in 
Mecp2−/Y mice. The alleviation of LC neuronal hyperexcitability may benefit brainstem autonomic 
function as THIP also improves breathing abnormalities in sMecp2+/− mice.  
8.4.1 Identification of symptomatic females 
In comparison to the Mecp2-null models, heterozygous Mecp2+/− mice recapitulate only 
some of the RTT-like phenotypes, and show relatively mild symptoms. They usually develop RTT-
like symptoms around 6 months of age, which is much later than the Mecp2-null mice. The number 
of mice with clear RTT-like phenotypes is not as high as expected based on the X chromosome 
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inactivation. According to our previous study, only 15-20% Mecp2+/− mice at ages of 1-6 months 
show breathing abnormalities [107]. These variations in phenotype manifestation, defect severity 
and symptom onset time complicate the pharmacological intervention to the female models.  
A crucial step to approach the female models is to identify the sMecp2+/− mice from the 
rest. Thus, a scoring system has been used previously [51]. In the present study, we adopted this 
scoring system with modifications. In addition, we have introduced the second tier of phenotypical 
identification based on two types of breathing abnormalities. Using this new screening system, we 
have identified sMecp2+/− mice for our electrophysiological studies in a ratio of approximately one 
in every three females at age of 6-9 months. Supporting such a phenotype identification procedure 
are our data showing that LC neurons with negative expression of MeCP2 are hyperexcitable to 
the same degree as in the sMecp2+/− mice.  
8.4.2 Neuronal hyperexcitability in female and male models and the THIP effects  
Imbalance in neuronal excitation-inhibition has been found in several brain regions of 
Mecp2-null mice, including the hippocampus, medial prefrontal cortex (mPFC) and brainstem [18, 
66, 68, 140, 147, 164, 165, 168, 197, 198]. In the hippocampus, the decreased inhibitory rhythmic 
activity in hippocampal CA3 circuit makes the cells prone to hyperexcitability [66, 197]. In the 
cortex, layer 5 pyramidal neurons of the mPFC are hyperexcitable due to the reduced GABAergic 
input [164]. In the brainstem, neurons in the solitary tract nucleus in the medulla show increased 
Fos expression associated with increased frequency of spontaneous and miniature EPSCs and 
increased amplitude of evoked EPSCs in Mecp2-null mice [68]. Interestingly, suppression of 
neuronal hyperexcitability with ketamine, an NMDA receptor antagonist, has been shown to 
benefit cortical neuronal hypoexcitability [199].  
 134 
 
In LC neurons of the Mecp2-null mice, we have previously shown that synaptic inhibition 
mediated by both GABAA-receptors and GABAB-receptors are markedly reduced with inadequate 
GABA release from presynaptic terminals [10], which may contribute to neuronal 
hyperexcitability, leading to the consequent defects in the autonomic system. Instability in Me5 
neuronal excitability was also reported in Mecp2-null mice [53, 56], which may affect 
proprioception of facial muscles and motor function [200-202], consistent with clinical 
manifestations of RTT showing defects in chewing, swallowing and teeth grinding [54, 55]. A 
previous study has shown that selective deletion of Mecp2 gene in GABAergic neurons 
recapitulates most of the symptoms as RTT, which indicated the GABA neurotransmission system 
may be a target to control the neuronal hyperexcitability and consequently alleviate RTT-like 
symptoms. Indeed, in Mecp2-null mice, administration of benzodiazepine or GABA reuptake 
blocker suppresses breathing defects [12, 13]. In addition, a recent study showed restoration of the 
Mecp2 gene in GABAergic neurons rescued some of the RTT-like symptoms substantially not 
only in Mecp2-null, but also Mecp2+/− mice [203]. Therefore, GABAergic neurons may be a key 
to control the excitation/inhibition balance in RTT mouse models. Indeed, we have found that 
chronic treatment of THIP reduced the LC hyperexcitability and alleviated a series of RTT-like 
symptoms in Mecp2-null mice [83]. With the chronic treatment, the GABAergic inhibition was 
persistently enhanced, which may result in the alteration of gene expression or functional 
improvement of the neuronal network, leading to the consequent persistent alleviation of neuronal 
hyperexcitability and the behavior abnormalities. 
8.4.3 MeCP2 expression and potential mechanisms underlying the THIP effects  
Although the mechanism is unclear, the X chromosome inactivation has an impact on RTT 
phenotype development [105]. The large individual variation of RTT symptoms has been 
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suggested attributable to the nonrandom X inactivation [106]. Another previous study also suggest 
that the nonrandom X inactivation caused by suppression of mutated paternal allele activation may 
lead to the milder phenotype clinically [204]. Therefore, altering the X inactivation ratio or the 
MeCP2 expression pattern in the CNS may be beneficial to the RTT symptoms. 
In this study, we have found neuronal hyperexcitability in two types of brainstem neurons 
in sMecp2+/− mice. The levels of the neuronal hyperexcitability in sMecp2+/− mice in age of 7~10 
months are comparable to those in 4~6 week old Mecp2-null mice. By grouping cells with or 
without MeCP2 expression, we have studied both types of LC neurons. Our results indicate that 
both MeCP2-positive and MeCP2-negative LC neurons show similar levels of hyperexcitability. 
This finding is a bit surprising as the MeCP2-positive neurons were supposed to be able to manage 
some of the defects. Although what makes both types of cells hyperexcitable is still unknown, it 
is reasonable to believe that certain exogenous factors may play a role, including the cellular micro-
environments and presynaptic modulation. This suggests that at the cellular level, defects may not 
be limited to neurons that lack MeCP2 expression in sMecp2+/− mice, while the defects seem to 
involve both pre- and postsynaptic mechanisms. Supporting the hypothesis is the GABA 
deficiency found in Mecp2-null and Mecp2+/− mice [69, 83], which is a significant presynaptic 
factor to LC neurons [10]. THIP, as the extrasynaptic GABAAR agonist, may favor the 
reinstallation of the GABAergic inhibition and lead to the consequent improvement of 
excitation/inhibition balance in the target cells in RTT mouse models. In addition, consistent with 
the hypothesis, previous studies have shown that cells expressing mutated Mecp2 gene in Mecp2+/− 
mice can affect the development of surrounding cells, including those with WT Mecp2 [109]. Also 
consistent with the hypothesis are our findings that the high firing rate of both MeCP2-positive 
and MeCP2-negative cells in sMecp2+/− mice is moderated with THIP pretreatment. The 
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hypothesis may explain the similar hyperexcitability between MeCP2-negative neurons and 
unidentified LC cells in sMecp2+/− mice as well, as both MeCP2-positive and MeCP2-negative 
cells exist in the sMecp2+/− mice, and as both these cells are hyperexcitable.  
8.4.4 Therapeutical implications 
THIP is currently under clinical trials for Angelman Syndrome, and may be moved to 
fragile X syndrome soon. As a potential therapeutical drug, THIP in the chronic exposure shows 
several beneficial effects in RTT models. In addition to counterbalancing neuronal 
hyperexcitability shown in the present study, we have recently shown that the THIP exposure 
improves general physical conditions, motor function, social behaviors and lifespan in Mecp2-null 
mice [83]. Although the genetic backgrounds of Mecp2-null and Mecp2+/− mice are different, their 
RTT phenotypical manifestations share many similarities. Also similar is the defective 
GABAergic transmission, which may allow intervention to the GABA system in both models. 
Indeed, chronic THIP treatment suppressed neuronal hyperexcitability in Mecp2+/− mice and 
alleviated mouse breathing disturbance as in Mecp2-null mice. Further studies are needed to 
evaluate systemically THIP as a potential therapeutic drug, including its effects on motor function, 
cognition and social behaviors with comparable hormone levels in each individual Mecp2+/− mouse 
as well as pharmacodynamics and pharmacokinetics. In this regard, the understanding of cellular 
changes in the CNS appears to facilitate the further studies of THIP in animal models of RTT. 
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Figure 8- 1. Firing activity of LC neurons in mice after a chronic exposure to THIP or the 
vehicle.  
 (A-B) Typical records of spontaneous firing rate in LC neurons from both WT (Mecp2+/+) and 
sMecp2+/− mice with and without prior THIP exposure. (C) The LC neurons in the sMecp2+/− mice 
showed significantly higher firing rate than the WT. (Mecp2+/+: n = 15; sMecp2+/−: n = 27; ** P < 
0.01; Student’s t-test) (D) The prior THIP exposure significantly reduced the LC neuronal 
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hyperexcitability in sMecp2+/− mice without any change in the WT. Note that open bars were from 
Figure 1C. Significant main effect of treatment (F = 11.87, df = 1, P < 0.001) and genotype (F = 
4.21, df = 1, P = 0.044) were observed, as well as the interaction of these two factors (F = 5.92, df 
= 1, P = 0.018). (Mecp2+/+: n = 15 and n = 11; sMecp2+/−: n = 27 and n = 22; Vehicle and THIP, 
respectively; ### P < 0.001; Two-way ANOVA; *** P < 0.001; Fisher’s LSD post hoc) 
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Figure 8- 2. The influence of MeCP2 expression on LC neuronal hyperexcitability in 
sMecp2+/− mice.  
 (A-C) Representative records of spontaneous firing rate from WT (Mecp2+/+), MeCP2 (+) 
(MeCP2-positve) and MeCP2 (-) (MeCP2-negative) LC neurons. (D) The MeCP2 expression 
pattern in MeCP2-positve and MeCP2-negative LC cells viewed with single cell PCR. (E) The 
firing rate of both MeCP2-positve and MeCP2-negative cells was significantly higher than the 
WT, whereas no difference was found between these two. (Mecp2+/+: n = 13; MeCP2+: n = 14; 
MeCP2-: n = 11; One-way ANOVA; * P < 0.05, ** P < 0.01; Fisher’s LSD post hoc) 
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Figure 8- 3. Chronic THIP exposure stabilized hyperexcitability of MeCP2-positve and 
MeCP2-negative LC cells.  
(A-B) Typical records of firing rate from MeCP2-positve and MeCP2-negative LC cells with and 
without prior THIP exposure. (C) The THIP exposure significantly reduced the firing rate of both 
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MeCP2-positve and MeCP2-negative LC cells without affecting the WT ones. Note that open bars 
were from Figure 2E. The main effect of treatment was significant (F = 8.81, df = 1, P = 0.004). 
No significant differences were found in the main effect of genotype (F = 2.27, df = 2, P = 0.112) 
and the interaction of these two factors was significant (F = 3.10, df = 2, P = 0.052). (Mecp2+/+: n 
= 13 and n = 11; MeCP2+: n = 14 and n = 11; MeCP2-: n = 11 and n = 9; Vehicle and THIP, 
respectively; ## P < 0.01; Two-way ANOVA; * P < 0.05, ** P < 0.01; Fisher’s LSD post hoc) 
(D) The THIP effect was compared between LC neurons that were MeCP2-positve, MeCP2-
negative and non-identified from sMecp2+/− mice after normalization of their firing rate to that of 
the vehicle control neuron. No significant difference was seen between these cells. (MeCP2+: n = 
11; MeCP2-: n = 9; sMecp2+/−: n = 20; P > 0.05; One-way ANOVA) 
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Figure 8- 4. Chronic THIP exposure did not change MeCP2 expression in LC neurons of 
Mecp2+/− mice.  
 (A) In the immunocytochemistry (ICC) experiment, similar numbers of MeCP2-positve and 
MeCP2-negative LC cells were seen in sMecp2+/− mice with or without the THIP exposure. (B) 
The ratio of MeCP2-positve vs MeCP2-negative LC cells did not show any statistical significance. 
(THIP: 4 animals; Vehicle: 4 animals; P > 0.05; χ2-test) (C) In the single cell PCR (scPCR) 
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experiment, 14 of 25 cells expressed MeCP2 in Mecp2+/− mice and THIP treatment did not 
significantly change the ratio. (THIP: 4 animals; Vehicle: 2 animals; P > 0.05; χ2-test) 
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Figure 8- 5. Chronic THIP exposure resumed Me5 neuronal excitability in sMecp2+/− mice.  
 (A-B) Me5 neurons did not fire action potentials spontaneously. With step depolarizing current 
injections, most Me5 neurons in sMecp2+/− mice fired multiple action potentials. The THIP 
exposure diminished the tendency of hyperexcitability. (C) With similar amount of current 
injections, the Me5 neurons in sMecp2+/− mice tended to fire more action potential in comparison 
to the WT (Mecp2+/+). (D) The THIP administration stabilized the neuronal excitability of Me5 
neurons in sMecp2+/− mice compared to the control. (Vehicle: n = 12 and n = 17, THIP: n = 10 and 
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n = 14, WT and sMecp2+/−, respectively; *** P < 0.001; Student’s t-test) (E-F) THIP did not affect 
the resting membrane potential (E) and input resistance (F) of the Me5 cells in both WT and 
sMecp2+/− mice (P > 0.05; Two-way ANOVA) 
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Figure 8- 6. The effect of chronic THIP exposure on neuronal excitability in Mecp2−/Y mice.  
 (A) Chronic THIP exposure significantly diminished the hyperexcitability of LC neurons in 
Mecp2−/Y mice without any significant change in WT ones. Significant differences were found in 
both main effect of genotype (F = 9.65, df = 1, P = 0.003) and treatment (F = 4.44, df = 1, P = 
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0.040). The significant interaction between the two factors (F = 12.27, df = 1, P = 0.001) was 
shown as well. (WT: n = 14 and n = 13, Mecp2−/Y: n = 14 and n = 13; Vehicle and THIP, 
respectively; # P < 0.05; Two-way ANOVA; *** P < 0.001; Fisher’s post hoc) (B1-B2) In Me5 
neurons with comparable current injections, the THIP exposure suppressed the evoked firing in 
Mecp2-null without any significant effect on WT cells. (WT: n = 14 and n = 18; Mecp2−/Y: n = 17, 
THIP: n = 16; Vehicle and THIP, respectively; *** P < 0.001; Student’s t-test) 
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Figure 8- 7. Comparison of THIP effects on neuronal excitability between Mecp2−/Y and 
sMecp2+/− mice. 
 (A1-A2) After normalization to their vehicle control, chronic THIP exposure suppressed the firing 
rate of LC neurons similarly between Mecp2−/Y and sMecp2+/− mice (A1). Also, THIP brought the 
firing rate of both Mecp2−/Y and sMecp2+/− neurons to their WT level in the mice (A2) (sMecp2+/−: 
n = 22; Mecp2−/Y: n = 13). (B1-B2) With 400~500pA injection, THIP treatment suppressed the 
firing rate of sMecp2+/− Me5 neurons by 60% after normalizing to the vehicle control, which is 
similar to the Mecp2−/Y ones (B1). In sMecp2
+/− mice, the THIP treatment kept Me5 neurons firing 
high rate to 256% compared to their WT control with same current injection, but still no difference 
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was found between the Mecp2−/Y and sMecp2+/− mice due to large variations (B1). (sMecp2+/−: n = 
13; Mecp2−/Y: n = 17; P > 0.05; Student’s t-test) 
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Figure 8- 8. The chronic THIP exposure improved breathing in sMecp2+/− mice.  
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 (A-B) Typical records of breathing activity from both Mecp2+/+ and sMecp2+/− mice with and 
without THIP treatment. Inspiration: downdraft. (C-D) The sMecp2+/− mice developed severe 
breathing abnormalities showing high apnea rate (C) and breathing frequency variation (D) 
compared to their WT (Mecp2+/+) control. The chronic THIP treatment abolished the difference 
between sMecp2+/− and WT mice in both apnea rate and f variation. (* P < 0.05, ** P < 0.01, *** 
P < 0.001; Fisher’s LSD post hoc) (C) The main effect of genotype (F = 21.28, df = 1, P < 0.001) 
and time (F = 5.37, df = 1, P = 0.025) were significant. The main effect of treatment (F = 3.04, df 
= 1, P = 0.088), interactions of genotype × treatment (F = 2.51, df = 1, P = 0.120), genotype × time 
(F = 0.14, df = 1, P = 0.712), treatment × time (F = 1.60, df = 1, P = 0.212) or genotype × treatment 
× time (F = 2.65, df = 1, P = 0.110) were not significant. (### P < 0.001; Three-way ANOVA) (D) 
The main effect of genotype (F = 30.13, df = 1, P < 0.001), treatment (F = 8.67, df = 1, P = 0.005) 
and interactions of genotype × treatment (F = 7.11, df = 1, P = 0.010) were significant. The main 
effect of time (F = 2.25, df = 1, P = 0.140), interaction of genotype × time (F = 1.55, df = 1, P = 
0.219), treatment × time (F = 1.73, df = 1, P = 0.195) or genotype × treatment × time (F = 2.25, df 
= 1, P = 0.140) were not significant. (WT: n = 7 and n = 7, Mecp2−/Y: n = 7 and n = 7; Vehicle and 
THIP, respectively; ### P < 0.001; Three-way ANOVA) 
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Figure 8- 9. Comparison of THIP effects on breathing activity between sMecp2+/− and 
Mecp2−/Y mice.  
 (A1-A2) THIP reduced the apnea rate of sMecp2+/− mice to ~56% after normalization to their 
vehicle control, which is not different from the Mecp2−/Y (A1). After normalization to their WT 
control, the THIP effects were similar between sMecp2+/− and Mecp2−/Y mice, though it appeared 
higher in the latter (A2) (sMecp2+/−: n = 7; Mecp2
−/Y: n = 8). (B1-B2) After normalizing to the 
vehicle control, the effect of THIP in the f variation of sMecp2+/− mice was reduced by 38%, which 
is significantly lower than the Mecp2−/Y (50%) (B1). THIP treatment made the f variation of 
sMecp2+/− mice very close to their WT control, which is similar to the Mecp2−/Y ones (B2) 
(sMecp2+/−: n = 7; Mecp2−/Y: n = 8; * P < 0.05; Student’s t-test). 
 
 
 153 
 
Table 8.1. Effects of chronic THIP treatment on LC and Me5 neurons in Mecp2+/+ and 
sMecp2+/− mice. 
  
Mecp2+/+ sMecp2+/−  
Vehicle THIP Vehicle THIP 
LC 
Vm (mV) 
-43.3 ± 0.5 
(n = 15) 
-43.6 ± 1.7 
(n = 11) 
-41.9 ± 1.4 
(n = 27)  
-42.0 ± 0.9 
(n = 22) 
Rm (MΩ) 
548.4 ± 43.0 
(n = 15)  
571.2 ± 44.1 
(n = 11) 
655.9 ± 41.6 
(n = 27) 
637.7 ± 58.2 
(n = 22) 
FR (Hz) 
4.0 ± 0.4 
(n = 15) 
4.0 ± 0.3 
(n = 11)  
5.7 ± 0.3 
(n = 27) 
3.8 ± 0.4*** 
(n = 22) 
Me5 
Vm (mV) 
-51.0 ± 1.2 
(n = 12) 
-52.8 ± 1.6 
(n = 10) 
-54.2 ± 1.2 
(n = 16) 
-51.6 ± 4.1 
(n = 14) 
Rm (MΩ) 
141.5 ± 37.6 
(n = 12) 
187.6 ± 54.4 
(n = 10) 
220.4 ± 34.3 
(n = 16) 
286.5 ± 47.5 
(n = 14) 
LC, locus coeruleus; Me5, mesencephalic trigeminal V; Vm, membrane potential; Rm, input 
resistance; FR, firing rate. Data are shown as means ± SE; n, number of cells; *** P < 0.001 
compared between treatment. 
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Table 8.2 THIP effects on LC neurons with and without MeCP2 expression 
LC 
Mecp2+/+ MeCP2-positive  MeCP2-negative  
Vehicle THIP Vehicle THIP Vehicle THIP 
Vm (mV) 
-43.4 ± 0.5 
(n = 13) 
-43.6 ± 1.7 
(n = 11) 
-41.8 ± 2.1 
(n = 14)  
-41.7 ± 1.1 
(n = 11) 
-41.6 ± 2.4 
(n = 11)  
-42.5 ± 1.6 
(n = 9) 
Rm (MΩ) 
563.9 ± 46.4 
(n = 13) 
571.2 ± 44.1 
(n = 11) 
678.0 ± 56.3 
(n = 14) 
632.4 ± 99.5 
(n = 11) 
637.5 ± 75.1 
(n = 11) 
653.1 ± 80.4 
(n = 9) 
FR (Hz) 
3.9 ± 0.4 
(n = 13) 
4.0 ± 0.3 
(n = 11)  
5.4 ± 0.5 
(n = 14) 
3.3 ± 0.6** 
(n = 11) 
5.7 ± 0.3 
(n = 11) 
4.1 ± 0.7* 
(n = 9) 
Vm, membrane potential; Rm, input resistance; FR, firing rate. ** P < 0.01, * P < 0.05 compared 
between treatment. 
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9 General discussions 
9.1 THIP administration  
9.1.1 Administration protocols  
RTT patients and mouse models start to develop symptoms a period after birth. In 
Mecp2−/Y mice, breathing disorders start at 2-3 weeks after birth, and defects in motor and social 
behaviors begin at 4-6 weeks. Pharmacological intervention before symptom manifestation in 
these RTT animals may prevent further development of the symptoms. To achieve such a goal, 
appropriate targets need to be found. The existence of extrasynaptic GABARs in the CNS 
enables such early intervention with respect to their spatial and temporal variations in subunit 
expressions, especially the δ subunit [80]. Thus, we chose to deliver THIP to the test animals 
starting from the date when they were born and continued the treatment till P53 in this study. 
With such treatment, our results show beneficial effects of THIP on RTT-like behaviors which 
might come from the early intervention by preventing the development of the neuronal defects. 
Indeed, the LC biosynthesis function was reinstalled and the THIP effects persisted one week 
after withdrawal, which indicated early treatment of THIP might innervate the gene expressions 
in the CNS of RTT mice, leading to the beneficial effects.  
In this study, THIP was also delivered to the animals after RTT-like breathing difficulties 
appearance, and the symptom was alleviated as well. This is consistent with the idea that THIP 
directly benefits neuronal excitability. Besides, in Mecp2+/− mice, most of the RTT-like 
symptoms show up after 6 months of age, and the symptoms vary between individuals, which 
makes the treatment in female RTT models quite complicated. Therefore, the identification of 
symptomatic Mecp2+/− animals becomes necessary. In our results, five weeks continuous THIP 
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treatment after symptoms were identified alleviated the breathing activities in sMecp2+/− animals 
by suppressing the neuronal hyperexcitability, regardless of Mecp2 mosaic expression pattern 
[205]. Therefore, chronic treatment of THIP seems to be able to correct neuronal abnormalities, 
leading to the alleviation of symptoms. Meanwhile, early intervention may reinstall the normal 
neuronal activity, which benefits the RTT animals as well.  
9.1.2 Pharmacokinetics  
THIP is a structural analog of GABA, which enables activation of extrasynaptic GABAA 
receptors, specific for those containing the δ subunit. As an investigational drug, THIP was 
originally developed as an analgesic and anxiolytic, and put in the clinical trials to treat 
insomnia. Tested as a potential clinical medicine, the pharmacokinetics of THIP has been well 
studied in multiple species, including mouse, rat, dogs and human [181-184]. In rats, 
subcutaneously injection of 2.5, 5 and 10 mg/kg THIP rapidly entered the CNS with a peak in 
the range of 0.7 to 3 µM. A preclinical study in mice, rats, and humans using 14C-labelled THIP 
showed a rapid absorption of THIP with the highest concentration in the kidney, and the peak 
concentration reached within 0.5 h in several organs including the brain. Three different 
metabolites were detected, of which glucuronic acid conjugated THIP seems to be the main one 
[184]. Although THIP has a characteristic short half-life, chronic treatment of THIP may allow it 
to be accumulated in the plasma and CNS to keep a constant and effective therapeutical 
concentration. Another clinic report on postural sway treatment indicated that THIP reached the 
maximum plasma concentration ~140ng/ml in 2.0 h in elderly humans with a daily dose of 10 
mg, and the half-life is 1.7 h [181]. Our preliminary studies suggested that 20 mg/kg THIP orally 
reached plasma concentration around 3 nM in mice. THIP started to have effects within 0.5 h 
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after i.p. delivery, while chronic treatment remained a reasonable level in the plasma in test 
animals. 
9.1.3 Potential side effects 
THIP was withdrawal in the clinical trials of insomnia treatment, due to the less efficacy 
and potential adverse effects. Indeed, THIP has been tested in over 3,000 patients with various 
dosages, (such as 10~120mg/day), among which some cases were reported with side effects at 
high doses of THIP, including sedation, confusion, dizziness and even hallucination [135]. 
However, high dosage treatment with synaptic GABAR agonists, such as barbiturate and 
benzodiazepine, may lead to the severer adverse effects, including breathing suppression, coma 
and death. THIP thus provides a relatively safer alternative, although further studies are still 
needed. The unsatisfactory efficacy for insomnia might be good for THIP application to RTT as 
the unnecessary sedative effects may be avoided. A report indicated THIP appeared to be more 
effective on women than man (44), which seems to be good for RTT treatment when considering 
the female dominance of the disease.  
In our study, the calculated dosage used in mice is 6.3 ± 0.4 mg/kg/day, which is similar 
to that in several previous studies of Fragile X syndrome and Angelman Syndrome in mice. No 
obvious side effects were reported before. Our test of spontaneous locomotion supports the non-
sedative effects of the dosage. THIP has been under clinical trials for Angelman Syndrome by 
Ovid Therapeutics and preclinical study for Fragile X syndrome since 2015. RTT shares multiple 
similarities with these rare diseases, such as impaired GABA system, neuronal hyperexcitability, 
and autism-like behaviors. Therefore, the information obtained in the present study seems likely 
to favor moving the drug for clinical trials. 
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9.2 Homeostasis between neuronal excitability and metabolic synthesis 
In LC neurons, NE is synthesized from tyrosine by a series of enzymes, including TH and 
DBH, and released with from vesicles into the synaptic cleft. The homeostasis between the LC 
neuronal excitability and the NE synthesis ensures the constant production and release of NE. 
Although increased firing rate of LC neurons may augment the NE level in the synaptic cleft by 
increasing the NE releasing frequency, persistent LC neuronal hyperexcitability may interrupt 
this balance between NE synthesis and release, and lead to impairment of the NE system. Such 
an idea was confirmed by a recent report in our lab that further stimulation of LC terminals failed 
to improve the modulation of hypoglossal neurons in the Mecp2−/Y brainstem [115]. Also, 
previous studies suggest that the TH and DBH expression levels are drastically reduced in 
Mecp2−/Y LC neurons [6, 50], consistent with the breathing disorders onset and development in 
our study. Meanwhile, our results also showed that in Mecp2−/Y mice, LC neuronal excitability 
increased with age and proportionally with the severity of breathing abnormalities. Thus, the 
defects in LC neuronal excitability may play a role in the deterioration of NE synthesis and the 
consequent development of the RTT-like symptoms in the mouse models. A moderation of 
neuronal hyperexcitability by THIP, or other GABAR agonists, may enable LC cells to correct or 
reinstall the homeostasis of NE synthesis/release, beneficial for the NE modulation of a variety 
of systems and functions in the CNS, in consideration of the broadcast LC-NE projections, such 
as to cortex, cerebellum and medulla  [12, 27, 50, 83]. The enhanced TH and DBH expression 
with THIP treatment in our results supports the homeostasis-rebuilt idea. 
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9.3 Potential compensation in GABAR system of LC area 
Previous studies have shown that selective knockout of Mecp2 gene in GABAergic neurons 
leads to a series of RTT-like phenotypes [11], suggesting the necessity and importance of GABA 
systems in the development of the disease. In patients with RTT and mouse models, the 
GABAergic inhibition was significantly suppressed showing global reductions in GABA level and 
GABARs expressions. In Mecp2−/Y LC, the subunit combinations of GABA receptors were altered. 
Both synaptic GABAARs and GABAB receptors were significantly reduced in Mecp2
−/Y mice, 
whereas the extrasynaptic GABAARs level were increased as shown in this study. The enhanced 
extrasynaptic GABAAR mediated tonic inhibition might work as a neuroadaptive process to 
compensate the insufficient GABA synaptic input. Indeed, such compensation has been reported 
in other regions of CNS. In Mecp2−/Y Me5 nuclei, the alteration of the subunits leads to the changes 
in the fast Na+ voltage-gated current and the consequent neuronal hyperexcitability. The reduced 
hyperpolarization-activated h current, resulting in smaller sag and PIR, may compensate the 
neuronal hyperexcitability [53]. Therefore, the compensatory mechanism may make the animals 
or patients with RTT viable with milder phenotypes despite the Mecp2 deficiency. In addition, our 
results suggest that the hyperexcitability of LC neurons leads to the reduced NE biosynthesis, 
although we cannot exclude the possibility that the excessive firing of the neurons was the 
compensatory results from the reduced metabolic function of the LC neurons.  
9.4 Impact of global enhancing the GABAergic inhibition 
Imbalanced inhibition/excitation ration was considered one of the mechanism leading to 
the development of a series psychiatry disease, such as schizophrenia and fragile X syndrome. 
The imbalanced inhibition/excitation ration might be one of the mechanism in the development 
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of RTT. The Mecp2 disruption causes the global deficiency of GABA and the consequent 
imbalance of excitation/inhibition, leading to the hyperexcitation or hyperactivity in central 
neurons. However, Kron et al. have shown that neuronal hypoexcitation occurs in the forebrain 
and midbrain, including PFC, somatosensory, auditory and motor cortices, which may affect 
stereotyped and repetitive behaviors consistent with the current observations of several RTT-like 
symptoms [206]. Meanwhile, neurons in the brainstem are mostly hyperexcited, especially the 
neurons in the respiratory centers, including LC and nTS [68]. Although accumulating evidence 
supports the beneficial effects of enhancing the GABAergic inhibition, its effect on the neuronal 
hypoexcitability needs to be considered. Would the global GABAergic augmentation cause 
adverse outcomes on some regions of the CNS? Available evidence suggests that enhancing the 
GABAergic inhibition ameliorated the hypoexcitability in forebrain as well. A previous study 
found that ketamine, the NMDA receptors antagonist, reversed the neuronal hypoactivity caused 
by Mecp2 deficiency via NMDA receptors, and improved the associated behaviors [68, 120]. 
This may be produced by disinhibition in the local network involving cortical pyramidal cells, so 
that reducing the glutamatergic excitation may restore this disinhibitory circuit function [125]. In 
this regard, it is possible that a global enhancement of the GABAergic inhibition may benefit the 
hypoexcitability of certain forebrain neurons and associated motor function and social behaviors 
similarly as ketamine does in Mecp2-null mice on. Furthermore, the glutamatergic excitation is 
elevated in Mecp2-null mice, which shifts the ratio to the excitatory side as well, leading to the 
region specific neuronal abnormality or disturbed network activity in the CNS of RTT. The 
global enhanced GABAergic inhibition may compensate the upregulation of excitatory 
glutamatergic regulation, leading to the amelioration of RTT-like symptoms. 
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9.5 Conclusion 
In Mecp2−/Y mice, extrasynaptic GABAAR-ergic tonic inhibition is retained in LC 
neurons and increased significantly, likely to be due to the overexpression of the GABAAR 
species containing the δ subunit. The presence of these δ containing extrasynaptic GABAARs in 
Mecp2−/Y mice allows a control of neuronal excitability with specific agonists. Early-life 
exposure to THIP, an agonist specific to δ containing extrasynaptic GABAARs, extends the 
lifespan of Mecp2−/Y mice, reduces breathing disorders and motor dysfunction, and improves 
social behaviors. Such effects persist for at least one week after THIP withdrawal. The beneficial 
effects are likely to be due to the stabilization of neuronal hyperexcitability of both LC and Me5 
neurons by THIP in mouse models of RTT without major effects on the neuronal intrinsic 
membrane properties. The expression of NE biosynthesis enzymes was also improved in 
Mecp2−/Y LC neurons. In identified LC neurons regarding their MeCP2 expression in sMecp2+/− 
mice, the hyperexcitability seems to be determined by not only the MeCP2 expression but also 
their environmental cues. Chronic treatment of THIP suppressed hyperexcitability of both 
neurons with and without the MeCP2 expression. Such a phenomenon seems to contribute to the 
relief of breathing disorders.  
Therefore, the extrasynaptic GABAAR agonist THIP in low dose with chronic exposure 
appears beneficial for symptom relief in RTT models, and seems to be a promising candidate for 
potential therapeutical intervention to RTT.  
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